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Abstract 
IL-23/TH17 inflammatory responses are regarded as central to the pathogenesis of 
inflammatory bowel disease (IBD).  Human genome wide association studies demonstrate 
that IL23R gene polymorphisms are associated with susceptibility to IBD. TH17 cells and 
the IL-17A cytokine are highly produced in the intestinal mucosa of patients with IBD. 
However, in clinical trials anti-IL-17A antibodies have shown low efficacy and increased 
infections in Crohn’s disease. Hence the role of the IL-23/TH17 axis in experimental colitis 
models and human IBD needs further examination. 
 
In order to study the IL-23/TH17 axis, a murine spontaneous colitis model, Winnie 
mice, were used in the study. Winnie mice have a single missense mutation in the Muc2 
mucin gene which results in misfolding of the mucin during biosynthesis, epithelial 
secretory cell endoplasmic reticulum stress, and mucosal inflammation. Thus in this model 
the defect arises in the epithelium, with the inflammation driven by the response from a 
competent immune system. Winnie mice share similarities with human ulcerative colitis, 
developing progressive intestinal inflammation and driven by a mixed but IL-23/TH17-
dominated proinflammatory response. 
 
In a transfer colitis model, IL-17A-/- or IL-17Ra-/- naïve T cells were transferred into 
immunodeficient recipient Rag1-/- mice. Rag1-/- recipients with an epithelial defect arising 
from the Winnie allele were also included to examine the contribution of a defect in 
intestinal epithelial integrity to the development of colitis. Results from transfer 
experiments demonstrated thatIL-17A production by the donor T cell is not necessary to 
induce transfer colitis, and IL-17Ra-deficient T cells were more colitogenic than wild type T 
cells, suggesting that IL-17Ra signaling in T cells plays a protective role in the transfer 
model of colitis. To further investigate the physiological role of IL-17A in intestinal 
inflammation, Il17a-/-/Winnie mice were generated by crossing Il17a-/- mice with Winnie 
mice. Il17a-/-/Winnie mice at 8 weeks of age had similar histological colitis compared to 
Winnie.  Interestingly, colitis severity did not progress with age in Il17a-/-/Winnie mice. 
Therefore, IL-17A is involved in the progression rather than the initiation of Winnie colitis.  
 
Next, in an attempt to mimic biological therapy with antibodies, the efficacy of anti-
IL-17A antibodies in Winnie with emerging and established colitis was assessed. 
Neutralizing IL-17A in Winnie mice with emerging colitis failed to alleviate colonic 
inflammation. Blocking IL-17A or IL-17Ra in Winnie mice with established colitis resulted in 
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similar severity of histological colitis compared to isotype treated mice, suggesting 
targeting the IL-17A-IL-17Ra axis using monoclonal antibodies is not capable of 
suppressing intestinal inflammation in the Winnie colitis model. 
 
In contrast, neutralizing IL-23 using an anti-p19 antibody significantly alleviated 
emerging colitis, downregulating Il17a and Il1b gene expression. Similarly, two weeks 
treatment with anti-p19 antibody significantly ameliorated established colitis compared to 
Winnie mice receiving isotype antibody. Anti-p19 decreased colon weight and histological 
colitis scores and was superior to anti-p40 antibody. In contrast to Winnie mice with 
emerging colitis, anti-p19 treatment of mice with established colitis did not modify 
proinflammatory cytokines. However, anti-p19 diminished colonic neutrophil infiltration, 
suggesting that the efficacy of anti-IL-23 treatment in Winnie established colitis may be 
due to mechanisms other than direct suppression of cytokine-producing immune cells. 
Anti-p19 downregulated Mip2a chemokine mRNA expression in isolated colonic epithelial 
cells and restored colonic goblet cell mucin production.  
 
IL-23 has previously been thought to act only on leukocytes, however, my 
experiments show that IL-23 acts directly on intestinal epithelial cells. Treatment of human 
colonic LS174T cells with recombinant IL-23 confirmed my in vivo findings. IL-23 treatment 
increased intracellular reactive oxygen species (ROS) levels in a Stat3 transcription factor-
dependent manner in this human colonic cell line. The IL-23-driven ROS decreased MUC2 
mucin production, and increased release of the chemokine, IL-8. Due to these multiple 
mechanisms of action, neutralization of IL-23 in colitis is likely to be efficacious not only via 
effects on immune cells, but by reducing chemokine-mediated recruitment of inflammatory 
cells into the intestine, and by replenishing intestinal mucus, thereby helping restore 
normal intestinal homeostasis. 
 
In summary, results from this thesis show that blocking TH17-associated effector 
cytokines or cytokine receptor is not effective in suppressing intestinal inflammation. 
However, targeting IL-23 alone is sufficient to suppress colitis in Winnie mice. The 
previously unrecognised adverse effects of IL-23 on colonic epithelial cells may partially 
underlie the protection from IBD conveyed by hypomorphic IL-23 receptor polymorphisms, 
and contribute to the efficacy of IL-23 neutralizing antibodies in IBD. 
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1.0 Literature Review 
1.1. The intestinal immune system 
The intestinal mucosa is the preferred niche of an enormous number of commensal 
bacteria (up to 1014) (Macpherson and Harris, 2004), and also requires selective 
permeability for nutrient absorption. Prevention of bacterial penetration into the submucosa 
and systemic spread is important to maintain mucosal homeostasis. More than 50% of the 
human body’s lymphocytes are resident in the mucosa of the intestine, and the intestinal 
mucosa harbours the largest number of tissue macrophages of any organ (Macpherson 
and Uhr, 2004a). Therefore, the intestinal immune system must be able to strike a balance 
between mounting an effective immune response against external pathogens and 
maintaining tolerance to commensal luminal microbes. Interactions between the highly 
adapted epithelial barrier and the underlying innate/adaptive immune system play a central 
role in this process.  
 
1.1.1 The epithelial barrier in maintaining intestinal homeostasis 
The epithelial barrier of the intestinal tract comprises a monolayer of epithelial cells, 
including enterocytes, enteroendocrine cells, goblet cells, Paneth cells and crypt-resident 
stem cells, which are interconnected by tight-junctions. The barrier is constantly renewed 
and regenerated by intestinal epithelial stem cells located at the base of the crypts. 
Enterocytes are the major cell population in the intestinal epithelium, which has an 
absorptive phenotype adapted for metabolic and digestive functions. Enteroendocrine cells 
secrete hormones and regulate digestive functions of the intestine. Other secretory 
epithelial cells including goblet cells and Paneth cells are specialized in maintaining barrier 
functions of the intestinal epithelium.  
 
The secreted mucus barrier, a viscous, gel-like film, serves as the first physical and 
chemical barrier to prevent direct contact of luminal contents with epithelial cells. Luminal 
microbes can only transverse into the outer mucus layer under normal physiological 
conditions, while the inner layer is sterile and filled with high concentrations of 
antimicrobial molecules (Johansson et al., 2008; McGuckin et al., 2009). Mucins, the major 
macromolecular components of the mucus layer, are highly glycosylated proteins usually 
secreted by specialized secretory cells known as goblet cells. Antimicrobial molecules, the 
other important component of mucus layer, in the small intestine are mainly produced by 
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Paneth cells, which are highly specialized epithelial secretory cells present at the base of 
crypts (Ayabe et al., 2000; Wilson et al., 1999). Paneth cells are not present in the non-
inflamed colon where other enterocytes produce anti-microbial molecules.  Upon exposure 
to microbes, Paneth cells can secret α-defensins (cryptidins in mice) and other 
antimicrobial molecules such as lysozyme to stop bacterial penetration into intestinal 
mucosa (Ouellette, 2010).  
 
Besides producing the secreted mucus barrier, epithelial cells are also actively 
involved in the process of defence against bacterial infiltration (Peterson and Artis, 2014). 
Intestinal epithelial cells internalize Gram-negative bacteria through Toll-like receptor 
(TLR)-4-dependent phagocytosis (Neal et al., 2006). Peyer’s patches in the small intestine 
are covered by follicle-associated epithelium lacking goblet cells and a secreted mucus 
barrier. Microfold cells (M cells) in this specialized epithelium allow uptake of luminal 
bacteria and a variety of antigens for presentation to underlying antigen presenting cells. 
Until recently, antigen transportation through the epithelium was thought to be a unique 
feature of M cells, however it has now been shown that small intestinal goblet cells can 
deliver luminal soluble antigens to underlying CD103+ dendritic cells which further induce 
IgA production and promote lamina propria regulatory T cell development (Knoop et al., 
2014; McDole et al., 2012). After epithelial cell phagocytosis, antigens are translocated to 
antigen presenting cells which migrate to the mesenteric lymph nodes, stimulating 
lymphocytes and inducing a non-inflammatory immune response characterized by IgA 
production by B cells (Hathaway and Kraehenbuhl, 2000; Macpherson and Uhr, 2004b).   
 
Intestinal epithelial cells are able to alter their phenotype and produce an array of 
proinflammatory chemokines, cytokines and antimicrobial defence molecules when 
stimulated by pathogenic luminal microbes or proinflammatory stimuli derived from cells in 
the intestinal mucosa (Kagnoff, 2014). It has been shown that probiotic Lactobacillus 
acidophilus NCFM induces IL-1α and IL-1β secretion via the NF-κB p65 and p38 mitogen-
activated protein kinase (MAPK) pathways in intestinal epithelial cells (Jiang et al., 2012). 
Metabolic products of the commensal flora including phytic acid (Wawszczyk et al., 2012) 
and butyrate (Kim et al., 2013b) play an important role in regulating IL-8 secretion from 
colonic epithelial cells via the MAPK pathway. In summary, intestinal epithelial enterocytes 
and secretory cells are more than a passive barrier; they act like innate immune cells and 
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are actively involved in regulating microbial antigen presentation to the immune system 
and maintaining intestinal immune homeostasis (Figure.1.1). 
 
Evidence from murine models demonstrates the importance of epithelial integrity 
and function for maintaining intestinal homeostasis. Epithelial-restricted gene mutations or 
deficiencies can lead to spontaneous colitis and result in inflammatory bowel disease-like 
phenotypes in the mouse colon (Heazlewood et al., 2008; Kaser et al., 2008; Nenci et al., 
2007; Park et al., 2009; Van der Sluis et al., 2006; Wei et al., 2012). 
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Figure 1.1 The intestinal epithelial barrier is actively involved in maintaining local mucosal 
immune homeostasis. Most of bacteria reside in the faecal material in the lumen or in the outer 
layer of mucus which covers the intestinal epithelial cells. Intestinal epithelial cells (IECs) form a 
biological and physical barrier that separates luminal microbes from the mucosal immune 
system. The intestinal epithelial cells include enterocytes, enteroendocrine cells, goblet cells, 
Paneth cells and crypt-resident stem cells which control the continuous regeneration of the 
epithelial cell layer. Differentiated IECs, with the exception of Paneth cells, migrate up the 
crypt–villus axis.  Secretory goblet cells and Paneth cells secrete mucus and antimicrobial 
proteins (AMPs) to keep the inner mucus layer sterile and promote the exclusion of bacteria 
from the epithelial surface. The release of secretory IgA (sIgA) further contributes to this barrier 
function. Microfold cells (M cells) and goblet cells are constantly sampling and mediating the 
transport of luminal antigens for presentation to antigen presenting cells. Occasionally, 
commensal microbes penetrate through the mucus layer and reach epithelial cells. Lamina 
propria resident macrophages are able to kill penetrating bacteria by phagocytosis, while some 
may live in DCs for several days after phagocytosis. This allows DCs to interact with B and T cells 
within the inter-follicular area and induce IgA production by B cells and non-inflammatory 
cytokine secretion by T lymphocytes (Peterson and Artis, 2014)(Copyright obtained from Nature 
Publishing Group). 
Reproduced from Nature Review Immunology 14:141-153 with copyright clearance  from Nature Publishing Group 
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1.1.2 Innate immune defence system of the intestinal tract 
Under physiological conditions, commensal microbes occasionally reach the 
epithelium. However, lamina propria innate immune cells are usually able to phagocytose 
these microbes, preventing further penetration whilst maintaining local tolerance. Unlike 
professional antigen presenting cells residing in other tissues, intestinal macrophages and 
dendritic cells (DCs) do not activate naïve T cells to induce inflammatory responses in 
response to TLR activation. Furthermore, both macrophages and DCs contribute to 
maintenance of intestinal homeostasis by induction of tissue resident Treg maturation 
(Coombes and Maloy, 2007; Denning et al., 2011; Hadis et al., 2011).  
 
Intestinal tissue macrophages are closely regulated by the luminal microflora. 
During the maturation of the intestinal immune system, macrophages down-regulate 
expression of co-stimulatory factors such as CD40, CD80 and CD86. Lamina propria 
resident macrophages do not express innate response receptors to lipopolysaccharide 
(LPS), IgA, IgG, growth factor receptors for IL-2 and IL-3 or toll like receptor 4 (TLR4) 
(Smythies et al., 2005). As a result, they are unable to respond to LPS and other microbe-
associated molecules derived from the luminal flora (Smith et al., 2001). Intestinal 
macrophages also greatly reduce production of proinflammatory cytokines in response to 
inflammatory stimuli, including IL-1β, IL-6, IL-12, TGF-β and TNF-α (Fadok et al., 1998). 
However, their strong phagocytic ability remains intact (Smith et al., 2005; Smythies et al., 
2005). Apoptotic cells or bacterial antigens taken up by macrophages can also induce T 
cell tolerance as a result of presentation in the absence of costimulatory factors 
(Hershberg and Mayer, 2000). Furthermore, a recent study demonstrates that IL-23 
producing intestinal CX3CR1+ mononuclear phagocytes induce IL-22 production in group 3 
innate lymphoid cells, which offers protection in a Citrobacter rodentium-induced 
experimental colitis model (Longman et al., 2014). 
 
Intestinal DCs are key players in mediating interactions between the epithelial 
barrier and adaptive immune cells. DCs are derived from circulating monocytes and 
migrate to the lamina propria, following chemokine-gradients produced by epithelial cells 
(Cook et al., 2000). Under healthy conditions, CD103+ DCs take up antigens from luminal 
commensal flora, and then migrate to mesenteric lymph nodes where they induce IgA 
production by B cells, and T cell tolerance (Huang et al., 2000; Schulz et al., 2009). 
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Internalized bacteria can survive several days within DCs restricted to the mucosal 
immune system, and this interaction is believed to help selectively induce IgA secretion, 
which helps prevent bacterial penetration of mucus (Macpherson and Harris, 2004). DCs 
present in Peyer’s patches under the M-cells of the dome epithelium are able to induce 
Foxp3+ regulatory T cell differentiation via a TGF-β and retinoic acid-dependent 
mechanism (Coombes and Maloy, 2007; Schulz et al., 2009; Sun et al., 2007).  
 
Innate lymphoid cells (ILCs) are a recently defined cell population playing an 
important role in intestinal homeostasis. ILCs have been found at multiple mucosal sites 
and barrier surfaces of the mouse and human, including lung (Monticelli et al., 2012), skin 
(Kim et al., 2013a) and intestine (Tait Wojno and Artis, 2012). They are actively involved in 
tissue remodelling, local inflammatory responses and early innate immune responses to 
infection. ILCs have been characterized according to their differing transcription factor and 
cytokine profiles into group 1, group 2 and group 3, which share similarities with the CD4+ 
TH1, TH2 and TH17 cells, respectively (Walker et al., 2013).   Group 1 ILCs, including the 
natural killer (NK) cells and innate lymphoid cell subset 1 (ILC1), produce the TH1-
associated cytokines IFN-γ and TNFα in response to IL-12 and IL-15 (Fuchs et al., 2013). 
In an important difference to NK cells, ILC1s are unable to produce perforin and granzyme 
B and therefore lack direct cytotoxic ability. The actual physiological role of ILC1s is still 
unclear, although a study reported that the frequency of ILC1s in the inflamed intestinal 
mucosa of Crohn’s disease patients was substantial increased (Bernink et al., 2013). 
Group 2 ILCs (ILC2) produce the TH2-associated cytokines IL-5 and IL-13. ILC2s have 
been shown play a protective role in early innate immune responses against intestinal 
helminth infection by promoting goblet cell hyperplasia and stimulating mucin secretion 
(Neill et al., 2010). Group 3 ILCs are driven by the transcription factor RORγt+, and 
produce the TH17 cytokines IL-17 and IL-22 in response to IL-23 (Bernink et al., 2013). IL-
22 produced by ILC3s has a protective role in stimulating intestinal epithelial regeneration 
following injury or bacterial infection (Sonnenberg et al., 2011; Zenewicz et al., 2008).  
ILC3-derived IL-22 has also been shown to regulate selective containment of lymphoid-
resident Alcaligenes to prevent systemic inflammation associated with chronic infections 
(Sonnenberg et al., 2012). ILC3-derived IL-17A is shown to have proinflammatory effects 
in murine colitis models as well as human inflammatory bowel diseases (IBD) (Buonocore 
et al., 2010a; Coccia et al., 2012; Geremia et al., 2011). Although the importance of ILCs 
in intestinal homeostasis has been appreciated in various murine models, much of the 
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research has been conducted in models lacking lymphocytes, and the contribution of ILCs 
to human disease pathogenesis needs further investigation.  
 
To regulate immune responses against luminal flora and maintain intestinal 
homeostasis, innate immune cells closely interact with intestinal epithelial cells. This cross-
talk is a two-way communication. Lamina propria DCs and intestinal resident macrophages 
are able to extend dendrites through epithelial tight junctions to sample luminal bacteria 
antigens, while the integrity of the epithelial layer is preserved as DCs also express tight-
junction proteins (Rescigno et al., 2001). On the other hand, epithelial cells produce thymic 
stromal lymphopoietin (TSLP), TGFβ and retinoic acid (RA) which induce conditioned non-
inflammatory DCs to further stimulate homeostatic TH2 and Treg immune responses 
(Peterson and Artis, 2014). Intestinal epithelial cells also play a crucial part in regulating 
ILCs in response to commensal bacteria and antigens. RORγt+ ILC3s are responsible for 
the majority of intestinal IL-22 production in health, especially in absence of adaptive 
immunity, and this is downregulated by IL-25 produced by epithelial cells in response to 
symbiotic microbes (Sawa et al., 2011). Intestinal epithelial cells are also able to induce 
TH2 immunity during helminth infection. Epithelial cell-derived TSLP and IL-25 stimulate 
the differentiation of haematopoietic progenitor cells towards myeloid progenitor and 
basophil progenitor phenotypes which produce type 2 cytokines and promote TH2 immune 
responses at the mucosal site to aid worm expulsion (Saenz et al., 2013; Saenz et al., 
2010; Siracusa et al., 2013) (Figure 1.2 Innate immune regulation).  
 
1.1.3 The adaptive immune system of gastrointestinal tract  
Intestinal B cells and differentiated T cells, together with epithelial secretory cells 
provide the last line of defence to luminal bacteria. Following antigen uptake by antigen 
presenting cells (APCs), mucosal B cells produce IgA (Kallies et al., 2004) and T cells 
produce IL-4 (Rimoldi et al., 2005), both of which boost the barrier to microbes in a non-
inflammatory way. Increased regulatory T cells in the intestinal mucosal system are 
another feature of mucosal adaptive immunity. The gut microenvironment and local 
cytokine milieu favors TCR activated CD4+ T cell differentiation into IL-10 and TGF-β 
producing cells with low proliferation ability (Dubois et al., 2005).  The generation of a 
TH2/Treg dominant regulatory environment is modulated by commensal flora and restricted 
to the mucosal immune system. Following stimulation in Peyer’s patches, activated B and 
T cells re-enter the bloodstream through intestinal lymphatics and then circulate back to 
8 
 
 
the intestinal mucosa (Figure 1.2). A specialized T cell population, intraepithelial 
lymphocytes (IELs), is present in the intestinal mucosa which has close interactions with 
epithelial cells in maintaining barrier functions (Satoh-Takayama et al., 2008). IELs 
including γδ T cells and NKT cells (Cheroutre et al., 2011; Ismail et al., 2011). Although the 
exact local environment in promoting IELs development is unknown, the intimate crosstalk 
between IELs and epithelial cells suggest that epithelial cells play an important role in 
regulating their differentiation and function. 
 
Epithelial cells also regulate the maturation process of naïve B cells to IgA-secreting 
plasma cells in the lamina propria. In response to commensal bacteria-induced NF-κB 
signalling, intestinal epithelial cells produce proliferation-inducing ligand (APRIL) and B 
cell-activating factor (BAFF) which directly stimulate heavy chain class-switch 
recombination of B cells (He et al., 2007; Xu et al., 2007). This process can be facilitated 
and amplified by epithelial cell-conditioned mucosal DCs and macrophages (Cerutti, 
2008). Epithelial-derived TSLP induces APRIL and BAFF production by mucosal DCs, 
which further acts on B cells to promote class-switching and IgA production (He et al., 
2007; Xu et al., 2007). Specialized intestinal epithelial cells, capable of  translocating 
luminal antigens, also express major histocompatibility complex (MHC) class I and class II 
molecules suggesting that epithelial cells may act like APCs for lamina propria CD4+ and 
CD8+ T cells (Zimmer et al., 2000). Unlike the classical presentation which stimulates T 
cell activation, epithelial cells induce T cell anergy due to a lack of costimulatory factors 
(Hershberg and Mayer, 2000). Highly adapted NK cells and T cells also reside within the 
intestinal epithelial layer (Cheroutre, 2005). The close and active communication between 
the epithelial barrier and innate and adaptive immune cells establishes a complex and 
effective surveillance system to preserve intestinal homeostasis.  
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Figure 1.2  The crosstalk between intestinal epithelial cells and underlying immune cells. 
Intestinal epithelial cell-derived cytokines IL-25, IL-33 and TSLP promote the expansion and 
differentiation of ILC2s, whereas IL-25 suppresses ILC1 and ILC3 function by limiting antigen 
presenting cell production of pro-inflammatory cytokines, especially IL-23. Epithelial cells prime 
migratory DCs and tissue resident macrophages towards a tolerogenic phenotype through the 
production of TSLP, TGFβ and retinoic acid. These DCs promote the differentiation of naive T 
cells into Treg cells and the maturation of B cells into IgA-secreting plasma cells. After trafficking 
to the intestine, Treg cells are expanded in number by macrophages that are conditioned to 
produce IL-10 by TSLP-mediated stimulation and through contact-dependent interactions with 
intestinal epithelial cells (Peterson and Artis, 2014)(Copyright obtained from Nature Publishing 
Group). 
 
1.2. Dysregulated T cell responses and inflammatory cytokines in inflammatory 
bowel diseases 
1.2.1 Inflammatory T cell responses in the intestinal immune system 
Although mucosal immune responses are tightly regulated, inappropriate host 
immune responses to the commensal microflora can occur, inducing local inflammation 
and tissue destruction. Intestinal inflammation can result from multi-level triggers including 
Reproduced from Nature Review Immunology 14:141-153 with copyright clearance  from Nature Publishing Group 
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primary defects in the epithelial barrier, chronic or continuous bacterial infection or 
penetration, changes in the threshold of immune responses against luminal commensal 
microbes and a deviation in the type of immune response (McGuckin et al., 2009).  These 
factors are not exclusive to each other, and combinations of triggers could result in a 
pathogenic inflammatory response involving both innate and adaptive immunity with 
increased proinflammatory cytokine production such as IL-1β, IFN-γ, IL-6, TNF-α, IL-17A 
and IL-23 (Figure. 1.3). IBD are chronic intestinal disorders of the gastrointestinal tract, 
and are typically classified as either Crohn’s disease (CD) or ulcerative colitis (UC), 
although these can be difficult to distinguish and can be classified as indeterminate colitis. 
The complex aetiology of IBD is still not fully understood, but increased inflammatory 
cytokine production and dysregulated T cell responses are associated with the initiation 
and perpetuation of intestinal inflammation (Kaser et al., 2010; Troncone et al., 2013). 
 
TH1 and TH2  
TH1 cells are induced by IL-12 and characterized as IFN-γ producing cells, whereas 
the signature cytokines of TH2 cells are IL-4, IL-5 and IL-13. CD was believed to be a TH1 
mediated disease, and UC was thought to be driven by a TH2 immune response. In 
patients with CD, disease pathology was linked with proinflammatory immune responses 
with greatly increased IL-12, IFN-γ and TNFα production, while high levels of IL-5 and IL-
13 secretion were observed in patients with UC (Fuss et al., 1996; Monteleone et al., 
1997). In addition, abundant production of IFN-γ from lamina propria lymphocytes was 
observed in patients with CD. High levels of STAT4 and T-bet, typical TH1 associated 
transcription factors, were isolated from inflamed mucosal of patients with CD indicative 
TH1 response may responsible for the progression of CD (Monteleone et al., 1997). An 
antibody against the IL-12 p40 unit proved effective in clinic trials in IBD supporting a 
pathogenic role of IL-12 (Mannon et al., 2004). However, with the discovery of IL-23 - a 
cytokine sharing the p40 subunit of IL-12 (Cua et al., 2003), the IL-23/TH17 axis has been 
demonstrated to play a major role in the pathogenesis of IBD (Elson et al., 2007; Hue et 
al., 2006). More detailed cytokine biology will be discussed in the following sections. 
 
TH17 
The physiological role of TH17 cells is to prosecute immune responses against 
extracellular pathogens, particularly in mucosal tissues such as the respiratory and 
intestinal tracts, through a mechanism of secreting inflammatory cytokines, chemokines 
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and anti-microbial proteins (Bettelli et al., 2008; Khader et al., 2007; Ye et al., 2001). TH17 
cells are most abundant in the lamina propria of the small intestine, where their presence 
is boosted by the colonization of the intestinal segmented filamentous bacteria (SFB) 
(Atarashi et al., 2008; Ivanov et al., 2009; Lochner et al., 2011). While SFB are regarded 
as commensals by many and are present in neonatal life in mouse and man, they bear 
many of the features of pathogens, including mucus penetration, attachment to epithelium, 
activation of an inflammatory immune response and subsequent immune-mediated 
clearance. The mechanism of TH17 induction by SFB has recently been revealed. SFB-
encoded peptide antigens induce specific antigen receptor-bearing T cells differentiated 
into RORγt-expressing TH17 cells, therefore, the effector function and antigen specificity of 
TH17 cells is determined by the type of antigen-producing bacteria (Yang et al., 2014). 
These findings further demonstrate that the initiation of TH17 responses and inflammatory 
diseases of the intestinal mucosa are closely related to the presence of commensal flora.  
 
Induction of the transcription factors, retinoic acid-related orphan receptor (ROR)-γt 
and ROR-α, by appropriate antigen presenting cell stimulation with TGF-β and IL-6 or IL-
21 drives TH17 cell differentiation (Ivanov et al., 2006; Mangan et al., 2006).  It is also 
reported that other transcription factors contribute to cytokine production by TH17 cells 
(Sato et al., 2011; Zhang and Kaufman, 2008). Human TH17 cells can also be generated 
from CD161+ precursors (Kleinschek et al., 2009). The cytokine IL-23 is not strictly 
necessary for differentiation of TH17 cells from naïve T cells which lack the IL-23 receptor 
(IL-23R), but IL-23 is crucial in the maintenance, expansion and terminal commitment of 
TH17 lineage via the STAT3 transcription factor (McGeachy et al., 2009; Stritesky et al., 
2008). Genome wide association studies showed that IL23R and STAT3 gene 
polymorphisms have strong associations with TH17-mediated IBD pathology (Jostins et al., 
2012a).  The pathogenicity of TH17 cells in intestinal inflammation has been attributed to 
the increased production of proinflammatory cytokines such as IL-17A, IL-17F and IFN-γ, 
and the suppression of Treg differentiation (Peluso et al., 2007).  
 
TH17 cells are a heterogeneous population with a relatively unstable phenotype. In 
a given tissue not all TH17 cells produce proinflammatory cytokines. An IL-17A-producing 
cell population co-expressing the regulatory T cell marker, transcription factor FOXP3, is 
present in the intestinal mucosa of CD patients (Hovhannisyan et al., 2011). In an anti-
CD3 induced tolerance model, TH17 cells transdifferentiated and acquired regulatory T cell 
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functions in the small intestine with increased IL-10 production and down-regulated TNF-α 
and IL-2 secretion, but not IL-17A (Esplugues et al., 2011). Besides sharing phenotypic 
and functional similarities with Treg cells, some TH17 cells also produce the TH1 cytokine 
IFN-γ. In an experimental autoimmune encephalomyelitis model, TH17 cells shut off IL-17 
production and become IFN-γ producing cells (Hirota et al., 2011). It has been shown that 
TGF-β is necessary for sustained production of IL-17F and IL-17A, whereas IL-23 and IL-
12 suppress IL-17A but stimulate IFN-γ production in a STAT4 and T-bet dependent 
manner (Lee et al., 2009a; Lee et al., 2009b). TH17 cells are also actively cross-regulated 
by cytokines produced by TH1 and TH2 cells, and vice versa. TH1- and TH2-associated 
cytokines like IFN-γ and IL-4 can inhibit TH17 cell differentiation and cytokine production, 
while IL-17A suppresses TH1 cell polarization by inhibiting IFN-γ production (Nakae et al., 
2007; Park et al., 2005).  Although TH17 cells have a plastic phenotype, TH17 
proinflammatory cytokines play important roles during intestinal infection and non-
infectious inflammation.  
 
Figure 1.3 Under local inflammation, the balance between pro- and anti-inflammatory cytokines 
favours an inflammatory response. Under healthy conditions, epithelial cell-derived TSLP, IL-6 
and retinoic acid condition APCs towards an anti-inflammatory phenotype. Following 
interactions with luminal bacteria, APCs secrete cytokines to directly induce an inflammatory 
TH1/TH17 response, while Treg functions are suppressed. IL-23 may play a role in restraining Treg 
function and thus propogate intestinal inflammation (Brand, 2009). 
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1.2.2 TH17-associated cytokines in IBD pathogenesis 
 TH17-associated cytokines are highly upregulated in patients with IBD suggesting 
their pivotal role in intestinal inflammation. For example, IL17 mRNA expression is 
increased in the mucosa of IBD patients (Kobayashi et al., 2008; Nielsen et al., 2003; 
Sugihara et al., 2010) as are serum levels of IL-17A (Fujino et al., 2003; Mohammadi et 
al., 2013). It is believed that TH17 cytokines contribute to the amplification and sustention 
of inflammatory processes by promoting antibody production, chemokine release, 
neutrophil recruitment and effector T cell activation (Korn et al., 2009). However, the actual 
functional role of TH17 cytokines in IBD pathogenesis is not fully understood. A recent 
clinical trial using secukinumab, an anti-IL-17A monoclonal antibody, demonstrated a lack 
of efficacy in treating CD patients with active disease (Hueber et al., 2012). Therefore, the 
role of TH17 cells in intestinal mucosal inflammation is complex, probably related to their 
ability to promote epithelial barrier function and fight against extra-cellular pathogens 
(Troncone et al., 2013). As a result, the physiological function of TH17-associated 
cytokines in the intestinal immune system needs further examination. 
 
IL-17A and IL-17F 
IL-17A and IL-17F are signature cytokines of TH17 cells and share the most 
homologous sequence compared to other IL-17 family cytokines. Their secretion is 
controlled by RoRγt and STAT3 transcription factors (Ivanov et al., 2006; Yang et al., 
2007; Yang et al., 2008b). Both IL-17A and IL-17F can form homodimers or heterodimers 
and are secreted in combination by activated human CD4+ T cells with all forms 
functionally active in vitro (Wright et al., 2007). Both IL-17A and IL-17F act through the 
same hetero-dimeric receptor composed of IL-17RA and IL-17RC subunits, with IL-17A 
exhibiting higher binding affinity compared to IL-17F (Kuestner et al., 2007; Toy et al., 
2006). It is clear that IL-17A release can induce myeloid cells to secrete specific 
chemokines, cytokines, matrix metalloproteinases (MMPs) and antimicrobial peptides 
which further lead to recruitment and accumulation of neutrophils and local inflammation  
(Xu and Cao, 2010), whereas the data for IL-17F action are less clear.  
 
IL-17A has been shown to be pathogenic in the context of autoimmune diseases 
such as multiple sclerosis and rheumatoid arthritis, the effect of IL-17A in the context of 
chronic intestinal inflammation is more complicated and varies with different mouse 
models of colitis. Neutralizing IL-17A reduces the experimental colitis induced in a model 
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of regulatory deficiency with conditional deletion of Stat3 in Foxp3+ Treg cells (Chaudhry et 
al., 2009). Yet in another regulatory deficiency model with IL-10-deficiency, blockade of IL-
17A by monoclonal antibody was insufficient unless IL-6 was also neutralized (Yen et al., 
2006). Contradictory findings have been reported in different chemically-induced colitis 
models. IL-17A-/- mice have less severe TNBS colitis compared to wild type mice (Jin et 
al., 2012), while in contrast another study found that IL-17A neutralization results in more 
severe colitis in mice treated with dextran sodium sulphate (DSS) (Ogawa et al., 2004; 
Yang et al., 2008a). Providing further evidence of a non-pathological role for IL-17 in 
experimental colitis, in a T cell dependent colitis model, lymphopenic host (Rag1-/-) mice 
transferred with IL-17A-deficient naïve T cells develop exacerbated colitis compared to 
recipients receiving wild-type (WT) T cells. Increased IFN-γ levels were found in the 
mucosa of mice lacking IL-17 signals indicating that IL-17A may exert protective properties 
by antagonizing production of the pro-inflammatory cytokine, IFN-γ (O'Connor Jr et al., 
2009). Thus, while IL-17A can contribute to immunopathology in colitis, this seems to be 
dependent on the specific nature of the inflammatory response. 
 
Although IL-17F signals through the same receptor as IL-17A, its role in the 
mucosal immune system is less clear. IL-17F deficiency leads to reduced DSS colitis 
compared to wild type mice (Yang et al., 2008a). However, IL-17F-deficient T cell transfer 
induces indistinguishable colitis compare to WT T cell recipients (Leppkes et al., 2009). 
SCID mice receiving anti-IL-17A and anti-IL-17F monoclonal antibody co-treatment had 
decreased histological colitis compared to mice receiving isotype control in a transfer 
colitis model (Wedebye Schmidt et al., 2013), indicating that IL-17F could play a redundant 
role to IL-17A in mediating intestinal inflammation. More studies are needed to elucidate 
the unique and overlapping roles of IL-17A and IL-17F and better understand their 
respective roles in the etiology of IBD.  
 
IL-17C 
 IL-17C is an IL-17 cytokine family member that is selectively induced by bacterial 
exposure and inflammatory stimuli (Song et al., 2011). IL-17C binds to a receptor complex 
consisting of the receptors IL-17RA and IL-17RE, which was preferentially expressed on 
epithelial cells (Chang et al., 2011). In contrast to IL-17A and IL-17F which are mainly 
produced by immune cells, IL-17C is distinctly produced by epithelial cells. IL-17C 
promotes inflammatory responses in the epithelial system by stimulating the expression of 
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proinflammatory cytokines, chemokines and antimicrobial peptides, which were similar to 
those induced by IL-17A and IL-17F (Ramirez-Carrozzi et al., 2011). IL-17C and IL-17RE 
signalling exerted protective functions in dextran sodium sulfate colitis model. Mice 
deficient in Il17re had increased body weight loss and more severe mucosal damage 
(Ramirez-Carrozzi et al., 2011).  In a recent study, IL-17C has been shown to promote 
colon cancer development by increasing intestinal epithelial cell survival (Song et al., 
2014).  In summary, IL-17C plays an essential autocrine role in regulating innate epithelial 
immune responses. 
 
IL-21 
IL-21 is a cytokine mostly produced by activated Th17 cells, not APCs (Parrish-
Novak et al., 2002). IL-21 signals through IL-21 receptor (IL-21R) consisting of the 
common receptor γ-chain and IL-21Rα which is widely expressed on immune cells and 
non-immune cells (Ozaki et al., 2000). IL-21R expression on intestinal epithelial cells is 
higher in IBD patients compared to healthy controls. An in vitro study has shown that IL-21 
acts on epithelial cells to induce production of T-cell chemo-attractants (Caruso et al., 
2007). This cross-talk between epithelial cells and immune cells demonstrates how IL-21 
may perpetuate intestinal inflammation. IL-21 can markedly enhance CD4+ and CD8+ T 
cell proliferation and counteract Treg differentiation (Peluso et al., 2007; Zeng et al., 2005). 
Enhanced IL-21 production is found in the mucosa and lamina propria mononuclear cells 
of IBD patients, likely contributing to the sustained TH1 immune response in CD patients 
(Monteleone et al., 2005a). Murine IL-21-deficient naïve T cells failed to differentiate into 
IL-17A producing cells under TH17-polarizing conditions in vitro and IL-21-deficient mice 
are protected from DSS colitis showing that IL-21 signalling is necessary to generate the 
Th17 cells which are involved in DSS-induced intestinal inflammation  (Fina et al., 2008). 
Although murine studies have demonstrated that IL-21 is a critical regulator of TH17 
responses and inflammation in the gut, there are no clinical studies targeting IL-21 in 
patients with IBD. 
 
IL-22 
IL-22 is a member of the IL-10 cytokine family mainly produced by activated effector 
CD4+ T cells and ILCs. It acts on the IL-22 receptor (IL-22R) comprising IL-10R2 and the 
IL-22R1 subunit (Wolk et al., 2004; Xie et al., 2000) which is only expressed on non-
immune cells, particularly epithelial cells in the skin and mucosal surfaces (Sabat et al., 
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2014). IL-22 is a bifunctional cytokine that exerts both tissue protective and pro-
inflammatory effects against pathogens in the intestinal mucosal system. IL-22 is involved 
in tissue repair and in wound healing by enhancing antimicrobial defensin secretion (Wolk 
et al., 2006). IL-22 plays an important role in the early phase of host defence against 
Citrobacter rodentium infection (Zheng et al., 2008). Citrobacter rodentium infection-
induced death in genetically obese and high-fat diet fed mice can be rescued by 
exogenous IL-22 administration (Wang et al., 2014).  IL-22-deficient mice had much 
greater body weight loss and a higher rate of mortality in DSS colitis (Sugimoto et al., 
2008). IL-22 sourced from both innate and adaptive immunity also plays a protective role 
in T transfer-induced colitis (Zenewicz et al., 2008). Furthermore, IL-22 is increased in the 
mucosa of mice with colitis and up-regulated in patients with Crohn’s disease (Brand et al., 
2006). IL-22 signalling can increase expression of proinflammatory genes, which may 
further stimulate intestinal epithelial cell migration and defensin production (Brand et al., 
2006). Local IL-22 gene delivery to colonic epithelial cells induces mucus production and 
goblet cell reconstitution in a murine model which leads to rapid amelioration of local 
intestinal inflammation (Sugimoto et al., 2008). Another approach to enhance IL-22 
production is through the aryl hydrocarbon receptor (AhR) activation. Studies using the 
AhR agonist, FICZ (6-formylindolo(3,2-b)carbazole), have demonstrated efficacy in 
preventing and treating multiple forms of experimental colitis through promotion of IL-22 
production (Monteleone et al., 2012; Monteleone et al., 2011c). Overall, evidence to date 
demonstrates that IL-22 is important for maintaining intestinal barrier integrity by improving 
barrier function and accelerating wound healing.  
 
IL-23 
IL-23, a heterodimeric cytokine composed of p40 and p19 subunits, is produced by 
macrophages, DCs, monocytes and endothelial cells upon antigen activation by ligands for 
pattern recognition receptors (eg. TLR2 and NOD2), prostaglandin E2 and CD40-ligand 
(Re and Strominger, 2001; Sheibanie et al., 2004; van Beelen et al., 2007). IL-23 binds to 
the IL-23 receptor which is composed of IL-12Rβ1 (shared with IL-12 receptor) and IL-23R 
subunits (Parham et al., 2002). IL23R polymorphisms have been associated with IBD 
susceptibility (Jostins et al., 2012a). IL-23R is widely expressed on innate and adaptive 
immune cells such as memory T cells, NK cells, DCs, macrophages and innate lymphoid 
cells (Buonocore et al., 2010b; Geremia and Jewell, 2012; Re and Strominger, 2001). In 
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response to IL-23 binding, STAT-JAK signalling is activated with predominant activation of 
STAT3 (Re and Strominger, 2001).  
 
Murine studies have shown that IL-23 is a key cytokine driving intestinal 
inflammation. In a Helicobacter hepaticus induced T cell-dependent colitis, IL-23 not IL-12 
has been shown to be the key driver of pathogenesis in intestinal inflammation (Kullberg et 
al., 2006). Spontaneous intestinal inflammation in IL-10 deficient mice can be ameliorated 
by specifically neutralizing IL-23 (ie. not also IL-12) with a monoclonal antibody against the 
p19 subunit (Yen et al., 2006). Transgenic mice over-expressing the p19 subunit of IL-23 
develop multi-organ inflammation including intestinal inflammation (Wiekowski et al., 
2001). Furthermore, IL-23 deficiency (but not IL-12 deficiency) in Rag1-/- recipients is 
protective in T cell transfer-induced colitis (Hue et al., 2006). IL-23 may suppress Treg 
differentiation from naïve T cells suggesting intestinal inflammation with high IL-23 
production could develop due to reduced immunosuppressive functions (Izcue et al., 
2008). IL-23 can activate innate lymphoid cells in Rag1-deficient mice to produce IL-17 
and induce mucosal inflammation (Uhlig et al., 2006). IL-23 has also been reported to work 
on hematopoietic stem and progenitor cells by stimulating extramedullary hematopoiesis 
which results in accumulation of inflammatory monocytes and neutrophils in the inflamed 
intestine (Griseri et al., 2012). Supporting this evidence, administration of an IL-23p19 
vaccine which induces antibodies selectively blocking IL-23 ameliorates TNBS-induced 
chronic murine colitis (Guan et al., 2013). 
 
Despite the pathogenic role of IL-23 in chronic intestinal inflammation, IL-23 is a 
critical element of intestinal immunity. For example, IL-23 is necessary for host protection 
against the attaching and effacing intestinal bacterial pathogen, Citrobacter rodentium, in 
mice (Mangan et al., 2006). Consequently, therapeutic blockade of IL-23 may result in 
increased susceptibility to enteric pathogen infections. Administration of antibodies against 
p40 (both IL-12 and IL-23) has proved effective in IBD patients in clinical trials (Mannon et 
al., 2004; Sandborn et al., 2012; Tuskey and Behm, 2014), while the efficacy of antibodies 
against p19 (IL-23 only) is still under study.  
 
1.3. Inflammatory Bowel Diseases 
IBD, typified by CD and UC, are remitting/relapsing chronic inflammatory disorders 
of the gastrointestinal tract which appear to result from inappropriate mucosal immune 
18 
 
 
responses in intestinal tissues to the presence of normal luminal microbes (Podolsky, 
2002). CD and UC have many similarities, but there are also several distinguishing 
pathological differences between them. Both CD and UC have a disease incidence of 10-
200 cases per 100,000 persons in western countries with a trend to progressively 
increasing incidence.  The disease prevalence is high especially in North America and 
Europe, and is now increasing rapidly in Asia, which suggests western lifestyle and 
environment might be relevant to the disease incidence (Bouma and Strober, 2003). 
Besides the environmental elements, genetic factors also play an important role in disease 
prevalence. IBD concordance in monozygotic twins is less than 50% in CD and less than 
20% in UC (Halfvarson et al., 2003).   
 
CD can affect any part of the gastrointestinal tract, most commonly, the terminal 
ileum, cecum and large bowel. A feature of CD is discontinuous lesions with apparently 
normal intestinal tract separating inflamed regions. Disease histology is characterized by 
mucosal inflammation, substantial infiltration by T cells and macrophages typically 
penetrating transmurally, and the presence of granulomas and submucosal fibrosis and 
structuring. Clinical complications of patients with CD such as diarrhoea, abdominal pain, 
bowel obstruction and abscess formation are observed (Kaser et al., 2010).  
 
The inflammatory process of UC usually involves the rectum and extends toward 
the proximal colon in a continuous fashion, but is usually limited to the colon. In contrast 
with CD, inflammation in UC typically affects only the superficial mucosal layer with loss of 
goblet cells, lymphocyte infiltration, surface ulceration and crypt abscesses. Patients with 
UC often experience severe diarrhea and intestinal bleeding. Defects in peristaltic function 
and the development of a rigid colonic tube can present in patients with severe UC. 
Chronic uncontrolled inflammation in UC increases the risk of colon carcinoma by 
approximately 10-fold (Kaser et al., 2010). 
 
1.3.1 Genetic factors involved in IBD 
Genome-wide association studies (GWAS) have revealed more than 163 genes are 
linked to the susceptibility of IBD, including amongst the genes with the highest relative 
risk, genes related to TH17 immunity (IL23R, IL12B, STAT3, JAK2 and CCR6), IL-10 
signaling (IL27, IL10 and IL10Ra), epithelial function (ERRFI1 and HNF4α) and innate 
sensors (NOD2, CARD9 and ATG16L1) (Jostins et al., 2012a; Khor et al., 2011).  As this 
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project focuses on the T cell immune response, particularly the TH17 response, gene 
variants associated with innate and adaptive TH17 arm immunity will be discussed. 
 
NOD2 is the strongest susceptibility locus for CD and it is particularly important in 
intestinal innate immunity and cells of the macrophage/monocyte lineage, dendritic cells 
and epithelial cells. Nucleotide-binding oligomerization domain containing 2 (NOD2) is a 
cytoplasmic protein product of NOD2 that acts as a pathogen recognition receptor sensing 
virus and all bacteria except mycobacteria and chlamydia (Girardin et al., 2003; Inohara et 
al., 2003). Mutation of NOD2 in patients with CD may lead to impaired autophagy induction 
which leads to dysregulated bacteria translocation and failed antigen presentation in the 
lamina propria dendritic cells (Cooney et al., 2010). Functional mutations in both alleles of 
NOD2 gene increases the susceptibility of CD by more than 30-fold (Cuthbert et al., 2002), 
making NOD2 the most powerful mutation found in CD. 
 
Genome-wide association studies demonstrate that an uncommon coding variant of 
the IL23R gene (rs11209026, c. 1142G> A, p. Arg381Gln) conferred strong association 
with both CD and UC (Duerr et al., 2006a; Jostins et al., 2012b; Zindl et al., 2013). 
Interestingly, some IL-23R SNPs are associated with increased disease risk, while others 
indicate decreased disease susceptibility (Ebrahimi Daryani et al., 2014; Lacher et al., 
2010; Lauriola et al., 2011; Mihaljevic et al., 2013; Pidasheva et al., 2011; Sarin et al., 
2011; Sarlos et al., 2014). Although the precise mechanism of the IL23R polymorphisms 
regulating IBD susceptibility is not fully understood, the current understanding is that the 
protective IL23R polymorphism is associated with impaired IL-23R signalling and reduced 
STAT3 phosphorylation in T cells, which contributes to reduced proinflammatory cytokine  
production (Cho, 2008; Pidasheva et al., 2011).  
 
The IL12B gene which encodes the p40 shared-subunit of heterodimeric cytokines 
IL-12 and IL-23 (Oppmann et al., 2000), has been linked with CD (Barrett et al., 2008a; 
Ferguson et al., 2010a), which further suggest that IL-12/IL-23 pathway plays a pathogenic 
role in chronic intestinal inflammation.  
 
The STAT3 gene (encodes signal transducer and activator of transcription 3) and 
JAK2 gene (encodes Janus kinase 2) encode signalling proteins downstream of IL-23R, 
but also activated by other cytokines such as IL-6, IL-10, IL-22 and IL-26 (Brand, 2009). It 
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has been shown that the genetic variants of the JAK2 and STAT3 genes have a strong 
association with IBD susceptibility (Barrett et al., 2008b; Ferguson et al., 2010b; Polgar et 
al., 2012). STAT3 has a central role in TH17 cell differentiation, and its activation by IL-23 
induces downstream proinflammatory IFN-γ and IL-17 production (Watford et al., 2004), 
which further suggest that the STAT3-JAK2 signalling pathway is integral to IBD 
pathogenesis. 
 
Evidence from GWAS strongly suggests that the IL-23 signalling pathway and TH17-
associated cytokines play an important role in IBD pathogenesis. Therefore, targeting 
cytokines or key components of this signaling pathway provide promise for treatment of 
IBD.  
 
1.3.2 Cytokines involved in the pathogenesis of IBD 
As an immune disorder characterized by a dysregulated inflammatory T cell 
response, elevated pro-inflammatory cytokine levels are often observed in patients with 
IBD. At the same time, production of regulatory cytokines such as TGF-β and IL-10 is 
decreased, indicating the balance between pro and anti-inflammatory responses is broken.  
 
Mucosal cytokine profiles determine the local T cell differentiation environment and 
may play an important role in the IBD pathogenesis. Cytokines from different T helper cell 
subsets are elevated in the inflamed mucosa of patients with UC or CD (Christophi et al., 
2012; Kobayashi et al., 2008; Leon et al., 2009). Some TH1 related cytokines including 
IFN-γ, IL-12 and TNF-α are overexpressed in the inflamed mucosa of both UC and CD 
patients (Christophi et al., 2012; Leon et al., 2009; Olsen et al., 2007). With the discovery 
of TH17 cells, now it is well accepted that IBD is associated with increased inflammatory 
cytokine production by multiple effector T cells, including TH17 cells.  TH17-associated 
cytokines such as IL-17A, IL-17F, IL-21 and IL-22 are excessively produced in both CD 
and UC (Monteleone et al., 2011a; Monteleone et al., 2011b).  
 
IL-17A is the signature cytokine produced by TH17 cells, and demonstrates strong 
proinflammatory functions (see 1.2.2 for details).  The average number of IL-17-producing 
cells is significantly increased in patients with active UC and CD, and mRNA gene 
expression and serum levels of IL-17A are also elevated in patients with IBD (Fujino et al., 
2003). Multiple cell types including δγT cells and innate lymphoid cells are the source of 
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IL-17A in the mucosa of IBD patients (Martin et al., 2009; Spits and Di Santo, 2011). 
mRNA expression of another TH17 effector cytokine, IL-17F, is also augmented in the 
inflamed lesions of CD (Seiderer et al., 2008), indicating that IBD is associated with an 
altered immune balance favoring an inflammatory TH17 response.  
 
IL-21 expression is higher in the mucosa of patients with CD and UC compared to 
healthy controls. In IBD most IL-21 is produced by IFN-γ producing CD4+ T cells rather 
than IL-17A producing cells. Neutralizing IL-21 in LPMC isolated from CD patients induces 
decreased expression of the TH1 associated transcription factors, STAT4 and T-bet 
(Caruso et al., 2007; MacDonald and Monteleone, 2005). Murine studies have 
demonstrated that IL-21 regulates IL-17 production by TH17 cells in chemically-induced 
murine colitis (Fina et al., 2008). Therefore IL-21 may contribute to IBD pathogenesis 
through augmentation of both inflammatory TH1 and TH17 responses.  
 
Increased IL-22 gene expression in mucosal lesions and elevated serum cytokine 
levels are observed in both CD and UC patients (Brand et al., 2006; Schmechel et al., 
2008), which together with the roles for IL-22 shown in mouse models (see 1.2.2 for 
details), suggests that IL-22 may contribute to epithelial healing, defensin production and 
suppression of local inflammation. 
 
IL-23 gene expression is upregulated in both UC and CD. Its upregulation 
correlates with increased IL-17A production in UC and IFN-γ secretion in CD, although 
TH17 cells exist in both diseases (Kobayashi et al., 2008). As IL-23 is the key cytokine 
driving TH17 cell differentiation and cytokine production, its elevation is consistent with the 
documented increase of proinflammatory cytokines such as IL-17 and IFN-γ in patients 
with IBD.  
 
1.3.3 Current treatments for IBD 
Corticosteroids 
Conventional corticosteroids such as prednisolone have been used to treat IBD for 
over 50 years and are the preferred initial treatment for patients with IBD. Corticosteroids 
are able to down-regulate proinflammatory cytokine production by effector T cells, reduce 
inflammation levels and effectively induce remission in patients with CD (Cottone et al., 
2011). Corticosteroids rapidly and effectively lead to short term clinical remission, but long 
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term use is limited by high relapse rates and side effects related to long term 
glucocorticoid use (Faubion et al., 2001). Corticosteroid treatment to induce remission may 
be less effective than combined immunosuppressive drugs in patients with newly 
diagnosed CD (D'Haens et al., 2008). Long-term use of corticosteroids is also associated 
with numerous systemic adverse events including opportunistic infections, diabetes 
mellitus, hypertension and increased fracture risk (Curkovic et al., 2013). 
 
 
Thiopurines 
The thiopurine drugs 6-Mercaptopurine (6-MP) and its pro-drug azathioprine (AZA) 
are purine analogues that competitively interfere with nucleic acid metabolism. Both drugs 
have immune modifier properties as a result of reducing leukocyte proliferation (Lennard, 
1992). Although many controlled clinical trials have investigated the efficacy of thiopurines 
to treat moderate-to-severe IBD patients, results have been conflicting and controversial. 
Meta-analysis of eight randomized placebo controlled trials of 6-MP and AZA therapy on 
patients with CD revealed thiopurine treatment is more effective than placebo for induction 
of remission in patients with active CD (Prefontaine et al., 2010). Combination therapy with 
thiopurines and anti-TNF antibodies improves response rates compared to anti-TNF 
antibody alone (Colombel et al., 2010; Panaccione et al., 2011). However, another meta-
analysis of five parallel-group randomized controlled trials failed to demonstrate that 
AZA/6-MP treatment alone has statistically significant benefit to induce remission in active 
CD and UC (Khan et al., 2011).  
 
Some severe side effects have been associated with thiopurine treatment, alone or 
in conjunction with corticosteroids, resulting in cessation of therapy in up to 25% of 
patients (Lakatos and Kiss, 2011). General or mild side effects include nausea, abdominal 
pain and flu-like symptoms, while severe side effects include suppression of white blood 
cell and platelet production, pancreatitis and hepatitis (Prefontaine et al., 2010). The strong 
immunosuppressive functions of thiopurines may also result in severe systemic infections 
and malignancy such as hepatosplenic T cell lymphomain some patients (Issa et al., 2007; 
Karran and Attard, 2008; Schneeweiss et al., 2009). 
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5-aminosalicylic acid 
5-aminosalicylic acid (5-ASA) has been used for the treatment of IBD especially UC 
for many years. Although 5-ASA can be used in combination with steroids to induce and 
maintain remission in patients with IBD (Pithadia and Jain, 2011), the exact mechanism of 
actions are still unclear. Several potential mechanisms have been suggested, including 
prevention of mucosal leucocyte proliferation and trafficking, inhibition of IL-1β and TNF-α 
production, inhibition of the lipoxygenase pathway, the scavenging of free radicals and 
oxidants, and inhibition of NF-κB transcription factor pathway (van Bodegraven and 
Mulder, 2006). While 5-ASA has long-established efficacy in treating UC (Hanauer et al., 
1993), the efficacy of 5-ASA in treating CD is less promising. A recent meta-analysis 
concluded that the role of 5-ASA in inducing remission in active CD and maintaining 
remission in CD remains uncertain (Ford et al., 2011). Side effects of 5-ASA, including 
headache, nausea and fatigue, happen in about 10 to 45% of patients. These reactions 
can be minimized by decreasing the dose. However, adverse effects occur in some 
patients, including severe allergic reactions, fever, hepatitis, pneumonitis, hemolytic 
anemia, and bone marrow suppression (Pithadia and Jain, 2011). 
 
Biological therapy 
Lack of significant efficacy of conventional treatments in IBD and better 
understanding of disease pathology has led to new therapies designed to target specific 
molecules of inflammatory response - the so called biological drugs. 
 
Patients that fail to respond to conventional steroids and immunosuppressive drugs 
are usually treated with anti-tumour necrosis factor-α (TNF-α) antibodies. Infliximab is a 
chimeric monoclonal antibody with proven efficacy in improving clinical response and 
maintaining remission in patients with refractory luminal CD. Infliximab rapidly and 
profoundly induces endoscopic healing (Hanauer et al., 2002; Present et al., 1999; Targan 
et al., 1997). There are multiple proposed mechanisms of actions of anti-TNF antibodies 
including neutralization of soluble TNF-α,  induction of lamina propria T cell apoptosis, 
CD68+ macrophage apoptosis and decreasing IL-17 expression (Caprioli et al., 2013; ten 
Hove et al., 2002). In a randomized, open-label study in paediatric patients with 
moderately-to-severe active CD, 10 weeks of infliximab demonstrated a clinical response 
rate of 88.4% (p<0.05 vs placebo) and remission rate of 58.9% (p<0.05), and a response 
rate of 63.5% (p=0.002) and remission of 55.8% (p<0.001) after one year of treatment 
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(Hyams et al., 2007). Infliximab also has demonstrated efficacy in patients with UC. 
Patients receiving 5mg and 10mg of infliximab both had increased clinical responses (69% 
and 61%, respectively) compared to those receiving placebo (37%, P<0.001 for both 
comparisons) (Rutgeerts et al., 2005). Other anti-TNF monoclonal antibodies – 
adalimumab, certolizumab pegol and golimumab have also shown clinical benefits for 
active IBD patients (Colombel et al., 2007; Hanauer et al., 2002; Peyrin-Biroulet et al., 
2007; Sandborn et al., 2014; Trinder and Lawrance, 2009).  
 
Despite the efficacy of TNF antagonists in IBD there are considerable issues with 
respect to safety and loss of response. The safety issues of anti-TNF treatment include 
risk of infection (resulting in tuberculosis, sepsis and opportunistic infection), malignancy, 
autoimmunity and paradoxical inflammation (Billiet et al., 2014). Among these side effects, 
increased risk for opportunistic infections is the most prominent issue. Several safety 
analyses on pooled-trial data found increased infections in anti-TNF-treated patients 
compared to the placebo control group (Burmester et al., 2013; Fidder et al., 2009; 
Lichtenstein et al., 2012a; Lichtenstein et al., 2012b).  Besides the side effects, non-
response limits the use of anti-TNF antibody in clinical treatment. Approximately one third 
of patients do not respond to anti-TNF therapy (primary non-response) (Hanauer et al., 
2006; Sandborn et al., 2007a; Targan et al., 1997). Within the initial responders, 
approximately 40% of patients will develop non-response or intolerance during treatment 
(secondary nonresponse), and require either dose escalation or switching to another anti-
TNF antibody (Colombel et al., 2007; Hanauer et al., 2002; Schreiber et al., 2007). 
Secondary non-response patients treated with class-switched anti-TNF antibodies 
generally have lower response rates compared to patients naïve to anti-TNF antibody 
treatment (Billiet et al., 2014; Sandborn et al., 2007b).  
 
IL-6 has been shown to play a pivotal role in the development of CD, both in animal 
colitis models and human studies (Atreya and Neurath, 2008; Yamamoto et al., 2000). 
Several monoclonal antibodies against IL-6 or IL-6 receptor (IL-6R) have been developed 
and tested in inflammatory diseases. Tocilizumab, a humanized anti-IL-6R monoclonal 
antibody, was developed initially to treat patients with autoimmune disease such as 
rheumatoid arthritis (Ding and Jones, 2006), but also has shown efficacy in treating 
patients with active CD. In a placebo-controlled phase II study, 80% of patients treated 
with Tocilizumab every two weeks had a clinical response compared to 31% of the 
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placebo-treated patients (P=0.019), and 20% of treated patients went into remission 
compared to 0% of the control group (Ito et al., 2004). Another fully humanized anti-IL-6 
monoclonal antibody PF-04236921 is being tested in two ongoing trials in CD patients who 
failed anti-TNF therapy. However, a recent trial using a novel humanized anti-IL-6 
monoclonal antibody BMS-945429 to treat active CD patients was prematurely 
discontinued due to severe intestinal perforations. Based on these results, targeting IL-6 in 
IBD needs further careful investigation.  
 
Three clinical trials have evaluated the efficacy of fontolizumab, a humanized anti-
IFN-γ monoclonal antibody, in patients with moderate-to-severe CD.  Although 
fontolizumab was well tolerated, a significant clinical response was not observed 
compared to the placebo group (Hommes et al., 2006; Reinisch et al., 2010; Reinisch et 
al., 2006). Therefore even though CD has a prominent TH1 response, neutralization of the 
main TH1 cytokine does not reverse pathology. 
 
Two fully humanised IgG1 monoclonal antibodies against the p40 subunit of IL-
12/23 cytokines have been developed: briakinumab and ustekinumab. A randomized study 
of briakinumab on 79 moderate-to-severe CD patients demonstrated that weekly 
subcutaneous injections of 3mg/kg body weight of anti-p40 antibody induced a higher 
clinical response rate compared to the placebo group at week 7, but not week 18 (Mannon 
et al., 2004). However, the remission rate was not significantly different between anti-p40 
antibody and placebo treated groups (Mannon et al., 2004). Later a double-blinded, 
placebo controlled, parallel-group cross-over trail of ustekinumab also exhibited some 
efficacy in treating patients with moderate-to-severe Crohn’s disease, with an increased 
clinical response rate at week 4 and week 6 after cross-over of treatments, but failed to 
reach the primary end-point at week 8  (Sandborn et al., 2008). A recent phase 3 clinical 
trial of ustekinumab has been carried out on patients suffering from moderate-to-severe 
CD who had previously failed anti-TNF therapy (Sandborn et al., 2012). Ustekinumab 
demonstrated significant benefit in inducing clinical responses compared to placebo, but 
not remission. In a subset of patients with an initial response to ustekinumab, further 
treatment with ustekinumab as a maintenance therapy again significantly increased clinical 
response rates compared to placebo (Sandborn et al., 2012). Taken together, these 
results show that anti-p40 antibody treatment is effective as an induction and maintenance 
therapy in subsets of CD patients. This might be particularly useful for patients who do not 
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respond to anti-TNF therapy or are intolerant to anti-TNF drugs. To date, these antibodies 
haven’t been tested or trialed in UC. Other large clinical trials with ustekinumab are 
underway which should help to define anti-p40 antibody efficacy in different treatment 
settings. 
 
In a double-blind, placebo-controlled clinical trial, patients with moderate-to-severe 
CD was treated with secukinumab, a humanized anti-IL-17A monoclonal antibody. 
However, secukinumab failed to demonstrate efficacy and blockade of IL-17A exacerbated 
CD in a subset of patients compared to placebo (Hueber et al., 2012). Another anti-IL-17A 
antibody, AMG827, was also ineffective in treating active CD patients. Evidence of disease 
worsening was observed compared to the placebo control group (Targan et al., 2012), 
indicating that targeting this single cytokine of the TH17 pathway is not sufficient to 
suppress intestinal inflammation. It is possible, based on mouse data (O'Connor Jr et al., 
2009), that neutralizing IL-17A fosters TH1 cells differentiation and promotes production of 
IFN-γ. In contrast to the antibody therapy targeting only IL-17A, Vidofludimus (SC12267), a 
small molecule targeting the JAK/STAT and NF-κB pathway and suppressing the 
expression of proinflammatory cytokines IL17A, IL17F and IFN-γ is efficacious in treating 
IBD (Herrlinger et al., 2013).  
 
Besides the current antibody treatment against specific inflammatory cytokines, 
other biologics as treatment have also been tested in clinical trials such as recombinant 
human IL-10, granulocyte-macrophage colony stimulating factor (GM-CSF), antibodies 
against leukocyte migration and drugs which induce T cell apoptosis. Vedolizumab, an 
antibody against α4β7 integrin which blocks lymphocyte trafficking, has shown efficacy as 
induction and maintenance therapy for UC (Feagan et al., 2013). However, vedolizumab 
did not show substantial efficacy in treating active CD patients (Sandborn et al., 2013).   
 
In conclusion, the most common treatment for IBD clinically is “step-up” which 
includes corticosteroids to induce remission and thiopurines or anti-TNF antibody 
treatment to maintain remission. Additional therapies targeting proinflammatory cytokines 
or combinations of different biologics to block the inflammatory cascade are needed for 
moderate-to-severe patients with IBD. Preferably these biologics should do this without 
substantially increasing the risk of infection. 
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Surgery 
Surgery plays a limited/last resort role in the management of IBD. It is indicated for 
patients with medical therapy failure, intolerable side effects of medications, toxic 
megacolon, perforation, high-grade or multifocal dysplasia and uncontrollable bleeding 
(Cohen et al., 2005). Total proctocolectomy may be curative for patients with isolated UC, 
while a high rate of surgical complications is noted in patients with CD. Therefore, surgery 
usually is restricted to patients with IBD that are refractory to other treatment options.  
 
1.4. Murine experimental models of colitis  
1.4.1 Colitis occurring as a consequence of gene mutations or introduction of transgenes 
In mice a wide range of genetic defects (gene knock-out or mutations) develop 
spontaneous intestinal inflammation.  These models include epithelial restricted knockouts 
(Muc2, Xbp1, Agr2, NEMO and fatty acid synthase deficient mice) (Heazlewood et al., 
2008; Kaser et al., 2008; Nenci et al., 2007; Park et al., 2009; Van der Sluis et al., 2006; 
Wei et al., 2012), regulatory cell defects (IL-10 deficient mice, IL-2 deficient mice and TGF-
β deficient mice) (Kuhn et al., 1993; Sadlack et al., 1993; Shull et al., 1992), defects 
causing increased effector cell function (Tnf mutant mice and Stat4 transgenic mice) 
(Kontoyiannis et al., 1999; Wirtz et al., 1999) and defects in antigen presentation (MHC II-
deficient mice) (Grusby and Glimcher, 1995). These models are useful when studying the 
effects of gene deficiency in the development of colitis and inflammation. However, some 
of the gene knockout mice have widespread immunopathology limiting their relevance to 
the type of inflammation present in IBD.  
 
1.4.2 Colitis induced by exogenous chemicals 
Exogenous chemical toxins such as DSS and trinitrobenzene sulfonic (TNBS) acid 
are widely used to induce colitis in mice. Histopathology of mice with DSS colitis usually 
includes oedema, epithelial damage, ulceration, crypt abscesses, neutrophilic infiltration 
and submucosal inflammation and this is considered a model for UC (Dieleman et al., 
1998). On the other hand the response to the hapten TNBS causes a more T cell 
mediated colitis that is considered to be CD-like. Chemically-induced colitis models are 
commonly employed as they are practically easy and achievable. However, this acute 
inflammation does not truly reflect the real progressive chronic disease process in human 
IBD, and these models do not provide strong predictive value for testing drugs applicable 
to human disease.  
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1.4.3 Colitis induced by transfer of naïve T cells into lymphopenic hosts 
Chronic colitis induced by transfer of T cells into lymphopenic recipients has been 
extensively studied and employed as a research model in the past decade (Powrie et al., 
1993). It is the best-characterised model of colitis induced by disruption of T cell 
homeostasis. In this model, CD4+CD45RBhigh donor T cells are transferred into a 
lymphopenic host such as SCID or Rag-deficient mice. In the absence of regulatory T cells 
and anti-inflammatory cytokines, donor naïve T cells induce severe colonic and small 
intestinal inflammation with the time post-transfer to develop colitis dependent on the 
microbial flora in the animal facility. Histopathological changes in the distal colon include 
mucosal inflammation, epithelial cell hyperplasia, goblet cell depletion, polymorphonuclear 
and mononuclear cell infiltration, crypt abscesses and epithelial erosion. Reconstituted 
mice exhibit varying degrees of diarrhoea, rectal bleeding, and body weight loss 
depending on the strains of donor and recipient mice (Powrie et al., 1993). Advantages of 
this model are that early T cell-mediated immune responses and inflammation can be 
examined, and it can be employed to study the effects of general immunological 
treatments on colitis. It is also a useful model to investigate the suppressive functions of 
regulatory T cells in limiting the onset and progression of inflammation (Ostanin et al., 
2009). However, colitis induced by adoptive T cell transfer develops in a severely 
lymphopenic host with an incompetent immune system, and IBD patients are not 
lymphopenic. Therefore, although a useful tool this scenario does not reflect disease 
development under physiological conditions with immune surveillance from regulatory T 
cells.  
 
1.4.4 Winnie mice - a spontaneous model of colitis 
Winnie mice, which are used extensively as a model of colitis in this thesis, were 
generated by ENU mutagenesis and were the first model that has a single missense 
mutation in the Muc2 mucin gene.  This mutation results in a proportion of the Muc2 
protein misfolding and accumulating in the endoplasmic reticulum (ER) which results in ER 
stress in intestinal goblet cells, a depleted intestinal mucus barrier and spontaneous 
colonic inflammation (Heazlewood et al., 2008).  The important feature of this model is that 
the Winnie mice have an epithelial defect with normal underlying immunity, making this 
substantially different to most models of IBD. 
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Our laboratory has fully characterized the nature of the inflammatory response in 
Winnie mice (Eri et al., 2011).  Immunophenotyping and analysis of expression/levels of 
cytokines from mesenteric lymph nodes (mLNs) were assessed in C57BL/6 and Winnie 
mice.  Immunophenotyping of colonic LPMCs showed an increased proportion of CD11c+ 
APCs and a 4-fold increase in activated DCs (CD11c+ MHC class IIhi) in Winnie 
accompanied by decreased production of the APC conditioning factor TSLP. Upon LPS 
stimulation, APCs from Winnie mice secreted elevated levels of IL-12/23p40, IL-6 and 
MIP-1α compared to the C57BL/6 mice suggesting a TH17 polarization.  Winnie mice also 
displayed a significant increase in the expression of TH17 signature genes Il17a, Il17f, Tgfb 
and Ccr6 in the intestinal mucosa and marked increases in IL-1β, particularly in the distal 
colon compare to C57BL/6.  Intestinal mLN leukocytes isolated from Winnie mice secreted 
multiple TH1, TH2 and TH17 cytokines upon stimulation, with a striking 100-fold 
augmentation in IL-17A in an age-dependent manner.   
 
Based on Winnie mice, our lab further generated RaW mice by crossing Rag1-/- with 
Winnie, which is a useful model to examine the effect of both effector and regulatory 
lymphocytes and cytokines in the Winnie model of colitis. The absence of T and B 
lymphocytes in RaW mice altered the pattern of inflammation but colitis persisted, 
particularly in the proximal colon, suggesting that innate immune cells play a role in 
mediating spontaneous colitis. There was no difference in colitis severity and clinical 
symptoms between young Winnie and RaW mice (8 weeks). However, RaW mice did not 
show the progressive increase in clinical symptoms and colitis characteristic of Winnie 
mice as they age. These data indicate that lymphocytes play an active role in progression 
of colitis in this model (Eri et al., 2011). 
 
In conclusion, the primary epithelial defect and mucosal barrier dysfunction in the 
Winnie mice results in complex multi-cytokine mediated colitis involving both innate and 
adaptive immune components with a dominant IL-23/TH17 response which share 
similarities to patients with IBD. Therefore, the underlying basis for my thesis was that 
targeting proinflammatory cytokines, especially TH17-associated cytokines, in Winnie mice 
will deepen understanding of the complex cytokine milieu in intestinal inflammation and 
hopefully indicate the best therapeutic approaches to manage IBD.   
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2.0 Rational and Aims 
IBD is a chronic relapsing inflammatory disorder without definitive cure. Current 
medical management of IBD does not treat the cause of disease, and these treatments are 
only effective in reducing the degree of inflammation and accompanying symptoms, but 
typically fail to suppress disease progression in the long term. Anti-inflammatory drugs with 
immune-suppressive functions have shown efficacy in treating IBD which further 
demonstrates the pathogenic role of lymphocytes and proinflammatory cytokines in 
disease progression. Although a range of different anti-cytokine antibodies and biologics 
have been studied in pre-clinical animal models and have in some cases entered clinical 
trial, only several of them have proved be effective in inducing remission in IBD patients. 
While these biologic drugs are in widespread use and are efficacious in many patients, 
some IBD patients remain unresponsive and a substantial proportion loses 
responsiveness during treatment.  Genetic and experimental evidence suggests that the 
IL-23/TH17 pathway is involved in IBD pathogenesis. There is enormous interest from 
researchers and the pharmaceutical industry in targeting the TH17 immune response to 
treat IBD. However, trials of IL-17 antagonism have been disappointing and the detailed 
mechanism of TH17 inflammation in the intestine is only partially understood, particularly 
as it involves multiple interacting cytokines and complex cross-talk between epithelial cells 
and leukocytes.  
 
This project using a unique mouse model of intestinal inflammation, Winnie mice, 
provides an opportunity to investigate the roles of TH17-associated inflammatory cytokines, 
especially IL-23 and IL-17A, in the mucosal inflammation setting. The primary epithelial 
defect and mucosal barrier dysfunction in the Winnie mice results in complex multi-
cytokine mediated colitis involving both innate and adaptive immune components with a 
dominant IL-23/TH17 response which share similarities to patients with IBD. The important 
feature of this model is that the Winnie mice have an epithelial defect with normal 
underlying immunity, making this substantially different to most models of IBD. Therefore, 
targeting TH17 associated cytokines in Winnie mice will provide insights into their role 
within the cytokine milieu in intestinal inflammation and hopefully will suggest improved 
therapeutic approaches to manage IBD. 
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2.1. Central Hypothesis 
Proinflammatory cytokines, especially IL-23 and TH17-associated cytokines 
contribute to the pathogenesis of chronic intestinal inflammation. 
 
2.2. Aims  
The hypothesis will be addressed via the following specific aims: 
 
1. To investigate if IL-17A or IL-17Ra signaling in T cells contributes to the 
intestinal inflammation in the T cell transfer experimental colitis model. 
 
2. To utilize IL-17A cytokine deficient mice to examine the importance of IL-17A for 
initiation and progression of colitis.  
 
3. To assess the efficacy of monoclonal antibodies against TH17 effector cytokines 
or their receptor in suppressing intestinal inflammation.  
 
4. To assess the efficacy of monoclonal antibodies against key TH17 regulatory 
cytokine, IL-23, in suppressing intestinal inflammation. 
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3.0 Materials and Methods 
3.1. Cell culture 
Three different human colorectal carcinoma cell lines were used, LS174T, LS513 
and HT29 (American Type Culture Collection, Manassas, USA). LS174T and HT29 cells 
were cultured in DMEM with 4.5g/L glucose and 0.11g/L pyruvate; and LS513 cells were 
cultured in RPMI1640 (Gibco, Life Technologies, NY, USA). Both media were 
supplemented with 10% FCS, 2 mM L-glutamine and 100U/ml penicillin-streptomycin 
(Gibco, Life Technologies). Cells were maintained in a 37°C incubator with a humidified 
atmosphere of 5% CO2. 
 
3.2. Treatment of cultured cells 
Cells were seeded at selected concentrations as specified in individual experiments 
in 24 or 96 well plates on the day before treatment. After 24 h incubation, cells were 
treated with various cytokines, recombinant human IL-17A, IL-22 and IL-23 (R&D 
Systems, MN, US) or various chemicals:  tunicamycin (Tm, Sigma-Aldrich, MO, US), ROS 
inhibitors-reduced glutathione (GSH, Sigma-Aldrich), NFκB inhibitor (BAY11-7085, Enzo 
Life Sciences, PA, US), Stat3 inhibitor (VI S3I-201), Stat5 inhibitor (573108). All Stat 
inhibitors were obtained from EMD Millipore Bioscience (CA, US). including The 
concentrations and specific treatment regimens used for each drug are described later in 
the results chapters and are indicated in the figure legends. Cytokines were dissolved in 
PBS and chemicals were dissolved in dimethyl sulphoxide (DMSO), with appropriate 
vehicle controls used in all experiments.  
 
3.3. Immunofluorescent staining of cells 
Cells were seeded on top of poly-D-lysine (0.1mg/ml) pre-coated coverslips in 24-
well plates at 1 x 106 cells/ml density. Various treatment regimens were carried out 24 h 
after plating as specified in the figure legends of the results chapters. For 
immunofluorescence staining, cells were fixed in 4% paraformaldehyde for 15 min at room 
temperature, followed by permeabilization with ice-cold methanol for 10 min at −20°C. 
Non-specific binding was blocked with 5% FCS in PBS for 60 min at room temperature. 
Primary antibodies diluted to specific concentrations in PBS supplemented with 1% BSA 
were incubated with cells overnight at 4°C. Cells were washed 3 times with PBS before 
incubation with fluorochrome-conjugated secondary antibodies for 1-2 h at room 
temperature. Coverslips with cells were mounted to slides with Prolong® Gold Antifade 
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Reagent with DAPI (Life Technologies). Fluorescent staining was examined using an 
Olympus BX63® motorized microscope with the cellSens software v.1.7 (Olympus, Tokyo, 
Japan).  
 
3.4. Quantification of intra-cellular reactive oxygen species concentrations by 
2’,7’-dichlorodihydrofluorescein diacetate (DCFDA) 
LS174T cells were seeded in black-walled 96-well plates with serum free media for 
at least 12 h before treatment. Cells were then treated as specified in the figure legends 
for 30 min, and intra-cellular ROS levels were measured.  Cells were pulse-labelled with 
10 µM DCFDA for 10 min at 37°C, followed by washing with warm serum free DMEM 
medium. Cytokines and stimuli were added to induce ROS within cells, which oxidize 
DCFDA into a fluorescent product. After 30 min incubation, fluorescence intensity of 
oxidized DCFDA was measured using a POLARstar Omega plate reader (BMG Labtech, 
Ortenburg, Germany) with excitation wavelength at 495 nm and emission wavelength at 
525 nm. 
 
3.5. Quantification of oxidative stress by dihydroethidium (DHE) oxidization   
To assess the intracellular ROS and oxidative stress level, freshly isolated mouse 
neutrophils were plated in 96-well plate and immediately treated with 2.5 μM 
dihydroethidium (DHE, Sigma-Aldrich) solution for up to 2 h at 37 °C. Cells were then 
washed with room temperature PBS 3 times for 5 min each. In presence of O2
−, cell-
permeable O2
− scavenger DHE is oxidized to fluorescent ethidium bromide which is then 
trapped in the nucleus by interaction with DNA. The number of fluorescent nuclei and the 
intensity of the ethidium fluorescence indicate the relative level of O2
− production. 
Fluorescence intensity was measured with excitation at 535 nm wavelength and emission 
at 610 nm wavelength using a POLARstar Omega plate reader (BMG Labtech).  
 
3.6. Unfolded protein response and ER stress reporter assay 
LS174T cells were transfected with pCAX-F-XBP1∆DBD-venus plasmid (splicing of 
XBP1 messenger RNA [mRNA] by IRE1α results in the translation of Venus-GFP but not 
an active form of XBP1, a gift from Prof. Masayuki Miura) (Iwawaki et al., 2004) using the 
Lipofectamine 2000 reagent according to the manufacturer’s instructions (Life 
Technologies). Briefly, cells were seeded 24 h before transfection. Transfection was 
performed when cells reached 70-90% confluence. One µL of Lipofectamine® 2000 
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Reagent was diluted in 100 µL of Opti-MEM® Medium and 1 µg of plasmid DNA was 
diluted in 100 µL of Opti-MEM® Medium. Then the diluted DNA was added to the diluted 
Lipofectamine® 2000 Reagent (1:1 ratio) and incubated for 15 min at room temperature. 
The DNA-lipid complex was then incubated with cells for 24 h before replacing the media 
with complete DMEM medium. Various treatments were carried out 48 h after transfection. 
Cytokine and drug concentrations are indicated in the figure legends in respective results 
chapters. Venus-GFP signal was detected using a POLARstar Omega plate reader (BMG 
Labtech) with excitation wavelength at 485 nm and emission wavelength at 525 nm. 
 
3.7. Flow cytometry 
Isolated or cultured cells were resuspended at 1 x 106 cells/ml concentration in 
FACS buffer (PBS with 3% FCS, filter sterilized) before staining. Pre-titrated antibody 
cocktails were added into 100 µL FACS buffer containing 1 x 105 cells and incubated on 
ice for 30 min in the dark. Cells were then washed 3 times with FACS buffer to remove 
unbound antibodies. Unstained, isotype antibody stained cells and single colour stained 
cells were included in each run in order to determining the compensation setting on the 
machine before acquisition. Cells were analyzed using CyAn™ ADP Analyzer (Beckman 
Coulter, NSW, Australia) and FlowJo v8.8.6 software.  
 
3.8. Mouse strains and general husbandry 
All mouse strains used in the project are listed below in Table 3.1. All animals were 
housed in PC2 animal facilities including the Mater Annex at the Mater Medical Research 
Institute and the UQ Biological Resource Facility at the Translational Research Institute. 
These facilities were free of Norovirus and Helicobacter pylori infection. All animal 
research and experiment protocols were approved by the Animal Ethics Committee of the 
University of Queensland, and conducted according to National Health and Medical 
Research Council guidelines (Approval number for the project 205/12, Appendix A). 
 
3.9. Mouse monitoring for experiments 
All experimental mice were fed with autoclaved food and water. Sample sizes for 
each animal experiment were determined by Power analysis based on α = 0.05, β = 0.80 
and a change of 2 standard deviations of the mean of the primary outcome measure, colon 
weight. Mixed genders of mice were used in all experiments. Mice were matched for age 
and sex between different strains, and mice in the same cage were randomly allocated to 
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different treatments. For all experiments, the general condition, behavior and bodyweight 
of mice were closely monitored using the scoring sheet for Intestinal Pathology 
Assessment in Mice (Appendix B).  
Table 3.1 Mouse strains used in the project 
Strain Genotype Characters Source 
C57BL/6 C57BL/6JArc Wild type mice Purchased from  
Australian Research 
Council (ARC, Western 
Australia) 
Rag1-/- B6.SVJ129-
Rag1tm1Bal/Arc 
Genetically modified on the 
C57/BL6 background, 
lacking the Rag1 gene 
Purchased from ARC 
Winnie C57BL/6JSfdAnu-
Muc2wnn/AnuApb 
Genetically modified 
through N-ethyl-N-
nitrosourea mutagenesis on 
C57/BL6, have a single 
missense mutation in the 
D3 domain of the MUC2 
mucin gene 
In house 
RaW  Muc2wnn/wnnRag1-/- In house 
IL-17A-/- C57BL/6-
Tg(Scgb1a1-
Il17a)3Cdon/J 
Genetically modified on 
C57BL/6 background, Il17a 
gene expression silenced 
Amgen Inc. (CA,US) 
IL-17A-/-
Winnie 
 Muc2wnn/wnnIL-17A-/-  In house 
IL-17Ra-/- C57BL/6Il17ra-/- Genetically modified on 
C57BL/6 background, 
lacking Il17ra gene 
Amgen Inc. (CA, US) 
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3.10. Transfer model of colitis 
Naïve T cells from wild type, IL-17A-/- and IL-17Ra-/- C57BL/6 donor mice were 
adoptively transferred into Rag1-/- and RaW C57BL/6 recipient mice. Firstly, spleens of 
donor mice were dissected and crushed in PBS. Red blood cells were lysed in ACK lysing 
buffer (1 x PBS containing 155mM NH4Cl, 10mM KHCO3 and 1.0mM EDTA at pH 7.4) for 
5 min on ice. After washing with PBS twice, single cell suspensions were obtained and 
counted under the microscope. More than 95% cell viability was confirmed by Trypan blue 
exclusion assay. CD4+ T cells were enriched using the mouse CD4+ T Cell Isolation Kit 
(Miltenyi Biotech, Germany) according to the manufacturer’s instruction. Briefly, single 
cells were labeled with a cocktail of biotin-conjugated antibodies against non-CD4 
antigens. Cells were then labeled with anti-biotin magnetic micro beads. The bead-bound 
non-CD4 cells were depleted by retaining on a MACS® Column (Miltenyi Biotech) in the 
magnetic field of an Auto MACS Separator (Miltenyi Biotech), while the unlabeled CD4+ 
cells were enriched through the column. Isolated CD4+ T cells were then stained and 
sorted on a FACS ARIA flow cytometer (BD Biosciences, CA, US) to obtain a pure 
CD4+CD62Lhi naive T cell population. Naive T cells (0.5 x 106/mouse) were transferred i.p. 
into Rag1-/- and RaW recipients. Bodyweight and behavior of mice were closely monitored 
after transfer. Mice were sacrificed to assess histological inflammation due to ethical 
requirements if they reached 80% or less of their original body weight. 
 
3.11. Antibody, cytokine and drug treatments in mice 
Antibodies, cytokines and drugs used are listed in Table 3.2. All reagents were 
reconstituted in sterile PBS. The dose and route of administration were chosen based on 
previous studies in experimental inflammatory diseases in mice. An isotype antibody or an 
irrelevant protein molecule was included in each experiment as a control, with the same 
concentration and delivery route. 
 
Table 3.2 Antibody, cytokine and drug information for mouse experiments  
Name Concentration Delivery route Source 
anti-IL-17A 0.5 mg/mouse  i.p. weekly A gift from Amgen Inc. 
anti-IL-17F 0.5 mg/mouse  i.p. weekly A gift from Amgen Inc. 
anti-IL-17E 0.5 mg/mouse  i.p. weekly A gift from Amgen Inc. 
anti-IL17Ra 0.5 mg/mouse  i.p. weekly A gift from Amgen Inc. 
37 
 
 
anti-p19 3 mg/kg weight s.c. biweekly A gift from Eli Lilly 
anti-p40 10 mg/kg weight s.c. biweekly A gift from Eli Lilly 
 
3.12. Mouse tissue end-point collection 
At the end of each experiment, tissues and organs were collected for assessment of 
intestinal inflammation. mLNs were collected for leukocyte stimulation and cytokine 
analysis. The whole colon, the caecum and ileum (distal 1/3 part of the small intestine) 
were removed from the mouse. Each segment of the intestine was opened longitudinally 
and the fecal contents were gently removed. Colon weight was measured and then the 
colon was dissected longitudinally into two sections. One of the sections was rolled (Swiss 
rolled) from the rectum along with cecum and ileum and fixed in 10% formalin. Swiss roll 
samples were used for histological examination and staining. The other section of the 
colon was dissected in equal halves, designated as ‘proximal’ and ‘distal’ colon and snap 
frozen in dry ice for later protein and RNA analysis.  
 
3.13. Nucleic acid extraction and synthesis 
Nucleic acid from tissues and cells were extracted as described below. Samples 
from individual experiments were processed at the same time in order to minimize batch to 
batch variation. Total yield and purity of the extracted nucleic acid was measured by the 
NANODROP1000 (NanoThermo,Thermo Fisher Scientific, MA, USA). The nucleic acid 
quantity was expressed as ng per μL and the purity was valuated based on the A260/280 
ratio. The extracted nucleic acids were kept at -70°C for long-term storage.  
 
3.14. Genomic DNA extraction  
Genomic DNA was extracted from mouse blood and tissue samples using Qiagen 
DNeasy Blood & Tissue Kit following the manufacturer’s instructions. Around 180 μl of 
mouse blood samples were collected into 1.5 ml tubes with pre added 20 μl of Protease K. 
Samples were thoroughly mixed by vortexing after adding 200 μl of buffer AL and 
incubated at 56°C for 10 min. 200 μl of ethanol (96–100%) was added to samples followed 
by vortexing. The sample mixtures were then loaded into the DNeasy Mini spin column. 
After washing the membrane with 500 µL washing buffer AW1 twice, DNA was eluted in 
buffer AE by centrifugation. From 100 μl of blood, 3 – 6 μg of genomic DNA was usually 
isolated. Mouse tail tip samples usually yielded 10 – 20 μg of DNA.  
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3.15. RNA extraction  
Total RNA was extracted from tissue and cell samples using Trizol (Invitrogen) in 
combination with the High Pure RNA Isolation Kit (Roche). Firstly, up to 1 x 106 cells or 0.1 
g of tissues were homogenized in 500 μl of Trizol reagent (Life Technologies) using a 
FastPrep-24 machine (MP Biomedicals, CA, US) with the lysing Matrix Beads (MP 
Biomedicals).  200 μl of chloroform was added into the tissue-Trizol mixture and vortexed 
till mixed well. The mixture was then centrifuged at 12,000 g for 20 min at 4°C.  The top 
aqueous layer containing RNA was carefully aspirated and transferred to a new tube and 
three volumes of 70% ethanol was added to precipitate the RNA.  The ethanol RNA 
mixture was transferred to Roche spin column and centrifuged. The overflow liquid was 
discarded and DNase treatment was performed by incubating 100 μl of DNase solution 
with the membrane for 20 min at room temperature. After incubation, the membrane was 
washed twice with RW1 wash buffer. The column was then dry spun for 2 min to clean up 
the membrane. To the dried column, 50 μl of RNAase free water was added and allowed 
to incubate for 1 min at room temperature before centrifugation. Eluted RNA was checked 
with NANODROP1000 for concentration and purity. From 50mg of mouse colonic tissue, 
around 50 to 150 μg of RNA was usually obtained.  
 
3.16. Synthesis of complimentary DNA  
Complimentary DNA (cDNA) was synthesized from total RNA using an iScript cDNA 
synthesis kit (Bio-Rad, CA, USA) according to the manufacturer’s instruction. Briefly, 1 μg 
of total RNA, 4 μL of 5 x iScript reaction mix (containing oligo dT and random hexamer as 
primer) and 1 μl iScript reverse transcriptase were mixed and toped up to 20 μl total 
volume with RNAase free H2O. The reaction program was, 25°C for 5 min, 42°C for 30 min 
and 85°C for 5 min. cDNA was then diluted 1 in 10 with DNAase free H2O for polymerase 
chain reaction. 
 
3.17. Polymerase Chain Reaction (PCR) 
3.17.1 Designing of oligonucleotide primers 
To design oligonucleotide primers for PCR reactions, the reference sequence of 
messenger RNA was obtained online from Genome Browser website (URL: 
http://genome.ucsc.edu/cgi-bin/hgGateway) and Primer 3 software v.0.4.0 (URL: 
http://bioinfo.ut.ee/primer3-0.4.0/primer3/input.htm) was used to design primers with exon-
spanning. The primer specificity was checked using nucleotide BLAST (NCBI, US). All 
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primers were obtained from GeneWorks (SA, Australia). Primer annealing temperature 
was determined first through gradient PCR. PCR conditions were deemed optimal if only a 
single PCR product of the correct size was amplified. For real-time PCR, the lowest primer 
concentration to give ≥ 95% efficiency without formation of primer dimers was used. All 
primers used for quantification of gene expression and their sequences are listed in Table 
3.3.  
 
Table 3.3 Primer sequences used for quantification of gene expression by real time PCR 
Genes Primer sequences (5’ - 3’) Annealing 
temperature (°C) 
Product 
size (bp) 
Primers for mouse genes 
Atoh1 GCTTCCTCTGGGGGTTACTC 
GAAGGCGACAGGTCCTTCTG 
60 104 
Ccl1 ACCATGAAACCCACTGCCAT 
GTAAGCATGCTCTTGCTGTCAA 
60 86 
Ccl22 CCTCTGATGCAGGTCCCTATG 
GCAGAGGGTGACGGATGTAG  
60 75 
Ccl3 CGTTCCTCAACCCCCATC 
TGTCAGTTCATGACTTTGTCATCAT 
60 91 
Ccl4 CTAACCCCGAGCAACACCAT 
GAGCCCATTGGTGCTGAGAA 
60 101 
Ccl5 ATATGGCTCGGACACCACTC 
GTGACAAACACGACTGCAAGA 
60 123 
Cxcl10 TCCTTGTCCTCCCTAGCTCA 
ATAACCCCTTGGGAAGATGG 
60 124 
Cxcl9 TGGAGTTCGAGGAACCCTAGT 
TTGTAGTGGATCGTGCCTCG 
60 78 
Gapdh AGCCCAAGATGCCCTTCAGT 
GACGTGCCGCCTGGAGAAAC 
60 92 
Grp78 TGCTGCTAGGCCTGCTCCGA 
CGACCACCGTGCCCACATCC 
60 257 
Hes1 GGTCCTAACGCAGTGTCACC 60 120 
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GAGAGGTGGGCTAGGGACTT 
Ifng GCTTTGCAGCTCTTCCTCAT 
GTCACCATCCTTTTGCCAGT 
60 162 
Il10 AGCTCCAAGACCAAGGTGTC 
TCCAAGGAGTTGTTTCCGTTA 
60 195 
Il12b GACCATCACTGTCAAAGAGTTTCTAGAT 
AGGAAAGTCTTGTTTTTGAAATTTTTTAA 
60 153 
Il17a CTCCAGAAGGCCCTCAGACTAC 
AGCTTTCCCTCCGCATTGACACAG 
60 141 
Il17f ATGTTGGGACTTGCCATTCT 
ACAGAAATGCCCTGGTTTTG 
60 155 
Il17ra GAAAACCGCCACCGCTTAC 
AGTGTTTCCTCTACCCAGCAC 
60 194 
Il1b GATCCACACTCTCCAG CTGCA 
CAACCAACAAGTGATATTCTCCATG 
60 152 
Il22 CCGAGGAGTCAGTGCTAAGG 
CATGTAGGGCTGGAACCTGT 
60 106 
Il23a GTCCTAGTAGGGAGGTGTGAAGTTG 
AGCGGGACATATGAATCTACTAAGAGA 
60 245 
Il23r TGTCACGGAGGAATCACAAG 
TGTGCATGTGAAGAGTTTGGA 
60 132 
Il6 TCAGGAAATTTGCCTATTGAAA 
GGAAATTGGGGTAGGAAGGA 
60 196 
Mip2a ACGTGTTCCAGGACACAACA 
ACAAACCCTCCCCACCTAAC 
60 181 
Muc2 CCATTGAGTTTGGGAACATGC 
TTCGGCTCGGTGTTCAGAG 
55 104 
Spdef AAAGCCACTTCTGCACGTTACCAG 
GTTGCCTGCTACTGTTCCCAGATG 
59 408 
sXbp1 GAGTCCGCAGCAGGTGC 
CAAAAGGATATCAGACTCAGAATCTGAA 
60 102 
41 
 
 
Tbp 
(Tata box binding 
protein) 
GGGAGAATCATGGACCAGAA 
CCGTAAGGCATCATTGGACT 
60 113 
Primers  for human genes 
ATOH1 AACGCCTTGTCCGAGCTGCTA 
TTTTGCAGGAGGCTGGAG 
60 73 
GAPDH CCTGTACGCCAACACAGTGC 
ATACTCCTGCTTGCTGATCC 
60 211 
GRP78 GCCTGTATTTCTAGACCTGCC 
TTCATCTTGCCAGCCAGTTG 
60 150 
HES1 AGTGAAGCACCTCCGGAA 
TCACCTCGTTCATGCACTC 
43 113 
IL8 TGCAGCTCTGTGTGAAGGTGCAG 
TGTGTTGGCGCAGTGTGGTCC 
60 145 
LGR5 TCACCTTCCCCAGGCCCCTT 
CGCATCCACACCAGCCAGCA 
60 231 
MUC2 CAGCACCCATTGCTGAGTTG 
GCTGGTCATCTCAATGGCAG 
55 140 
SPDEF GCACTGCAGCAGACA 
GGGGATACGCTGCTC 
59 105 
sXBP1 GAGTCCGCAGCAGGTGC 
CAAAAGGATATCAGACTCAGAATCTGAA 
60 102 
 
3.17.2 Quantification of gene expression by SYBR Green real-time PCR 
Gene expression levels were determined by quantitative real-time PCR in 384-well 
plate format using SYBR Premix Ex Taq (Takara, Shiga, Japan) and Applied Biosystems® 
HT7900 or ViiA™ 7 Real-Time PCR Systems (Life Technologies). The total PCR reaction 
volume is 7.5 µL and master mix contents, and concentrations of each component are 
listed in Table 3.4. qPCR thermocycling conditions were 40 cycles amplification including 
15 s at 95°C and 60 s at annealing temperature with an initial hold cycle for 10 min at 
95°C. The selected annealing temperatures of individual primers are listed in Table 3.3.   
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Table 3.4 qPCR reaction master mix contents. 
Reagent Volume Final Concentration 
SYBR® Premix Ex Taq II (2×) 3.75 μl 1 × 
Forward Primer (2 μM)  0.75 μl 0.2 μM 
Reverse Primer (2 μM) 0.75 μl 0.2 μM 
ROX Reference Dye (50 × ) 0.15 μl 1 × 
Template (< 100 ng) 2.5 μl − 
dH2O (sterile distilled water) 0.35 μl − 
Total 7.5 μl − 
 
3.18. Histological staining, morphometry and assessment of colitis 
3.18.1 H&E staining 
Formalin fixed tissue samples were processed into paraffin blocks and sections with 
the help of QIMR Histology Service and TRI Histology Service. After de-waxing in Xylene 
and re-hydrating through ethanol gradients (100%, 95%, 90% 70% and dH2O), paraffin 
sections were placed in Haematoxylin reagent (Gill’s formula, No.2, Sigma-Aldrich) for 30 
s and then washed under running tap water for 5 min.  Slides were then placed in Eosin Y 
reagent (Sigma-Aldrich) for 30 s. After Eosin staining, slides were dehydrated in 90%, 
100% ethanol and xylene, followed by mounting with Pertex® mounting medium (Medite, 
Burgdorf, Germany) and examination under a bright field microscope for histology. 
 
3.18.2 Immunohistochemistry  
Paraffin embedded tissue sections were de-waxed in xylene, re-hydrated through 
ethanol gradients (100%, 90% and 70%) and placed in PBS. Different antigen retrieval 
methods were used for different antigens. For Muc2 staining, slides were boiled in citric 
acid buffer (10 mM citric acid and 0.05% Tween-20, pH 6.0) for 20 min in a microwave 
oven. For neutrophil staining, slides were treated with Medical Diva retrieval buffer 
(Biocare Medical) for 15 min at 105 °C using the Biocare Medical decloaking chamber. For 
F4/80 staining, Carezyme I Trypsin Kit (Biocare Medical) was used according to the 
manufacturer’s instructions. Briefly, slides were incubated with 1 in 2 diluted trypsin 
concentrate solution for 15 min at room temperature. After antigen retrieval steps, the 
endogenous hydrogen peroxidase activity was quenched by incubating slides with 3% 
hydrogen peroxidase in PBS for 10 min. Sections were then blocked with 10% KPL 
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blocking solution (KPL Inc, USA) in PBS for 1 h at room temperature. Each primary 
antibody was titrated first to define the optimal staining concentration. For Muc2, 1 in 500 
diluted rabbit anti-mouse Muc2 antibody (Muc2.3) was incubated with slides overnight at 
4°C. For neutrophil staining, rat anti-mouse Ly-6G/6C (clone: NIMP-R14, Abcam) antibody 
was diluted 1 in 100 in Biocare Medical Da Vinci Green and incubated with sections 
overnight at 4°C. For F4/80, rat anti-mouse F4/80 antibody (clone: A3-1, Abcam) was 
diluted 1 in 350 in PBS with 5% FCS and applied with sections for 90 min at room 
temperature. After incubation with primary antibody, slides were washed 3 times in PBS. 
HRP-conjugated secondary antibodies against the species primary antibody raised in were 
incubated with sections for 2 h at room temperature. Unbound antibodies were washed 
with PBS and signal was detected using diaminobenzidine solution (Dako, CA, US). After 
counter-stained with haematoxylin, sections were dehydrated ethanol gradient and Xylene 
before mounting with Pertex® mounting medium (Medite).  
 
3.18.3 Immunofluorescent staining on tissue section 
Immunofluorescent staining was performed on tissue sections. For tissue samples, 
the same procedures were followed as immunohistochemistry staining except sections 
were incubated with a fluorochrome conjugated secondary antibody and mounted with 
ProLong® Gold Antifade Reagent with DAPI (Life Technologies). Staining was examined 
using BX63 Motorized Upright Microscope (Olympus). 
 
3.18.4 Alcian blue and periodic acid Schiff’s (PAS) staining 
Alcian blue and periodic acid Schiff’s staining was used to assess the goblet cell 
mucin storage. After de-waxing in xylene and re-hydrating through ethanol gradients, 
paraffin sections were placed in Alcian blue solution (1% Alcian blue in 3% acetic acid, pH 
2.5) for 10 min and washed under running tap water. Then slides were treated with 1% 
periodic acid for 5 min and washed with dH2O before staining in Schiff’s fuchsin-sulfite 
reagent  (Sigma) for 10 min. Slides were washed under running tap water for 5 min and 
then counterstained with haematoxylin (Gill’s Formula No.2, Sigma) for 30 s, dehydrated 
and mounted with Pertex® mounting medium (Medite). 
 
3.18.5 Morphometry 
To quantify positive staining in tissue sections after immunohistochemistry and 
histochemistry staining, multiple pictures from areas with longitudinally sectioned crypts 
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were taken randomly using an Olympus bright field microscope with a 40× lens in order to 
keep sampling process unbiased.  In each image, positive staining was defined by RGB 
pixel picking tool in NIS-Elements software v.3.0 (Nikon, Tokyo, Japan). The percentage of 
the longitudinally sectioned crypt area occupied by positive staining was calculated (Figure 
3.1) for multiple crypts within each specimen and the average for that specimen 
determined, and used for statistical analysis. 
 
Figure 3.1  Quantification of positive staining by using NIS-Elements software. Positive staining 
was defined by RGB pixel picking tool in NIS-Elements software. For example, to quantify goblet 
cell volume in a longitudinally sectioned crypt, the percent of positive staining per crypt is 
calculated as the area covered by positive staining divided by the area of the crypt.  
 
3.19. Histological scoring of colitis 
H&E stained mouse intestinal sections were scored microscopically in a blinded 
manner by RW and MAM including assessments of crypt architecture, crypt abscesses, 
tissue damage, goblet cell depletion, inflammatory cell infiltration and local neutrophil 
counts. Crypt length was measured using cellSens software (Olympus). The maximum 
combined score for each part of the intestine was 25 as per a standard scoring system 
(Appendix B). 
Positive staining area = 2034 px2
% of positive staining per crypt = area covered by positive staining / area of the crypt
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3.20. Mesenteric lymph node (mLN) culture 
Mouse mesenteric lymph nodes were dissected from mesenteric fat. After carefully 
removal of the connective and adipose tissue, mLNs were crushed and filtered through a 
40μM cell strainer. A single cell suspension of leukocytes were resuspended in RPMI 1640 
medium supplemented with 10% FCS, 2 mM L-glutamine, 200 U/ml penicillin and 200 
µg/ml streptomycin. 2 x 106 cells were plated in 24-well plate (1ml per well) and stimulated 
with anti-CD3 and anti-CD28 antibodies (eBioscience) for 48 h. Culture supernatants were 
collected and stored at -80°C for further analysis. 
 
3.21. Colonic epithelial cell isolation  
To prepare colonic epithelial cells, mouse colons were opened longitudinally, rinsed 
with PBS and then Hanks' Balanced Salt solution (HBSS) with 200 U/ml penicillin and 200 
µg/ml streptomycin for four times to remove the fecal content. Washed colons were cut 
into approximately 1 cm pieces and digested in HBSS with 5 mM EDTA and 1 mM DTT at 
37°C in a shaking water bath for 15 min. The epithelial cells were then dislodged from the 
muscular layer and submucosa by vigorous shaking for 20 s. The supernatant containing 
crypts was pooled together from sequential digestions. After settling at 1 x g for 5 min, the 
supernatant was discarded. Crypts containing colonic epithelial cells were washed with 
PBS and collected by further centrifugation at 500 x g for 5 min. The pellet containing 
crypts was snap frozen on dry ice then stored at -80°C for further analysis.  
 
3.22. Cytokine quantification by enzyme linked immunosorbent assay (ELISA) 
Cytokines were measured in mLN culture and cell line culture supernatants using 
commercially available enzyme linked immunosorbent assay (ELISA) kits. Mouse IL-17A, 
IL-17F and human IL-8 levels were detected by kits from R&D System, and all other 
cytokines were detected by kits from BD Biosciences following the manufacturer’s 
instructions. Briefly, cytokine concentrations were quantified using double determinant 
assay systems with capture, detection antibody and horseradish peroxidase (HRP) 
conjugates. Antibody binding was visualized by adding a tetramethylbenzidine (TMB) 
chromagen and hydrogen peroxide substrate solution mixture. Development of color was 
stopped by the addition of 50 μl 1N H2SO4. Color absorbance was measured at 450 nm 
wavelength with correction at 570 nm wavelength using a iMark™ Microplate Reader (Bio-
Rad, CA, US). A 4-parameter logistic standard curve was generated with each assay using 
the MPM6 software v.6.1 (Bio-Rad). Samples having an absorbance value falling out of 
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the top range of the standard curve were diluted and re-measured. Samples having an 
absorbance value falling out of the bottom range of the standard curve were given the 
concentration of the lowest standards.  
 
3.23. Mouse peritoneal polymorphonuclear cell (PMN) isolation 
To isolate PMN from the mouse peritoneal cavity, mice were administered 1 ml of 9% 
(w/v) casein (sodium salt, Sigma-Aldrich) in PBS (with 0.9 mM CaCl2 and 0.5 mM MgCl2). 
After overnight development of the inflammatory response, the casein injection was 
repeated the next morning with or without recombinant IL-23 (50 µg/kg). Three hours after 
the second injection, mice were euthanized by carbon dioxide asphyxiation. For PMN 
harvest, a ventral midline incision on the mouse abdominal skin was made with scissors, 
the abdominal skin was retracted with forceps and the intact peritoneal wall was exposed. 
Five ml of sterile harvest solution (PBS with 0.02% EDTA, filter sterilized) was injected into 
the mouse peritoneal cavity using a 21-G needle. After gentle massage the abdomen of 
the mouse, peritoneal fluid with PMN was taken out via a 21-G needle and transferred to a 
50 ml sterile falcon tube. The process was repeated in order to remove the remaining cells 
from the mouse peritoneum. Harvested cells were washed with PBS (calcium and 
magnesium free) and counted with viability assessment by trypan blue exclusion. PMNs 
were purified by Percoll density gradient centrifugation:  3-5 x 104 peritoneal exudate cells 
resuspended in 1 ml of PBS were mixed with 9 ml of Percoll gradient solution in a 10 ml 
Beckman ultracentrifuge tube followed by ultracentrifugation at 60,650 x g for 20 min, 4°C. 
PMN was collected from the second opaque layer of the tube and washed with PBS twice. 
PMN number and viability were checked by trypan blue dye exclusion assay. More than 95% 
cell purity was confirmed by Giemsa staining after each isolation.  
 
3.24. Immunoblot analysis  
LS174T cells were seeded in 6-well culture plates at 80% confluence. After 
overnight attachment, LS174T cells were treated with recombinant human TNF-α (50 
ng/ml, R&D System) and IL-23 (50 ng/ml, R&D System) for different time points (see 
Figure 6.10 legend for details). Then cells were collected, washed twice with cold PBS, pH 
7.4 and then lysed on ice for 45 min with RIPA cell lysate buffer (RIPA buffer: 50 mM Tris-
HCI, pH 7.5, 150 mM NaCI, 1.0 % Nonidet  P-40, 0.1% sodium deoxycholate, and 1.0% 
protease inhibitor cocktail) while stirring every 5 min.  The resulting lysates were 
centrifuged at 16,000 g for 20 min at 4°C to remove cell debris.  Aliquots of the cell lysates 
47 
 
 
from each treatment condition were resuspended in SDS-PAGE Laemmli buffer (0.05M 
Tris-HCI, pH 6.8, 1% 2-mercaptoethanol, 1.0% SDS, 5% glycerol, and 0.15 bromophenol 
blue), boiled for 5 min at 100°C, and resolved on 4-12% acrylamide gel.  Resolved 
proteins were transferred to polyvinylidene difluoride (PVDF) membranes, probed with 
anti-β-actin (Novus Biologicals, Littleton, CO, USA), anti-NF-ĸBp65 (phospho-536, Cell 
Signaling Technology) and phospho-468, Cell Signaling Technology), anti-phospho-IĸBα 
(Cell Signaling Technology), or anti-phospho-p38 (Cell Signaling Technology) antibodies, 
followed by appropriate secondary antibody labelling. Detection was performed by dual-
label infra-red analysis on ODYSSEY® CLx machine (LI-COR, NE, US). Data was 
analyzed using Odessay v.3.0 software. 
 
3.25. MUC2 quantification by inhibition ELISA 
 Supernatants (containing secreted MUC2) and cell lysates (containing intra-cellular 
MUC2) were collected from LS174T cells after various treatments. Samples were first 
reduced using 50 mM DTT and then alkylated by 0.125 M iodoacetamide before further 
analysis. Human MUC2 antibody (Santa Cruz Biotechnology) was used to determine the 
levels of intra-celullar and secreted MUC2 using an enzyme-linked immunosorbent 
inhibition assay we previously described (Devine et al., 1993). Briefly, purified MUC2 was 
coated onto assay plates overnight, wells were washed and non-specific binding blocked 
with 2% BSA in PBS, and standards containing MUC2 or samples diluted in 2% BSA 
containing diluted anti-MUC2 antibody in PBS introduced into the wells. In this inhibition 
assay MUC2 in standards or samples inhibits antibody binding to the MUC2 coated onto 
the plate. MUC2 concentrations are presented as arbitrary units/ml using standard curves 
derived from purified LS174T MUC2.  
 
3.26. Statistical analysis 
Statistical analyses were performed using GraphPad PRISM version 5.01 
(GraphPad Software, Inc, California). To compare differences between groups, the 
Kolmogorov-Smirnov test was performed to confirm if values come from a normal 
distribution. If data appeared log-normally distributed, values were log transformed before 
assessing the normality of the distribution, and if so then log-transformed values were 
used for subsequent parametric analysis. Parametric tests (One-way ANOVA with 
Bonferroni’s multiple comparison test) were performed after confirmation of a normal 
distribution, or, where a normal distribution could not be confirmed or sample size was 
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small, non-parametric Mann-Whitney U-tests or the Kruskall-Wallis test with a post-hoc 
test were performed as indicated in the figure legends. For survival analysis, the Log-rank 
(Mantel-Cox) test was used to compare difference between two groups.   
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4.0  Roles of IL-17A - IL-17Ra Axis in Experimental 
Models of Colitis 
4.1. Overview  
Although TH17 cells are involved in the pathogenesis of several autoimmune 
diseases and inflammatory disorders such as psoriasis, multiple sclerosis and rheumatoid 
arthritis, and are generated in large amounts during intestinal inflammation (Tesmer et al., 
2008), the actual role of the TH17 effector cytokines in intestinal inflammatory pathology is 
less clear. Contradictory findings have been reported in different murine models of colitis. 
In a T cell dependent colitis model, lymphopenic Rag1-/- mice transferred with IL-17A 
deficient naïve T cells develop exacerbated colitis compared to recipients of wild-type 
(WT) T cells. Increased IFN-γ levels were found in the intestinal mucosa of mice lacking T 
cell-derived IL-17, which indicated that IL-17A cytokine production by T cells exerts 
protection by antagonizing production of another pro-inflammatory cytokine, IFN-γ 
(O'Connor Jr et al., 2009). In an acute experimental colitis model, IL-17A-/- mice had 
exacerbated DSS-colitis compared to WT (Yang et al., 2008a). However, another T cell 
transfer study showed that neither IL-17A nor IL-17F is necessary for T cell transfer-
induced colitis (Izcue et al., 2008). Therefore, the physiological role of the IL-17A - IL-17Ra 
pathway in intestinal inflammation and colitis progression needs further examination.  
 
The T cell transfer model of colitis has been extensively studied and widely 
employed as an experimental colitis model in the past decade (Powrie et al., 1993). It is 
the best-characterized model of colitis induced by disruption of T cell homeostasis. In this 
model, donor naive T cells are transferred into a severe lymphopenic host such as SCID or 
Rag1/2-deficient mice. In the absence of regulatory T cells and anti-inflammatory 
cytokines, donor naïve T cells induce severe colonic and small intestinal inflammation with 
the time post-transfer to develop colitis dependent on the microbial flora in the animal 
facility. Histopathological changes in the distal colon include mucosal inflammation, 
epithelial cell hyperplasia, goblet cell depletion, polymorphonuclear and mononuclear cell 
infiltration, crypt abscesses and epithelial erosion. Recipient mice exhibit varying degrees 
of diarrhoea, rectal bleeding, and body weight loss depending on the strains of donor and 
recipient mice (Powrie et al., 1993). The significant advantage of this model is that T cell-
mediated immune responses and inflammation can be examined (Ostanin et al., 2009). At 
the same time, T cell transfer colitis develops in a lymphopenic host, which does not reflect 
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the nature and complexity of human colitis. Thus findings from this model need to be 
confirmed with other relevant experimental colitis models.  
 
In mice a wide range of genetic defects (gene knock-out or mutations) develop 
spontaneous intestinal inflammation.  These models are useful when studying the effects 
of gene deficiency in the development of colitis and intestinal inflammation. Unlike T cell 
transfer induced colitis, murine models of genetic deficiency allow study of the roles of 
cytokines from a more systemic perspective.  
 
In this chapter, to evaluate the role of the IL-17A - IL-17Ra axis in T cells, the naïve 
T cell-induced transfer colitis model was used. IL-17A-/- or IL-17Ra-/- T cells were 
transferred into immunodeficient recipient Rag1-/- mice. Rag1-/- recipients with an epithelial 
defect arising from Winnie allele were included to examine the contribution of a defect in 
intestinal epithelial integrity to development of colitis. To investigate the physiological role 
of IL-17A in intestinal inflammatory pathology, IL-17A-/-Winnie mice were generated by 
crossing IL-17A-/- mice with Winnie mice. Intestinal inflammation of mice was assessed at 
8 weeks and 14 weeks of age to study the contribution of IL-17A to the development and 
progression of colitis.  
 
4.2. Methods 
4.2.1 Naïve T cell transfer model of colitis 
Purified naïve T cells were transferred into 6 week old Rag1-/- or RaW mice (Rag1-/- 
carrying the Winnie mutation in Muc2, see 3.10 for details).  Colitis development was 
closely monitored by bodyweight measurement and observation of behavior. Mice were 
sacrificed on ethical grounds when bodyweight loss was more than 20% of their initial 
weight.  The experiment was stopped when any whole group of mice had been sacrificed 
due to colitis or otherwise at 12-14 weeks post-transfer (Figure 4.1).  
 
4.2.2 Generation of IL-17A-/-Winnie mice 
IL-17A-/-Winnie mice were generated by cross breeding IL-17A-/- mice and Winnie 
mice. Blood or tissue samples were obtained from their litters to isolate genomic DNA and 
determine the genotype. Both Winnie and Il17a alleles were genotyped by PCR and only 
litters with the right genotype were selected to breed. 
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Figure 4.1 Experiment outline of the transfer model of colitis 
 
Winnie allele genotyping – allelic discrimination assay 
To genotype the Winnie allele, primers and Taqman probes against the single-
nucleotide polymorphism (SNP) in Muc2 gene were designed (Table 4.1, Applied 
Biosystems, Life Technologies). PCR reaction constituents are listed in Table 4.2, and 
conditions are summarized in Figure 4.2 A. Results were analyzed using Rotor Gene 6000 
software (Qiagen, Australia). Basically, the reaction threshold was set to 0.1 to determine 
amplified or non-amplified reactions. Samples that yielded a product in FAM-Green 
channel, but no product in the VIC-Yellow channel were genotyped as Winnie. Samples 
that yielded a product in the VIC-Yellow channel, but no reaction in the FAM-Green 
channel were genotyped as wild type. Samples producing products in both channels were 
defined as Winnie+/- (Figure 4.2 B, C).  
 
Table 4.1 Primer and probe information of Winnie allelic discrimination assay 
SNP name Sequences 
Forward primer TCTTCCCAAGCTGGAGACTCTT 
Reverse primer TGAAGTCATTTTTTGGTCTGGTCATCA 
Wild type allele probe - VIC (Yellow) AGGGCACTATATGTGGTCT 
Winnie allele probe - FAM (Green) AGGGCACTATATATGGTCT 
IL-17A-/- or 
IL-17Ra-/- mice 
Naïve T cellsNaïve T cells
Sacrifice
Colitis development 
12 to 14  weeks
Donors
Recipients
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Table 4.2 Master Mix contents of Winnie allelic discrimination assay 
Reagents Volume for 1 reaction (µL) Final Concentration 
2 x TaqMan universal PCR master mix 5 1 x 
20 x working stock of SNP 0.5 1 x 
DNase-free H2O 3.5 − 
DNA template (10 ng/μl) 1 1 ng/μl 
Total 10 − 
 
 
Figure 4.2 Winnie allele genotyping – allelic discrimination assay. (A) Assay program on Rotor-
Gene 6000. (B) Allelic discrimination assay results on Winnie, Winnie+/- and wild type mice 
control samples (C) Gene amplification plot for 40 PCR cycles. Threshold set to 0.1 to 
differentiate amplified vs non-amplified reactions.   
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Il17a allele genotyping  
To genotype the Il17a allele, primers of the Il17a allele were designed to amplify the 
inserted Scgb1 sequence which yields a bigger product. Primers were designed using 
Primer3 software and obtained from Geneworks. Primer sequences and PCR master mix 
contents are listed in Table 4.3 and Table 4.4. The PCR reaction included a hot start at 95° 
for 10 min, followed by 40 cycles of amplification with 15 s at 95°C, 30 s at 60°C and 30 s 
at 72°C, finished by final extension stage at 25°C for 10 min. PCR products were checked 
using 1% agarose gel, with an example of results in Figure 4.3.  
 
 
Table 4.3 Primer information for Il17a allele genotyping 
Primers Sequences 
Il17a+/+ allele (forward primer) TACAAGGCGCTTGTTGATTG 
Il17a+/+ allele (reverse primer) TCATCACAGCAACCCTTCAG 
Il17a-/- allele (forward primer) TACAAGGCGCTTGTTGATTG 
Il17a-/-  allele (reverse primer) TACTACCAGCAACCCTTCAG 
 
 
Table 4.4 Master Mix contents of Il17a allele PCR 
Reagents Volume for 1 reaction (µL) Final Concentration 
SensiMix HRM™ 6.25 1 x 
Il17a+/+  primer mix (10 µM) 1 0.8 µM 
Il17a-/-  primer mix (10 µM) 1 0.8 µM 
DNase-free H2O 2.25 − 
DNA template (10 ng/μl) 2 1.6 ng/μl 
Total 12.5 − 
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Figure 4.3  Il17a genotyping PCR products of wild type (Wt), heterozygous (Het) and knockout 
(Ko) control DNAs on 1% Agarose gel 
 
4.2.3 Characterization of IL-17A-/-Winnie mice 
It is known that Winnie colitis progresses while aging. In order to examine the role 
of IL-17A cytokine in colitis initiation and progression, 8 and 16 week old C57BL/6, IL-17A-
/-, Winnie and IL-17A-/-Winnie mice were sacrificed to examine the intestinal inflammation. 
Mice colon, caecum and terminal ilium were dissected and colon weight was measured 
(see 3.10 for details). Proximal and distal colons were dissected accordingly for 
histological colitis examination (see 3.19 for details).  Proinflammatory cytokine gene 
expression was measured in both proximal and distal colon tissue samples by qRT-PCR. 
Gene expression was corrected to each sample’s housekeeping gene first before being 
normalized to the average of the control group (see 3.17.2 for details). 
 
4.3. Results 
4.3.1 Mice with an epithelial defect develop more severe transfer colitis but IL-17A 
deficient and wild type T cells are equally colitogenic 
We have previously reported that the progression of Winnie colitis is associated 
with T lymphocyte expansion and activation in the mLNs, especially TH17 cells. This was 
confirmed and characterized by using T and B lymphocyte deficient Rag-/- mice carrying 
Winnie alleles (RaW mice, see chapter 1.4.4 for details) (Eri et al., 2011). Here, in order to 
500bp Il17a-/- allele product
206bp Il17a+/+ allele product
Wt Ko Het
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use Rag-/- and RaW mice as transfer colitis recipients and further investigate the role of 
naïve T cells in driving transfer colitis development, we monitored the body weight change 
of Rag-/- and RaW mice over the time period of 14 weeks starting from 6 weeks of age as 
well as the histological colitis at the end of monitoring. Both naïve Rag-/- and RaW mice 
showed progressively increasing body weight over the 14 weeks (Figure 4.4 A).  However, 
on sampling at 20 weeks of age, RaW mice had higher colon weights and histological 
colitis scores in proximal and distal colon than Rag-/- mice (Figure 4.4 B,C). Elevated 
spontaneous colitis in RaW mice suggests that epithelial defect initiates mild innate local 
intestinal inflammation that develops in the absence of lymphocytes.  
 
Figure 4.4 RaW mice develop mild spontaneous colitis. (A) Body weight monitoring over 14 
weeks starting from 6 weeks (percentage of initial weight in Rag1-/- and RaW mice). (B) Colon 
weight, and (C) Histological colitis score at 20 weeks of age. Statistics: Mean ± SEM, n=6, mixed 
gender, single experiment; B and C: One-way ANOVA with Bonferroni’s multiple comparison 
tests, (*P< 0.05; **P< 0.01; ***P< 0.001). These mice were the same cohort monitored alongside 
the experiment in Figure 4.6.  
 
To determine the role of IL-17A in an epithelial defect model of intestinal 
inflammation, we employed the naïve T cell transfer induced colitis in both Rag-/- and RaW 
recipients. RaW mice transferred with WT and IL-17A-/- T cells had accelerated body 
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weight loss and decreased survival compared to Rag1-/- recipients (Figure 4.5, A, B). RaW 
mice developed more severe colitis than Rag1-/- recipients, as indicated by increased 
colon weight and histological colitis scores (Figure 4.6, A, B). However, within each mouse 
genotype, WT and IL-17A-/- T cells resulted in similar body weight loss, survival, colon 
weight and histological colitis. Collectively, these results indicate that, although the primary 
epithelial defect due to the Winnie allele drives a more rapid and severe onset of colitis, IL-
17A production by donor T cells is not required to induce transfer colitis in either Rag-/- or 
RaW recipients. 
 
 
Figure 4.5 WT and IL-17A-/- T cells result in similar body weight loss and survival in recipient 
mice. Rag1-/- and RaW mice were transferred with naïve WT (IL-17A+/+) or IL-17A-/- T cells. (A) 
Body weight (percentage of initial weight in Rag1-/- and RaW recipients post–transfer including 
mice sacrificed due to reaching 80% of their original weight). (B) Survival of mice to the ethically 
determined end point of 80% of original body weight. Statistics: Mean ± SEM, n=13-14, mixed 
gender, single experiment; A: One-way ANOVA with Bonferroni’s multiple comparison tests; B:  
log-rank (Mentel-Cox) test (***P< 0.001).  
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Figure 4.6 WT and IL-17A-/- T cells result in similar severity of histological colitis in recipient mice. 
Rag1-/- and RaW mice were transferred with naïve WT (IL-17A+/+) or IL-17A-/- T cells. (A) Colon 
weight. Mice were assessed at different time points due to need to sacrifice (B) Histological 
colitis score. (C) Representative H&E stained sections of the distal colon. Statistics: Mean ± SEM 
or individual data points, n=13-14, mixed gender, single experiment; A: One-way ANOVA with 
Bonferroni’s multiple comparison tests; B: Kruskal-Wallis test with Dunn’s multiple comparison 
tests (***P< 0.001). Scale bars = 200 µm. 
 
4.3.2 IL-17 receptor signaling in donor T cells reduces the severity of transfer colitis in 
both Rag1-/- and RaW recipients 
It is known that IL-17A cytokine signals through the IL-17 receptor (IL-17R) which is 
a heterodimeric complex consisting of IL17Ra and IL17Rc. To determine the importance of 
IL-17A responsiveness of T cells, IL-17Ra deficient T cells were transferred into 
lymphopenic hosts. Similarly to the previous IL-17A-/- T cell transfer experiment, RaW mice 
with the Winnie epithelial defect receiving WT and IL-17Ra-/- T cells had accelerated body 
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weight loss and reduced survival compared to the Rag1-/- recipients transferred with WT 
and IL-17Ra-/- T cells, respectively (Figure 4.7 A, B). However, unlike the situation with IL-
17A-/- cells, within each strain, IL-17Ra-/- T cells induced more severe colitis than WT T 
cells. Loss of body weight was greater in both Rag1-/- and RaW transferred with IL-17Ra-/- 
T cells compared to mice receiving WT T cells (Figure 4.7 A). Reduced survival was also 
observed in both Rag1-/- and RaW mice receiving IL-17Ra-/- T cells compared to mice 
receiving WT T cells (Figure 4.7 B).  
 
 
Figure 4.7 IL-17Ra-/- T cells transfer results in greater body weight loss and lower survival in 
recipients compared to WT T cells. Rag1-/- and RaW mice were transferred with naïve WT (IL-
17Ra+/+) or IL-17Ra-/- T cells. (A) Body weight (percentage of initial weight in Rag1-/- and RaW 
recipients post–transfer including mice sacrificed due to reaching 80% of their original weight). 
(B) Survival of mice to the ethically determined end point of 80% of original body weight. 
Statistics: Mean ± SEM, n=6, male only, single experiment; A: One-way ANOVA with Bonferroni’s 
multiple comparison tests; B:  log-rank (Mentel-Cox) test (*P< 0.05, ***P< 0.001).  
0 20 40 60 80 100
0
20
40
60
80
100
0 7 14 21 28 35 42 49 56 63 70 77 84
0
20
40
60
80
100 Rag
-/-
 with  WT T cells
RaW with  WT T cells
Rag
-/-
 with  IL-17Ra
-/-
 T cells
RaW with  IL-17Ra
-/-
 T cells
Rag-/- with IL-17Ra-/- T cells
Rag-/- with WT  cells 
RaW with IL-17Ra-/- T cells
RaW with WT  cells **
*
*
*
Days
7 16 23 30 37 44 51 58 65 72 79
80
90
100
110
120 Rag
-/-
 with  WT T cells
RaW with  WT T cells
Rag
-/-
 with  IL-17Ra
-/-
 T cells
RaW with  IL-17Ra
-/-
 T cells
Rag-/- with IL-17Ra-/- T cells
Rag-/- with WT  cells 
RaW with IL-17Ra-/- T cells
RaW with WT T cells 
**
*
**
*
**
*
**
*
Days
B
o
d
y
 w
e
ig
h
t
(%
 o
f 
in
it
ia
l)
A
B
0 20 40 60 80 100
70
80
90
100
110
120
S
u
rv
iv
a
l 
(%
)
59 
 
 
 
 
Figure 4.8 IL-17Ra-/- T cells induce more severe colitis. (A) Colon weight. (B) Histological colitis 
score. (C) Representative H&E stained sections of the distal colon. Statistics: Mean ± SEM and 
individual data points, n=6, male only, single experiment; A, B: One-way ANOVA with 
Bonferroni’s multiple comparison tests (*P< 0.05, **P< 0.01,***P< 0.001). Scale bars = 200 µm. 
 
 RaW mice receiving IL-17Ra-/- T cells also had higher colon weights and histological 
colitis scores than Rag1-/- mice that received IL-17Ra-/- T cells indicating more severe 
colitis (Figure 4.8 A, B). Within RaW mice, WT and IL-17Ra-/- T cell recipients had similar 
colon weight, but increased histological colitis was found in IL-17Ra-/- T cell recipients 
compared to WT T cell recipients (Figure 4.8 C). The score was statistically significantly 
increased in the proximal colon, and there was a non-significant trend in the distal colon. 
However, no changes in the mRNA expression of the genes encoding the proinflammatory 
cytokines, IFN-γ, IL-17A IL-1β, IL-6 and TNF-α, were observed between different T cell 
types and recipients (Figure 4.9). In summary, more severe intestinal inflammation 
developed in both Rag1-/- and RaW recipients in the T cell transfer model in the absence of 
IL-17Ra signaling in T cells.   
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Figure 4.9 Proinflammatory cytokine gene expression did not change in Rag1-/- and RaW mice 
transferred with naïve WT or IL-17Ra-/- T cells. Ifng, Il17a, Il1b, Il-6 and Tnfa mRNA expression 
levels in both proximal (upper panel) and distal colon (lower panel) tissue samples of Rag1-/- and 
RaW mice receiving WT (IL-17Ra+/+) or IL-17Ra-/- T cells. 
 
4.3.3 IL-17a deficiency does not suppress the initiation of colitis in Winnie mice 
After observing that IL-17A - IL-17Ra signaling in T cells is non-pathogenic in the 
experimental transfer model of colitis, I decided to examine the effects of systemic 
deficiency of IL-17A in colitis development. Firstly, IL-17A-/- mice were cross bred with 
Winnie mice to generate the IL-17-/-Winnie strain, which lacks IL-17A cytokine production 
and also has an epithelial defect. As Winnie spontaneous colitis exacerbates while aging, 
both young (8 weeks) and old (14 weeks) IL-17-/-Winnie vs Winnie mice were studied to 
examine the contribution of IL-17A in the initiation and progression stages of colitis.  
 
As expected, at 8 weeks of age, Winnie and IL-17A-/-/Winnie mice had increased 
colon weight and histological colitis scores compared to age matched WT (C57BL/6) and 
IL-17A-/- mice. However, somewhat unexpectedly, there was no difference in these 
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parameters between Winnie and IL-17A-/-/Winnie mice apart from a modest non-significant 
trend toward less histological colitis in the proximal but not distal colon (Figure 4.10 A, B).  
 
Examining inflammation at the molecular level, IL-17A-/-/Winnie mice had elevated 
Ifng mRNA in the proximal colon compared to IL-17A-/- and Winnie mice (Figure 4.10 C). In 
contrast, in the distal colon Ifng expression was significantly lower in IL-17A-/-/Winnie than 
Winnie mice (Figure 4.10 D). Thus IFN-γ inversely mirrors any changes in histological 
colitis, demonstrating that cytokine IFN-γ is not responsible for histological colitis. IL-17A-/- 
mice had higher expression of Il17f than WT in both the proximal and distal colon, 
suggestive of a compensatory mechanism upregulating this cytokine. However, Il17f only 
trended up in the proximal colon and decreased (not significant) in the distal colon of IL-
17A-/-/Winnie mice (Figure 4.10 C, D). Il1b was elevated in the proximal and distal colon of 
both Winnie and IL-17A-/-Winnie mice with no evidence of suppression with IL-17A 
deficiency. Il22 gene expression was dramatically upregulated in distal colon of Winnie 
compared to WT mice, Il17a gene deficiency increased Il22 gene expression in WT mice, 
but reduced Il22 expression in the Winnie distal colon. Il22 expression pattern was not 
altered in the proximal colon of WT and Winnie mice deficient in IL-17A (Figure 4.10 D). IL-
17A deficiency changes the molecular pattern of inflammation with distal colon more 
protected compared to proximal colon, although histological colitis remains the same. 
Together this experiment suggests that genetic deficiency of IL-17A has no overall effect 
on the emergence of immunopathology.    
 
4.3.4 IL-17A deficiency suppresses progression of colitis in Winnie mice 
We have previously reported that intestinal inflammation in Winnie progresses with 
age (Eri et al., 2011), and therefore examined progression of colitis with IL-17A deficiency. 
Interestingly, given IL-17’s limited effects on emergence of colitis, colitis severity did not 
progress with age in IL-17A-/-/Winnie mice. At 14 weeks of age colon weight (Figure 4.11 
A) and histological colitis scores (Figure 4.11 B) were significantly lower in Winnie mice 
deficient in IL-17A compared to Winnie mice. Statistical analysis has shown that the colitis 
level in IL-17-/-/Winnie mice did not progress while aging (Figure 4.12 A,B).Histological 
examination revealed less aberrant crypt architecture, less goblet cell depletion, fewer 
crypt abscesses and less inflammatory cell infiltration, particularly in the distal colon of IL-
17A-/-/Winnie compared to Winnie mice (Figure 4.11 C). Ifng and Il1b mRNA were 
decreased in both the proximal and distal colon of IL-17A-/-/Winnie mice compared to 
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Winnie, with Il22 expression only decreased in the distal colon of IL-17A-/-/Winnie mice 
(Figure 4.11 D, E). Il17f mRNA was increased in IL-17A-/- vs WT colons, but was similar 
between IL-17A-/-/Winnie and Winnie. Together, this experiment shows that IL-17A 
contributes to the progression of Winnie colitis.  
 
Figure 4.10 IL-17A deficiency does not modify development of colitis in Winnie mice. Naïve 
C57BL6 (WT), IL-17A-/-, Winnie and IL-17A-/-Winnie mice were sacrificed at 8 weeks of age. (A) 
Colon weight. (B) Histological colitis scores. (C) Representative H&E stained proximal and distal 
colon sections with an average histological colitis score from their group. (D, E) mRNA 
C
o
lo
n
 w
e
ig
h
t 
(g
)
0.0
0.1
0.2
0.3
0.4
0.5
0
5
10
15
20
25
0
5
10
15
20
25
H
is
to
lo
g
ic
a
l 
c
o
li
ti
s
 s
c
o
re Proximal colon Distal colon
***
*** ******
***
***
A B
0.001
0.01
0.1
1
10
100
1000
BL6
IL-17A-/-
Winnie
IL-17A-/- /Winnie
WT
IL-17A-/-
IL-17A-/ /Win ie
innie
0.1
1
10
100
0.01
0.1
1
10
100
0
5
10
15
20
0
20
40
60
80
100
0
2
4
6
8
0
20
40
60
Ifng
Ifng
Il17f
Il17f
Il1b
Il1b
***
** **
*** **
**
*
**
**
D
E
*
***
**
0.1
1
10
100
1000
Il22
0.01
0.1
1
10
100
Il22
***
Distal colonProximal colon
IL-17A-/-
/Winnie 
Winnie 
C
Proximal colon
Distal colon
G
e
n
e
 e
x
p
re
s
s
io
n
(f
o
ld
 c
h
a
n
g
e
)
G
e
n
e
 e
x
p
re
s
s
io
n
(f
o
ld
 c
h
a
n
g
e
)
63 
 
 
expression levels in the proximal and distal colon. Fold change corrected to Tata and normalized 
to WT. Statistics: Mean ± SEM and individual data points, n=8-16, mixed gender, single 
experiment; a,c,d: One-way ANOVA with Bonferroni’s multiple comparison test; b: Kruskal-
Wallis test with Dunn’s multiple comparison tests (*P< 0.05, **P< 0.01, ***P< 0.001).  
 
Figure 4.11 IL-17A deficiency ameliorates colitis progression in Winnie mice. Naïve C57BL6 (WT), 
IL-17A-/-, Winnie and IL-17A-/-Winnie mice were sacrificed at 14 weeks of age. (A) Colon weight. 
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(B) Histological colitis scores. (C) Representative H&E stained proximal and distal colon sections 
with an average histological colitis score from their group. (D, E) mRNA expression levels in the 
proximal and distal colon. Fold change corrected to housekeeping gene Tata and normalized to 
the WT group. Statistics: Mean ± SEM and individual data points, n=7-15, mixed gender, single 
experiment; a,d,e: One-way ANOVA with Bonferroni’s multiple comparison test; b: Kruskal-
Wallis test with Dunn’s multiple comparison tests (*P< 0.05, **P< 0.01, ***P< 0.001). Scale bars 
= 100 µm. 
 
Figure 4.12 The histological colitis of Winnie mice deficient in IL-17A did not progress compared 
to Winnie mice. (A) Colon weight. (B) Histological colitis scores. Statistics: Mean ± SEM and 
individual data points, n=7-16, mixed gender; One-way ANOVA with Bonferroni’s multiple 
comparison test (*P< 0.05). 
 
4.4. Discussion 
The first group of the experiments reported in this chapter demonstrate that T cell 
derived IL-17A is not required for transfer induced colitis in Rag1-/- recipients with or 
without an epithelial defect. These findings are consistent with previous studies showing 
that IL-17A signaling was not essential for the colitogenic ability of T cells (Leppkes et al., 
2009). In our experiments, the inflammation induced by IL-17A-/- T cells was not due to a 
compensatory increase in IFN-γ production by TH1 cells, which is supported by a previous 
similar study (Izcue et al., 2008).  In contrast to the findings of O’Connor et al., we did not 
find IL-17A-/- T cells to be more colitogenic than wild type T cells in our transfer colitis 
experiments using either Rag1-/- and RaW recipients (O'Connor Jr et al., 2009). Although 
we concur with their findings that IL-17Ra-/- T cells generate more severe colitis than wild 
type T cells, no evidence of skewing to a TH1 immune response was observed in our 
experiments. Although we used similar T cell transfer protocols, colitis was induced much 
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more quickly in their experiments. The cause of this discrepancy is uncertain, but may 
reflect differences in the intestinal microbiota between facilities, which in turn may alter the 
nature of the inflammation in the colon.  
 
The difference observed between IL-17A-/- T cell and IL-17Ra-/- T cell transfer 
experiments was not unexpected, as IL-17A is not the only cytokine that binds to IL-17Ra. 
IL-17F, another effector cytokine from IL-17 family, also signals through receptor 
consisting IL-17Ra (Kuestner et al., 2007; Toy et al., 2006).  Therefore, the pathogenic role 
of IL-17Ra-/- T cells in inducing transfer colitis could be due to the unresponsiveness of 
these cells to TH17 cytokines other than IL-17A. 
 
Impacts of genetic deficiency of IL-17A on colitis development have not been 
thoroughly studied.  A previous study showed that IL-17A-/- mice had exacerbated DSS-
colitis compared to WT controls, indicating that IL-17A has a suppressive role in 
chemically induced acute colitis or is involved in the wound healing process (Yang et al., 
2008a). In this chapter, by using a spontaneous colitis model, Winnie mice, I found that IL-
17A is more likely to play a role in the progression of colitis, rather than the initiation stage, 
as colitis did not show the characteristic increase in severity in old IL-17-/-Winnie mice 
compared to age match Winnie mice.  
 
Within the IL-17 family cytokines, IL-17A and IL-17F share the greatest homology. 
Both cytokines can form homo-dimers or IL-17A/IL-17F hetero-dimers which exert 
proinflammatory functions by activating tissue resident cells to secrete cytokines or 
chemokines. IL-17F may play a redundant role to IL-17A (Leppkes et al., 2009), but is less 
potent than IL-17A in recruiting neutrophils and stimulating downstream inflammatory 
cytokine production (Yang et al., 2008a). Results of IL-17A-/-Winnie mice show that genetic 
deficiency of IL-17A results in elevated colonic IL-17F mRNA. IL-17F gene expression was 
also upregulated in IL-17A-/- mice lacking the Winnie allele, confirming that IL-17F could 
play a redundant role in absence of IL-17A.  Interestingly, although Il17f gene expression 
increased in old IL-17-/-Winnie mice, the progression of intestinal inflammation was 
attenuated, suggesting that IL-17F is probably less proinflammatory than IL-17A, at least in 
the absence of IL-17A. 
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Intestinal microflora colonization plays a critical role in the initiation and 
perpetuation of intestinal inflammation. Accumulating evidence demonstrates that the 
presence and the colonization by intestinal segmented filamentous bacteria (SFB) drives 
proliferation of TH17 cells in the lamina propria of the small intestine (Atarashi et al., 2008; 
Ivanov et al., 2009; Lochner et al., 2011). However, how genetic deficiency of IL-17A 
affects the commensal microflora composition hasn’t been fully characterized. Results 
from this chapter showing that IL-17a deficiency suppresses colitis progression could be 
explained by colonic microflora changes. Although IL-17A‒/‒/Winnie and Winnie mice were 
bred from the same colony and housed under the same conditions in the same animal 
facility throughout the experiments to limit any impact of differences in intestinal microbial 
flora on colitis development, the possibility that change of microflora composition underlies 
the lack of progression of colitis in IL-17A‒/‒/Winnie compared to Winnie mice cannot be 
excluded.  
 
In summary, IL-17A - IL-17Ra signaling in T cells is non-pathogenic in transfer 
colitis, whereas IL-17A contributes to the progression of colitis in Winnie mice. The 
experimental colitis models used in this chapter have limitations in translating the findings 
into clinical therapy. Although T cell transfer colitis is a useful tool, this scenario does not 
reflect disease development in IBD patients under physiological conditions with immune 
surveillance from regulatory T cells. Also, cytokine knockout mice have immune deficiency 
and develop metabolic changes (Zuniga et al., 2010) making it hard to distinguish whether 
the assessments we have made are primary or secondary to intestinal mucosal 
inflammation. Therefore, cytokine targeting approaches mimic clinical therapies need to be 
explored. The efficacy of monoclonal antibodies against IL-17A or IL-17Ra in suppressing 
colitis will be investigated in the next chapter.  
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5.0 Assessment of the Therapeutic Efficacy of 
Monoclonal Antibodies against TH17 Associated 
Cytokines or Cytokine Receptors in Suppressing 
Intestinal Inflammation in Winnie Mice 
5.1. Overview 
 In the previous chapter my experiments demonstrated that IL-17 is involved 
in the progression of colitis in the Winnie model, but did not show whether therapeutic 
targeting of IL-17 would ameliorate pathology. To target IL-17A - IL-17Ra signaling in a 
clinical scenario, monoclonal antibodies against the IL-17A cytokine or IL-17A cytokine 
receptor have been developed and tested in several human autoimmune diseases. It has 
been reported that a humanized anti-IL-17A monoclonal antibody, ixekizumab, improved 
the clinical symptoms of psoriasis. The effects of ixekizumab occur at one week and are 
sustained through the 20 week treatment (Leonardi et al., 2012). In another phase two, 
randomized, double-blind, placebo-controlled, dose-ranging study, brodalumab, a human 
anti-IL-17 receptor monoclonal antibody also significantly improved plaque psoriasis after 
12 weeks treatment (Papp et al., 2012). Anti-IL-17A antibody, AIN457, has also been 
shown effective in treating rheumatoid arthritis and chronic noninfectious uveitis (Hueber et 
al., 2010). These clinical trial findings demonstrate that IL-17A is involved in the 
pathophysiology of diverse inflammatory diseases including psoriasis, rheumatoid arthritis, 
and noninfectious uveitis. 
 
In a double-blind, placebo-controlled clinical trial, patients with moderate-to-severe 
Crohn’s disease was treated with secukinumab - a humanized anti-IL-17A monoclonal 
antibody. In contrast to the findings of IL-17 targeting in other inflammatory diseases, 
secukinumab failed to demonstrate efficacy for Crohn’s disease, and blockade of IL-17A 
exacerbated disease in a subset of patients compared to placebo (Hueber et al., 2012). It 
is possible, based on mouse data, that neutralizing IL-17A promotes the production of the 
proinflammatory cytokine, IFN-γ, and fosters differentiation of TH1 cells. IL-17A deficient 
naïve T cell transfer into Rag mice induced more severe colitis and increased intestinal 
IFN-γ mRNA, indicating IL-17A plays a partially protective role by antagonising  pro-
inflammatory TH1 responses (O'Connor Jr et al., 2009), although my results presented in 
Chapter 4 failed to verify the antagonism of IFN-γ by IL-17A. 
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Based on results of Chapter 4 showing that genetic deficiency of Il17a slows the 
progression of colitis in Winnie mice, experiments in this chapter sought to evaluate the 
effect of IL-17 signaling in immunocompetent mice by examining the efficacy of anti-IL-17A 
or anti-IL-17Ra antibodies in Winnie mice with emerging or established colitis.  Monoclonal 
antibodies against other TH17 associated cytokines including IL-17F and IL-17E were also 
tested in the Winnie colitis model. 
 
5.2. Methods 
As Winnie colitis progresses with age, antibody treatments were carried out at two 
stages of colitis progression. To model the early stage of colitis development, 4 week old 
Winnie mice were treated with anti-IL-17A antibody for 4 weeks (Figure 5.1 A). To model 
therapy in established colitis, 12 week old Winnie mice were treated with anti-IL-17A and 
anti-IL-17Ra antibodies for 2 weeks (Figure 5.1 B). Antibody details are listed in Chapter 
3.11 and treatment regimens are summarized in Table 3.2. Anti-cytokine antibodies were 
delivered i.p. weekly with appropriate isotype control antibodies in control mice as 
specified in Table 3.2. During the antibody treatment, body weight of mice was measured 
twice weekly (see 3.9 for details). At the end of the experiment, mice were sacrificed to 
examine intestinal inflammation. On the day of sacrifice, intestine tissue and mLN were 
collected to assess the colitis severity (see 3.12 for details). Mice colon, caecum and 
terminal ilium were dissected and colon weight was measured (see 3.10 for details). 
Proximal and distal colons were dissected accordingly for histological colitis examination 
(see 3.19 for details).  Tissue total RNA was isolated and reverse transcribed to cDNA 
(see 3.15 and 3.16 for details). Expression of proinflammatory cytokine genes was 
measured in both proximal and distal colon tissue samples. Gene expression was 
corrected to each sample’s housekeeping gene first before being normalized to the 
average of the control group (see 3.17.2 for details). Histological colitis was quantified 
using Winnie mice chronic or acute colitis scoring sheet (see 3.19 for details).  
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Figure 5.1 Antibody treatment regimens in C57BL6 (WT) and Winnie mice at different age. (A) 
anti-IL-17A (aIL-17A) and isotype antibody treatment of 4 week old Winnie mice with emerging 
colitis. (B) aIL-17A, anti-IL-17 receptor A (aIL-17Ra) and isotype antibody treatment of 12 week 
old Winnie mice with established colitis. 
 
5.3. Results 
5.3.1 Antibody neutralization of IL-17A promotes TH1 immunity in Winnie mice with 
emerging colitis 
During the 4 week antibody treatment, starting from 4 weeks of age, increases in 
body weight were similar in Winnie and WT mice, although both strains of mice showed 
increased body weight after receiving aIL-17A (Figure 5.2 A), which is similar to a previous 
study showing that IL-17A inhibits adipogenesis and genetic deficiency of IL-17A 
enhances diet-induced obesity in mice (Zuniga et al., 2010). Winnie mice treated with aIL-
17A antibody developed more severe colitis compared to mice treated with isotype 
antibody as indicated by increased colon weight (Figure 5.2 B). Consistent with the 
increase in colon weight, aIL-17A treatment failed to ameliorate the histological colitis 
scores which actually trended worse in the proximal colon of antibody-treated Winnie mice 
(Figure 5.2 C). Increased inflammatory cell infiltration and tissue damage were observed in 
the distal colon of Winnie mice receiving aIL-17A antibody compare to isotype control 
(Figure 5.2 D).   
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An increase in IFN-γ production was observed in the mLN leucocytes isolated from 
aIL-17A treated Winnie mice compared to those obtained from the isotype control group 
(Figure 5.3 A). qPCR using distal colon tissue cDNA samples showed that Ifng expression 
in distal colon of aIL-17A treated Winnie mice was upregulated, but difference was not 
significant compared to isotype control treated group (Figure 5.3 B). The expression of 
TH1-associated transcription factor T-bet was trended upward in the distal colon of aIL-17A 
treated Winnie mice (Figure 5.3 B), suggesting that neutralizing TH17 effector cytokine IL-
17A could induce TH1 skewing in intestinal mucosa. This experiment demonstrates the 
importance of understanding the cytokine milieu present during intestinal inflammation. 
 
 
Figure 5.2 Neutralizing IL-17A fails to ameliorate emerging colitis in Winnie mice. WT and Winnie 
mice at 4 weeks of age were treated for 4 weeks with anti-IL-17A (aIL-17A) or isotype control 
antibody and then sacrificed. (A) Body weight. (B) Colon weight. (C) Histological colitis scores. 
(D) Representative H&E stained proximal and distal colon sections with a colitis score close to 
the median of the group. Statistics: A, B and C: Mean ± SEM and individual data points, n=7-10, 
single experiment; One-way ANOVA with Bonferroni’s multiple comparison test (**P< 0.01). 
Scale bars = 100 µm. 
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Figure 5.3 Proinflammatory cytokine production in WT and Winnie mice at 8 weeks of age after 
4 weeks treatment with aIL-17A or isotype control antibody.  (A) IFN-γ and IL-17A cytokine 
concentration in isolated mLN leucocyte culture supernatants measured by ELISA. (B) Ifng and 
Il17a mRNA expression levels in distal colon of WT and Winnie mice. Statistics: Mean ± SEM and 
individual data points, n=7-10, single experiment; One-way ANOVA with Bonferroni’s multiple 
comparison test (*P< 0.05). 
 
5.3.2 Antibody neutralization of IL-17A fails to alleviate established colitis in Winnie mice 
Efficacy of the anti-IL-17A antibody was also examined in established colitis using 
12 week old Winnie mice. After treatment with aIL-17A monoclonal antibody for two 
weeks, the colon weight of Winnie mice did not differ from mice treated with the isotype 
control (Figure 5.4 A). However, Winnie mice receiving aIL-17A antibody had decreased 
histological colitis scores in the proximal colon (Figure 5.4 B) with less inflammatory cell 
infiltration (Figure 5.4 B, lower panel). The overall severity of histological colitis did not 
diminish in the distal colon where colitis is greatest (Figure 5.4 B). mRNA levels of 
proinflammatory cytokine genes, Ifnγ, Il17a and Il1b, did not change in either the proximal 
or distal colon (Figure 5.5) suggesting that blocking IL-17A alone is not sufficient  to 
suppress established colitis in Winnie mice. 
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Figure 5.4 Neutralizing IL-17A fails to ameliorate established colitis in Winnie mice. C57BL/6 
(WT) and Winnie mice at 12 weeks of age were treated for 2 weeks with anti-IL-17A (aIL-17A) or 
isotype control antibodies and then sacrificed. (A) Colon weight. (B) Histological colitis scores. 
(C) Representative H&E stained proximal and distal colon sections with a colitis score close to 
the median of the group. Statistics: A and B: Mean ± SEM and individual data points, n=7-10, 
single experiment; One-way ANOVA with Bonferroni’s multiple comparison test (**P< 0.01). 
Scale bars = 100 µm. 
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Figure 5.5 mRNA expression of proinflammatory cytokine genes in WT and Winnie mice at 12 
weeks of age treated for 2 weeks with anti-IL-17A (aIL-17A) or isotype control antibodies and 
then sacrificed.   (A) Proximal colon and (B) distal colon cytokine gene expression. Statistics: 
Mean ± SEM and individual data points, n=7-10, single experiment; One-way ANOVA with 
Bonferroni’s multiple comparison test.  
 
5.3.3 Antibody neutralization of IL-17Ra does not alleviate established colitis in Winnie 
mice 
To further confirm the role of IL-17A signaling in intestinal colitis, 12 week old 
Winnie mice with established colitis were treated with anti-IL-17Ra monoclonal antibody 
(aIL-17Ra) for 2 weeks. Similarly, two weeks treatment of 12 week old Winnie mice with 
aIL-17Ra did not reduce intestinal inflammation, with colon weight (Figure 5.6 A) and 
histological colitis scores (Figure 5.6 B) unchanged compared to Winnie receiving isotype 
control antibody. In fact, increased mucosal neutrophil recruitment was observed in the 
distal colon of Winnie mice treated with anti-IL-17Ra antibody (Figure 5.6 B lower panel), 
suggesting that the IL-17Ra mediated signaling is not the dominant driver of neutrophil 
recruitment in the intestinal mucosa. IFN-γ and IL-17A cytokine production by mLN 
leucocytes did not differ after the treatment. Overall, in contrast to genetic deficiency, 
blocking the IL-17A-IL-17Ra axis with neutralizing antibodies was insufficient to ameliorate 
Winnie colitis.  
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Figure 5.6 Neutralizing IL-17Ra fails to ameliorate established colitis in Winnie mice. WT and 
Winnie mice at 12 weeks of age were treated for 2 weeks with anti-IL-17Ra (aIL-17Ra) or isotype 
control antibody. (A) Colon weight. (B) Histological colitis scores and (C) Representative H&E 
stained sections of the proximal and distal colon with a colitis score close to the median of the 
group. (D) IFN-γ and IL-17A cytokine concentrations in isolated mLN leucocyte culture 
supernatants measured by ELISA.  Statistics: A, B and C: Mean ± SEM and individual data points, 
n=7-10, single experiment; One-way ANOVA with Bonferroni’s multiple comparison test (**P< 
0.01). Scale bars = 100 µm. 
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5.3.4 Antibody treatments against other TH17 associated cytokines fails to show efficacy 
in reducing colitis severity 
 As the TH17 response has a strong proinflammatory phenotype, effector cytokines 
of TH17 cells became promising candidates to target in suppressing intestinal 
inflammation. In a pilot experiment, the efficacy of antibodies against TH17-associated 
cytokines other than IL-17A was examined in Winnie mice with established colitis. 
Unfortunately, anti-IL-17F alone, anti-IL-17E alone and anti-IL-17F in combination with 
anti-IL-17A treatment did not ameliorate Winnie colitis. Indeed, 2 weeks anti-IL-17F 
treatment increased colon weight and inflammatory cell infiltration, indicating more severe 
intestinal inflammation developed compared to the isotype control group (Figure 5.7). In 
summary, this small underpowered study provided no evidence that targeting TH17 
cytokines other than IL-17A, or combinations of these cytokines, by monoclonal antibodies 
is likely to be effective in suppressing colitis in the Winnie mice.   
 
Figure 5.7 12 week old Winnie mice treated with anti-IL-17F, anti-IL-17E, IL-17F in combination 
with anti-IL-17A, or isotype control antibody for 2 weeks. (A) Colon weight of mice on the day of 
sacrifice. (B) Representative H&E stained sections of the distal colon with a colitis score close to 
the median of the group. Statistics: mean and individual data points; n=3, mixed gender, single 
experiment. Scale bars = 100 µm. 
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5.4. Discussion 
In this chapter, the efficacy of blocking TH17 associated cytokines or the cytokine 
receptor using monoclonal antibodies has been assessed. Results have shown that 
neutralizing either TH17 effector cytokines or the IL-17Ra cytokine receptor does not 
suppress colitis in the Winnie model. Although IL-17A is not responsible for the induction 
of experimental colitis, it exerts a strong proinflammatory function on myeloid and 
mesenchymal cells to induce granulocyte colony-stimulating factor and IL-6 production, 
which subsequently promotes recruitment of neutrophils and monocytes (Xu and Cao, 
2010). This function of IL-17A links adaptive and innate immunity with implications for both 
host defence and tissue inflammation. A recent study demonstrates that the presence of 
TH17 cells requires segmented filamentous bacteria colonization in mice (Yang et al., 
2014), suggesting that the commensal microbiota could be involved in the evolution of 
tissue inflammation processes.  IL-17A also stimulates antimicrobial molecule production 
and enhances host defense against extra cellular pathogens at various mucosal sites 
(Khader et al., 2009), potentially providing an explanation for the results of a clinical trial in 
which treating active Crohn’s disease patients using anti-IL-17A monoclonal antibody not 
only failed to show efficacy, but increased the incidence of fungal infection (Hueber et al., 
2012). Our finding that neutralizing IL-17A failed to suppress intestinal inflammation is 
consistent with the results of this clinical trial. Bacterial or fungal infections were not 
observed in our experiments; however, evidence of infection was not definitively sought.   
Evidence from human clinical trials suggest that anti-IL-17A antibody treatment is effective 
in treating autoimmune disease involving inflammatory TH17 responses like psoriasis, 
rheumatoid arthritis, and uveitis (Hueber et al., 2010; Leonardi et al., 2012; Papp et al., 
2012). However, the pathogenesis of inflammatory bowel disease is closely entwined with 
the luminal microbiota, unlike the other autoimmune diseases that involve tissues with less 
or no microbial exposure. While the physiological role of IL-17A in intestinal immunity is 
obviously complex, neutralizing IL-17A may perturb fine tuning of the immune balance 
between host defence and tissue inflammation.  
 
IL-17A signals through a heterodimeric receptor complex including the IL-17Ra and 
IL-17Rc subunits (Toy et al., 2006).  IL-17Ra is ubiquitously expressed on various cell 
types and involved in IL-17A and IL-17F signaling (Korn et al., 2009).  IL-17Ra is critical for 
inducing neutrophil migration during acute lung infection (Crowe et al., 2009), and is 
indispensable for IL-17A-mediated IL-6 and chemokine production in rheumatoid arthritis 
77 
 
 
(Zrioual et al., 2008). IL-17Ra is able to activate NF-κB and the Janus kinase 1-associated 
phosphoinositide 3-kinase signaling pathway independently (Huang et al., 2007; Yao et al., 
1995), suggesting its involvement in infection and inflammation. However, our results show 
that blocking IL-17Ra is insufficient to suppress colitis and limit tissue neutrophil 
recruitment, and that targeting IL-17Ra is unlikely to be effective in treating intestinal 
inflammation.  
 
As discussed in the previous chapter, IL-17A and IL-17F share the most homology 
within the IL-17 effector cytokine family. Both cytokines have proinflammatory functions, 
with IL-17F less potent than IL-17A in recruiting neutrophils and stimulating downstream 
inflammatory cytokine production (Leppkes et al., 2009; Yang et al., 2008b). Surprisingly, 
results from this chapter show that neutralizing IL-17A and IL-17F concomitantly with 
monoclonal antibodies does not alter colitis severity in Winnie mice, indicating other 
proinflammatory cytokines are more substantial contributors to intestinal 
immunopathology. 
 
IL-17E, also known as IL-25, is a TH17 family cytokine that can also be produced by 
TH2 cells, mast cells, eosinophils and basophils (Ikeda et al., 2003; Tamachi et al., 2006) 
involving in TH2 cell expansion and allergic reactions (Angkasekwinai et al., 2007; Fort et 
al., 2001). IL-17E has been shown to inhibit IL-17A and IFN-γ production and suppress 
TH17-mediated pathology, suggesting its protective role in antagonizing TH17 responses 
(Kleinschek et al., 2007; Owyang et al., 2006). Recombinant IL-17E treatment was 
reported to ameliorate chemically-induced colitis and decrease IL-12 and IL-23 levels in 
the intestinal mucosa (Caruso et al., 2009), indicating that IL-17E is important in 
maintaining intestinal homeostasis. Therefore, it is not surprising to observe that anti-IL-
17E treatment increased the colon weight of Winnie mice. However, a properly powered 
experiment with sufficient numbers of mice needs to be performed before we can 
confidently conclude that neutralization of IL-17F and IL-17E is not therapeutic in Winnie 
mice.  
 
In summary, neutralizing TH17-associated effector cytokines or cytokine receptor 
fails to alleviate the intestinal inflammation in Winnie mice. This could be due to the dual 
function of TH17 cells in fighting against pathogens and inducing tissue inflammation. As 
targeting TH17-associated effector cytokines or cytokine receptor were not able to 
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suppress Winnie colitis, antibodies against the critical upstream cytokine of the TH17 
pathway, IL-23, were tested for their in suppressing Winnie colitis in the next chapter.  
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6.0 Antibody Neutralization of IL-23 Suppresses 
Winnie Colitis 
6.1. Overview 
Given that blocking IL-17A, the major effector cytokine of proinflammatory TH17 
cells, did not ameliorate colitis in Winnie mice, we hypothesized that blocking IL-23, the 
upstream cytokine of IL-17A producing immune cells, would reduce intestinal 
inflammation.  
 
IL-23, comprising p40 (shared with IL-12) and p19 subunits, is a member of the IL-
12 cytokine family known to promote and sustain proinflammatory TH17 T cells and is 
linked by genetic and experimental evidence to the pathogenesis of IBD. IL-23 is secreted 
by antigen presenting cells upon exposure to pathogens (Langrish et al., 2004). Lamina 
propria CD103+CD11b+ dendritic cells are able to produce IL-23 in response to the 
bacterial TLR5-ligand, flagellin (Kinnebrew et al., 2012). In response to IL-23, 
effector/memory T cells actively produce proinflammatory cytokines, including IL-17A, 
thereby driving local tissue inflammation (Aggarwal et al., 2003). In a Helicobacter 
hepaticus infection and T cell transfer induced colitis model, p19-/-Rag1-/- recipients lacking 
the ability to produce IL-23 had attenuated transfer colitis compared to IL-23-producing 
Rag1-/- recipients (Kullberg et al., 2006). In addition to the direct effect on effector T cells, 
IL-23-dependent ILCs producing IL-17A and IL-17F have been found in Crohn’s disease 
patients (Geremia et al., 2011). These observations are supported by experimental studies 
in mice lacking T cells, showing that IL-23 can drive innate intestinal pathology through IL-
17A production by ILCs (Buonocore et al., 2010a). IL-23 also suppresses Treg 
differentiation, suggesting that in the presence of IL-23 intestinal inflammation could 
develop due to reduced Treg-mediated immunosuppression (Izcue et al., 2008). In 
addition, human GWAS demonstrate that an IL23R gene polymorphism resulting in 
impaired IL-23 receptor signaling confers strong protection against Crohn’s disease and 
ulcerative colitis (Duerr et al., 2006a). Thus human genetics indicates that functional IL-23 
signalling is required for the development of intestinal inflammation. Due to IL-23’s multiple 
mechanisms of actions on a range of effector and immunomodulatory immune cells, 
targeting IL-23 to suppress intestinal inflammation has promise as an approach to treat 
IBD.  
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ABT-874 and Ustekinumab (CNTO 1275), two humanized monoclonal antibodies 
against the p40 subunit of IL-12/23 cytokines, have been trialed in treating moderate-to-
severe Crohn’s disease. Crohn’s disease patients receiving ABT-874 antibody 
demonstrated an increased clinical response rate compared to a placebo group (Mannon 
et al., 2004). Ustekinumab was effective in moderate-to-severe Crohn’s disease patients in 
a double-blinded cross-over trial (Sandborn et al., 2008). Ustekinumab also significantly 
increased response and remission rates as a maintenance therapy in treating Crohn’s 
disease patients refractory to anti-TNF therapy (Sandborn et al., 2012). BI 655066, an 
antibody against IL-23 only, is being tested in an ongoing double-blind, placebo-controlled, 
phase II dose-ranging study in patients with moderate-to-severe Crohn’s disease 
(NCT02031276, ClinicalTrials.gov). However, these antibodies are yet to be systematically 
tested in ulcerative colitis.  
 
Winnie spontaneous colitis arises from an epithelial defect due to a single missense 
mutation in the Muc2 mucin gene (Heazlewood et al., 2008) (see 1.4.4 for detail).  The 
unfolded or misfolded MUC2 accumulates in the ER of the intestinal secretory goblet cells 
and causes ER stress. ER stress refers to a physiological state that unfolded or misfolded 
proteins accumulate in the ER lumen, due to increased demand or improper protein folding 
which further cause imbalances between the protein folding load and the capacity of the 
ER (Zhang and Kaufman, 2008). To prevent the accumulation of unfolded or misfolded 
proteins in the ER, eukaryotic cells have evolved a mechanism to cope with ER stress and 
to resolve the protein folding defect – a response referred to as the unfolded protein 
response (UPR) (Schroder and Kaufman, 2005).  The main UPR signaling cascade is 
initiated by three major ER localized proteins. They are inositol-requiring 1α (IRE1α), 
double-stranded RNA-dependent protein kinase (PKR)-like ER kinase (PERK) and 
activating transcription factor 6 (ATF6) (Ron and Walter, 2007; Schroder and Kaufman, 
2005). Severe or unresolved ER stress triggers downstream inflammatory responses 
through multiple UPR-dependent and independent mechanisms (Hasnain et al., 2012; 
McGuckin et al., 2010). Intestinal goblet cell ER stress can lead to depletion of the mucus 
barrier and increased microbial exposure (Eri et al., 2011). 
 
ER stress and the UPR are closely interconnected with inflammation through 
various mechanisms. Although the UPR is effective in maintaining ER homeostasis, 
prolonged ER stress can trigger inflammatory signaling (Hasnain et al., 2012) and even 
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secretory cell apoptosis (Ron and Walter, 2007; Schroder and Kaufman, 2005). As major 
mediators of inflammation, it is emerging that inflammatory cytokines also play a vital role 
in regulating ER stress in secretory cells. Besides the fact that intracellular stress signals 
can activate the NF-kB pathway resulting in inflammatory cytokine production, some 
cytokines can also promote ER stress by increasing oxidative stress, and thereby 
exacerbate inflammation. It has been reported that TNF-α induces ER stress by modifying 
oxidative stress (Xue et al., 2005), while other cytokines like IL-10 and IL-22 alleviate 
oxidative stress (Shkoda et al., 2007). A recently published finding from our group 
demonstrated that IL-23 is a very potent cytokine in inducing ER stress and oxidative 
stress in pancreatic β-cells (Hasnain SZ, 2014), which have many similarities to goblet 
cells, suggesting a possible role for IL-23 in directly driving pathology in intestinal secretory 
cells thereby exacerbating pathology.  
 
In order to define the capacity of anti-IL-23 to suppress intestinal inflammation and 
further study IL-23’s mechanism of actions, particularly with respect to effects on goblet 
cell ER stress, I tested the efficacy of monoclonal antibodies against the p40 or p19 
subunits of IL-23 in Winnie mice with emerging and established colitis. Histological colitis, 
cytokine gene expression, inflammatory cell infiltration and goblet cell phenotype were 
assessed to determine the relative efficacy of anti-p40 and anti-p19 antibodies. In vitro 
assays were performed to further investigate the effect of IL-23 on colonic epithelial cells in 
the context of inducing ER stress and oxidative stress. 
 
 
6.2. Methods  
Antibody neutralization of IL-23 was carried out in three colitis models: (a) 5 to 6 
week old Winnie mice with emerging colitis were treated with anti-p19 (ap19) and anti-p40 
(ap40) antibodies for 2 weeks; (b) 5 to 6 week old Winnie mice were treated with anti-p19 
(ap19) and isotype antibodies for 4 weeks, and (c) 12 week old Winnie mice with 
established colitis were treated with anti-p19 and anti-p40 antibodies for 2 weeks. At the 
end of the experiment, mice were sacrificed to examine the intestinal inflammation. On the 
day of sacrifice, intestinal tissue was collected to assess the colitis severity (see 3.12 for 
details). The whole colon, caecum and terminal ilium were dissected and colon length was 
measured. Colon weight was assessed after removal luminal contents (see 3.10 for 
details). Proximal and distal colons were dissected for histological colitis examination (see 
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3.19 for details).  Total tissue RNA was isolated and reverse transcribed to cDNA (see 
3.15 and 3.16 for details). Proinflammatory cytokine gene expression was measured in 
both proximal and distal colon tissue samples. Expression of each gene was corrected to 
each sample’s housekeeping gene before being normalized to the average of the relevant 
control group (see 3.17.2 for details). H&E staining of intestinal sections was carried out to 
assess histological pathology. Histological colitis was quantified using the chronic or acute 
colitis scoring system (see 3.19 for details). Representative sections of proximal and distal 
colon with a colitis score close to the median of the group were presented. 
 
Figure 6.1 Antibody treatment regimens for C57BL/6 (WT) and Winnie mice at different ages. (A) 
5 to 6 week old Winnie mice with emerging colitis were treated with anti-p19 (ap19) and anti-
p40 (ap40) antibodies for 2 weeks. (B) 5 to 6 week old Winnie mice with emerging colitis were 
treated with anti-p19 antibody for 4 weeks.  (C) 12 week old Winnie mice with established colitis 
were treated with anti-p19 and anti-p40 antibodies for 2 weeks.  
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Immunohistochemistry for Ly6G/6C was performed to assess neutrophil infiltration 
in the colon (see 3.18.2 for details). Morphometry was used to quantify staining as 
described in 3.18.5. To investigate whether IL-23 is involved in neutrophil activation, 
multiple assays were carried out. Firstly, IL-23R expression on freshly isolated mouse 
peritoneal neutrophils was determined by flow cytometry. Isolated mouse peritoneal 
neutrophils were co-cultured with or without 50 ng/ml IL-23 for 2 h, intra-cellular ROS 
levels were measured by the DCFDA assay (see 3.4 for details) after treatment to 
compare the activation state of neutrophils. To examine if IL-23 is involved in neutrophil 
recruitment in vivo, 12 week old C57BL/6 mice were administered IL-23 (50 μg/kg body 
weight, i.p.) 2 h before being sacrificed. ROS and oxidative stress levels were assessed by 
the DCFDA assay (see 3.4 for details) and the DHE dye oxidation assay (see 3.5 for 
details) in isolated peritoneal neutrophils with or without IL-23 pre-exposure. 
 
Alcian blue and PAS staining was used to examine mucin production by goblet cells 
(see 3.18.4 for details). Morphometry was used to quantify staining as described in 3.18.5. 
To confirm the in vivo findings, the human colonic epithelial cell line that contains MUC2-
producing goblet cells, LS174T, was treated with IL-23 (50 ng/ml). Various treatment 
regimens were used and intra-cellular ROS levels, ER stress, chemokine IL-8 secretion 
and MUC2 production were measured to study the effects of IL-23 on colonic epithelial 
cells.  
 
6.3. Results 
6.3.1 Neutralizing IL-23 alleviates emerging colitis in Winnie mice 
5 to 6 week old Winnie mice with emerging colitis were treated with monoclonal 
antibodies against the p40 or p19 subunit of IL-23 for two weeks. Although anti-p19 
antibody treatment did not modify the colon weight (Figure 6.2 A), the histological colitis 
score was reduced in both the proximal and distal colon of Winnie mice (Figure 6.2 B). 
H&E staining of colon sections revealed that Winnie mice receiving anti-p19 antibody had 
less inflammatory cell infiltration and improved crypt structure compared to untreated mice 
(Figure 6.2 C). Inflammatory cytokine gene expression was not elevated in the proximal 
colon of young Winnie mice, and was not modified by the anti-p19 antibody treatment 
(Figure 6.2 D). However, cytokine and chemokine genes were increased in the distal colon 
of Winnie mice and anti-p19 treatment significantly downregulated Il17a, Il1b and Mip2α 
mRNA expression (Figure 6.2 E), suggesting that IL-23-driven production of the 
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proinflammatory cytokines, IL-17A, IL-1β and chemokine Mip-2α, by inflammatory cells 
contributes to the intestinal pathology in Winnie emerging colitis. Anti-p40 antibody 
treatment also downregulated Il17a, Il1b and Mip2α mRNA expression in the distal 
mucosa of Winnie mice (Figure 6.2 E), but it did not alleviate the overall histological colitis. 
The anti-p40 antibody, which neutralizes both IL-12 and IL-23, was not as effective as anti-
p19 antibody in ameliorating Winnie colitis. Of potential relevance, though not significant, 
anti-p40 appeared to reduce expression of the TH1 cytokine, Ifng, whereas anti-p19 did 
not, potentially explaining the differing effects of targeting IL-23 alone vs IL-12 and IL-23. 
 
6.3.2 Neutralizing IL-23 suppresses progression of colitis in Winnie mice 
Winnie spontaneous colitis is progressive with the most severe inflammation in the 
distal colon (Eri et al., 2011). Based on the results from the short term experiment in 6.3.1, 
in an attempt to mimic maintenance therapy in the clinic, 5 to 6 week old Winnie mice were 
treated with anti-p19 antibody for four weeks to assess its efficacy in alleviating colitis 
progression. After four weeks treatment, Winnie mice receiving anti-p19 antibody 
treatments had lower histological colitis scores in the distal colon (Figure 6.3 B), although 
the overall colon weight (Figure 6.3 A) and histological colitis score in the  proximal colon 
(Figure 6.3 B) were similar to isotype treated mice. Anti-p19 antibody treated Winnie mice 
also exhibited improved crypt structure and reduced inflammatory cell infiltration compared 
to untreated mice (Figure 6.3 C). Inflammatory cytokine and chemokine genes were 
elevated in both proximal and distal colon of Winnie mice and anti-p19 treatment 
significantly downregulated Il17a, Il1b and Mip2α mRNA expression (Figure 6.2 D and E), 
suggesting that anti-IL-23 antibody alleviated the progression of colitis characteristic of 
Winnie mice by reducing production of proinflammatory cytokines and chemokines in the 
intestinal mucosa.  Similar to the previous experiment, Ifng gene expression in the 
proximal and distal colon did not change with anti-p19 treatment, indicating that IFN-γ may 
not contribute to the overall immunopathology in Winnie colitis as it becomes more severe 
with age. 
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Figure 6.2 Neutralizing IL-23 using anti-p19 antibody ameliorates emerging colitis in Winnie 
mice. WT and Winnie mice at 5-6 weeks of age were treated with anti-p40, anti-p19 or isotype 
antibodies for 2 weeks. (A) Colon weight. (B) Histological colitis scores. (C) Representative H&E 
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stained sections of proximal and distal colon with a colitis score close to the median of the group 
(black arrows indicate increased inflammatory cell infiltration). (D) Proximal colon and (E) distal 
colon cytokine and chemokine gene expression relative to the mean of untreated C57BL/6 mice. 
Statistics: Mean ± SEM and individual data points, n=6-10, mixed gender, single experiment; B, D 
and E: One-way ANOVA with Bonferroni’s multiple comparison test (*P< 0.05, **P< 0.01). Scale 
bars = 100 µm. 
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Figure 6.3 Neutralizing IL-23 using anti-p19 antibody ameliorates emerging colitis in Winnie 
mice. WT and Winnie mice at 5 weeks of age were treated with anti-p19 or isotype antibodies 
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for 4 weeks. (A) Colon weight. (B) Histological colitis scores. (C) Representative H&E stained 
sections of proximal and distal colon with a colitis score close to the median of the group. (D) 
Proximal colon and (E) distal colon cytokine and chemokine gene expression relative to the 
mean of untreated C57BL/6 mice. Statistics: Mean ± SEM and individual data points, n=6-7, 
mixed gender, single experiment; B, D and E: One-way ANOVA with Bonferroni’s multiple 
comparison test (*P< 0.05, **P< 0.01, ***P<0.001). Scale bars = 100 µm. 
 
6.3.3 Neutralizing IL-23 ameliorates established colitis in Winnie mice  
The intestinal inflammation of Winnie mice progresses with age accompanied by 
increasing IL-23 expression (Figure 6.4 A) and prominent distal colitis by 12 weeks of age 
featuring goblet cell depletion, epithelial damage, disruption of crypt architecture and 
substantial neutrophilic infiltration (Figure 6.4 B). To examine the efficacy of anti-IL-23 
antibodies in treating severe intestinal inflammation, 12 week old Winnie mice with 
established colitis were treated with monoclonal antibodies against the p40 or p19 subunit 
of IL-23 for two weeks. Anti-p19 antibody treatment ameliorated established colitis. Colon 
weight was reduced (Figure 6.5 A), accompanied by decreased histological colitis scores 
in the distal colon (Figure 6.5 B), with reduced crypt hyperplasia, epithelial damage and 
inflammatory cell infiltration (Figure 6.5 C). In contrast, anti-p40 treatment failed to reduce 
colon weight, nor did it alleviate histological colitis (Figure 6.5 A, B, C). Decreased Ifnγ 
mRNA expression in the distal colon was found after anti-p40 but not anti-p19 treatment, 
suggesting that blocking IL-12 and IL-23 by using anti-p40 antibody suppressed production 
TH1 cytokines. However, decreased IFN-γ production did not result in reduced colitis 
severity, again suggesting that the TH1 arm of immunity, though activated, may not be a 
major contributor to mucosal immunopathology in Winnie colitis, and could even be 
somewhat protective. Surprisingly, although anti-p19 treatment suppressed histological 
colitis, the mRNA levels of Il17a and Il-1b in the distal colon of Winnie mice did not differ 
between treatments (Figure 6.5 D, E). This experiment indicates that the efficacy of anti-IL-
23 treatment in Winnie established colitis may due to mechanisms other than directly 
suppressing IL-17A-producing immune cells. 
 
As distal colonic neutrophil infiltration is a key feature of Winnie colitis, 
immunohistochemistry of Ly6G/6C was performed to quantify the colonic neutrophil 
infiltration.  Although the Ly6G/6C antigen can also be present on myeloid-derived 
suppressor cells, positive cells invariably had a polymorphonuclear phenotype and 
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therefore analysis of Ly6G/6C staining is likely to quite accurately reflect neutrophil 
content. Two weeks anti-p19 treatment significantly decreased colonic neutrophil 
infiltration in Winnie mice compared to the isotype treated group and was more effective 
than anti-p40 antibody (Figure 6.6 A, B). IL-17 is regarded as an important neutrophil 
chemoattractant during TH17 immune responses, yet Il17a gene expression did not 
change with any of the treatments, therefore the chemokine Mip-2α (Cxcl2) and cytokine 
IL-1β (Il1b) also involved in neutrophil recruitment was measured. Although Mip2α (Figure 
6.6 C) and Il1b (Figure 6.5 C,D) gene expression levels were similar in RNA extracted 
from whole tissue homogenates of the distal colon, Mip2α and Il1b expression was 
significantly downregulated in isolated colonic epithelial cells, with both anti-p40 and anti-
p19 treatments (Figure 6.6 D), suggesting that IL-23-driven Mip-2α and Il1b production by 
colonic epithelial cells contributes to Winnie established colitis. IL-23 dependent epithelial 
cell chemokine and cytokine production could be explained by (a) IL-23 acting on non-
epithelial mucosal cells to trigger production of factors driving epithelial activation and 
chemokine production, (b) IL-23 having a direct effect on epithelial cells, and/or (c) IL-23 
directly acting as a neutrophil chemoattractant.  
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Figure 6.4 12 week old Winnie mice have increased Il23p19 gene expression and distal colonic 
neutrophil infiltration compared to 6 week old Winnie mice. (A) Il23p19 mRNA expression 
relative to the mean of the 6 week group. (B) Immunohistochemistry of Ly6G/6C staining (black 
arrows indicate neutrophils). Statistics: Mean ± SEM and individual data points, n=7, mixed 
gender, single experiment; A: One-way ANOVA with Bonferroni’s multiple comparison test 
(***P< 0.001). Scale bars = 100 µm. 
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Figure 6.5 Neutralizing IL-23 ameliorates established colitis in Winnie mice. WT and Winnie mice 
at 12 weeks of age were treated with anti-p40, anti-p19 or isotype antibodies for 2 weeks. (A) 
Colon weight. (B) Histological colitis scores. (C) Representative H&E stained proximal and distal 
colon sections with a colitis score close to the median of the group. (D) Proximal colon and (E) 
distal colon cytokine and chemokine gene expression relative to the mean of untreated C57BL/6 
mice. Statistics: Mean ± SEM and individual data points, n=6-8, experiment performed twice, 
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data from one experiment; A, B, D and E: One-way ANOVA with Bonferroni’s multiple 
comparison test (*P< 0.05, **P< 0.01, ***P< 0.001). Scale bars = 100 µm. 
 
 
 
Figure 6.6 Winnie mice with established colitis treated for 2 weeks with anti-p19 antibody have 
reduced neutrophil infiltration in the distal colon. 12 week old Winnie mice were treated with 
isotype, anti-p40 and anti-p19 antibodies for 2 weeks. (A) Representative Ly6G/6C 
immunohistochemistry showing neutrophil infiltration in distal colon sections. (B) Quantification 
of Ly6G/6C staining in the distal colon. (C) Mip2α gene expression in whole colon tissue. (D) 
Mip2α gene expression in isolated colonic epithelium.  Statistics: Mean ± SEM and individual 
data points, n=5-7, mixed gender, representative data from two experiments; A, B, C and D: 
One-way ANOVA with Bonferroni’s multiple comparison test (*P< 0.05). Scale bars = 100 µm.  
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Figure 6.7 IL-23 exposure did not modify the activation state of mouse peritoneal neutrophils. 
(A) IL-23R expression on isolated mouse peritoneal neutrophils by flow cytometry. (B) 
Intracellular ROS level in isolated mouse peritoneal neutrophils after treatment with or without 
20ng/ml PMA, 50 ng/mL IL-23 or the ROS inhibitor reduced-glutathione (ROS Ihb) for 2 h. (C) 
Intracellular ROS levels measured by the DCFDA assay in freshly isolated peritoneal neutrophils 
from naïve C57BL/6 mice or IL-23 (50µg/kg body weight, i.p.) 2 h pre-exposed mice. (D) 
Intracellular ROS level measured by the DHE assay in mice of (C). (E) DHE dye intensity in 
neutrophils over 2 h in mice of (C). Statistics: B, C, D:  Box plots showing median and inter-
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quartile range, n= 5-6, male mice, experiment performed once; B: One-way ANOVA with 
Bonferroni’s multiple comparison test (***P< 0.001). 
 
 Based on the results above, it is possible that IL-23 is directly involved in colonic 
neutrophil mediated intestinal pathology. A recent report showed that in response to IL-23 
human neutrophils increased expression of the IL-17 receptor and IL-17 itself, albeit this 
study was conducting using very high concentrations of both IL-23 and IL-6 (Taylor et al., 
2014). To address this hypothesis, firstly, IL-23R expression was assessed on freshly 
isolated mouse peritoneal neutrophils by flow cytometry. Around 7% of neutrophils isolated 
from the peritoneum of casein-stimulated mice were IL-23R positive (Figure 6.7 A). 
However, in vitro IL-23 treatment of isolated neutrophils did not modify the intracellular 
ROS level as a measure of activation. Notably, control neutrophils have high basal levels 
of ROS production which can be suppressed by the ROS inhibitor reduced-glutathione, 
suggesting that neutrophils could be artificially activated during the isolation and 
purification procedures (Figure 6.7 B). Similar with these finding, peritoneal neutrophils 
isolated from mice administered IL-23 into the peritoneal cavity had similar levels of 
intracellular ROS to neutrophils isolated from control C57BL/6 mice (Figure 6.7 C, D). As 
an indication of whether IL-23 is directly or indirectly a chemoattractant, numbers of 
neutrophils in the peritoneum were counted, however, no difference was observed. DHE 
oxidation indicated that neutrophils actively generate ROS over time, but the ROS 
producing ability was similar between naïve and IL-23 pre-exposed neutrophils (Figure 6.7 
E). These results suggest that IL-23 alone at relevant physiological concentrations does 
not promote neutrophil activation.   
 
6.3.4 IL-23 exerts direct adverse effects on colonic epithelial cells by increasing intra-
cellular ROS  
Anti-IL-23 therapy in older Winnie mice with established colitis alleviated 
histopathology in the absence of any decrease in proinflammatory cytokine gene 
expression in the colon, indicating that IL-23 could promote inflammation via other cell 
types. In addition to downregulating Mip2α mRNA in colonic epithelial cells, anti-p19 
antibody treatment also partially restored mucin production in the distal colonic goblet cells 
of Winnie mice (Figure 6.8 A, B). Alcian blue and PAS staining revealed that the relative 
volume of mature mucin stored in goblet cell theca within the crypt was increased, 
suggesting improved mucin biosynthesis in goblet cells of Winnie mice with anti-p19 
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treatment. Interestingly, mRNA levels of the major mucin in the mouse intestine, Muc2, 
were only slightly elevated with anti-p19 antibody treatment in Winnie mice (Figure 6.8 C), 
suggesting that post-transcriptional regulatory mechanisms or improved protein 
biosynthesis pathways could  underlie increased mucin production by the intestinal goblet 
cells. 
 
Given the improved goblet cell phenotype and decreased Mip2α gene expression in 
intestinal epithelial cells following anti-IL-23 treatment, and reports that colonic epithelial 
cells express the IL-23 receptor (Suzuki et al., 2012), the direct effects of IL-23 on human 
LS174T colon cancer cells which include MUC2-producing goblet cells were investigated. 
It has been shown previously that proinflammatory cytokines induce ER stress by 
increasing cellular oxidative stress (Xue et al., 2005), therefore ROS were measured by 
DCFDA oxidation after 2 h IL-23 treatment in LS174T cells. LS174T cells have been 
cultured in serum-free DMEM media for at least 12 h before the assay was performed, 
Intra-cellular ROS increased significantly in LS174T cells after exposure to IL-23 (Figure 
6.9 A). Pharmacological inhibition studies showed that IL-23-induced ROS production was 
dependent on the STAT3 and STAT5 transcription factors known to be downstream of IL-
23R signalling (Figure 6.9 A). Interestingly, ER stress (measured by the ERAI reporter for 
XBP1-splicing) was also substantially increased by IL-23 (Figure 6.9 B). IL-23-induced ER 
stress was dependent on STAT3 activation and production of ROS, but not STAT5 (Figure 
6.9 B). Production of IL-8, the human chemokine equivalent to Mip-2α, by LS174T cells 
was significantly increased after exposure to IL-23 for 24 h (Figure 6.9 C). IL-23-induced 
IL-8 production was dependent on STAT3 and partially on ROS, but not STAT5 (Figure 6.9 
C). Administering exogenous ROS at increased concentrations caused a dose-dependent 
increase in IL-8 secretion (Figure 6.9 D). STAT5 mediated IL-23 induced ROS production, 
but not ER stress or downstream chemokine release, suggesting that ER stress could be 
promoted independently of oxidative stress. Further study is needed to elucidate the detail 
of the intracellular pathways activated by IL-23 in colonic epithelial cells. 
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Figure 6.8 Two weeks treatment using anti-p19 antibody partially restored mucin production in 
colonic goblet cells of Winnie mice with established colitis. Winnie mice at 12 weeks of age were 
treated for 2 weeks with anti-p40 and anti-p19 antibodies. (A) AB/PAS staining showing goblet 
cell mucin stores in the distal colon. (B) Quantitation of AB/PAS staining in the distal colon. (C) 
Muc2 gene expression in the distal colon relative to untreated control Winnie mice. Statistics: 
Mean ± SEM and individual data points, n=5-7, mixed gender, representative data from two 
experiments; B: One-way ANOVA with Bonferroni’s multiple comparison test (*P< 0.05). Scale 
bars = 100 µm. 
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The secreted mucin, MUC2, contains N- and C-terminal cysteine-rich domains 
which require N-glycosylation in the ER, and formation of intra- and inter-molecular 
disulphide bonds, extensive folding and dimerization before transporting to the Golgi 
complex. Consequently, MUC2 biosynthesis is closely related to ER capacity and affected 
by ER stress (McGuckin et al., 2010). However, the effect of ROS on MUC2 production 
has not been studied. Thus, I hypothesized that IL-23 may suppress MUC2 production by 
inducing ER stress and increasing intracellular ROS. Total MUC2 protein in LS174T cells 
was significantly downregulated by 24 h treatment with IL-23 (Figure 6.9 E). IL-23-
mediated inhibition of MUC2 production was blocked by the STAT3 inhibitor and ROS 
inhibitor (reduced glutathione), but not the STAT5 inhibitor (Figure 6.9 E). Exogenous ROS 
decreased MUC2 biosynthesis and secretion in a dose dependent manner with near 
complete inhibition above 10 μM (Figure 6.9 F). Overall, these results show that IL-23 
directly induces ER stress via increasing ROS production within colonic epithelial cells in a 
STAT3-dependent manner, which in turn induces IL-8 secretion as well as suppressing 
mucin biosynthesis and secretion.  
 
ROS have previously been shown in various cell types to induce IL-8 transcription 
and secretion via NFκB activation (p65 phosphorylation) (Gloire et al., 2006).  I therefore 
hypothesized that IL-23-induced IL-8 secretion is dependent on NF-κB activation. To 
address this hypothesis, LS174T cells were treated with 50 ng/ml of IL-23. Activation of 
two major NF-κB pathway components, p65 phosphorylation and IκBα phosphorylation, 
were assessed over a time course by immunoblotting. Comparing to positive control TNF-
α treatment, IL-23 treatment of LS174T cells did not promote p65 phosphorylation at 
serine 468 or IκBα phosphorylation (Figure 6.10 A), suggesting that IL-23 induced IL-8 
production is not via the canonical NF-κB pathway. However, inhibition of IL-8 production 
by the NF-κB inhibitor BAY11-7082 (Figure 6.10 B) suggests that IL-23 could promote IL-8 
secretion through the non-canonical NF-κB pathway. Interestingly, a basal level of p65 
phosphorylation at serine 536 was detected in LS174T cells (Figure 6.10 A), but IL-23 had 
no effect on serine 536 phosphorylation.  IL-23 stimulated p38 mitogen-activated protein 
kinase (MAPK) phosphorylation between 15 to 60 min later (Figure 6.10 A).  The p38 
MAPK phosphorylation inhibitor SB 203580 inhibited IL-8 production by IL-23 and the 
inhibitory effect was enhanced in combination with the NFκB inhibitor BAY11-7082 (Figure 
6.10 B). In summary, the direct effects of IL-23 on colonic epithelial cells is via STAT3 
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dependent oxidative stress and ER stress induction, which further promotes IL-8 secretion 
through activation of the non-canonical NF-κB pathway and p38 MAP kinase (Figure 6.10 
C).  
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Figure 6.9 IL-23 directly stimulates proinflammatory chemokine production and suppresses 
mucin production by intestinal epithelial cells. (A) Intracellular ROS in LS174T cells ± 50 ng/mL IL-
23 and/or 50 μM Stat3 inhibitor-VI S31-201 (Stat3 Ihb) or 50 μM Stat5 inhibitor CAS 285986-31-4 
(Stat5 Ihb) for 2h. (B) ER stress indicated by XBP1 splicing (C) IL-8 production (E) Total MUC2 
protein measured by ELISA in LS174T cells ± 50 ng/mL IL-23 and/or Stat3 Ihb, Stat5 Ihb or 50 μM  
ROS Ihb (reduced-glutathione) for 24h. (D) IL-8 production by LS174T cells exposed to 2.5-20 μM 
ROS (H2O2) for 4 h. (F) Intracellular and secreted MUC2 protein measured by ELISA in response 
to 24 h exposure to increasing concentrations of ROS.  Statistics: A, B, C, D, E, F:  Box plots 
showing median and inter-quartile range, n=4-6, experiment performed three times; One-way 
ANOVA with Bonferroni’s multiple comparison test (#P< 0.05, ***/###P< 0.001). * Compared to 
the control group; # compared to the IL-23 treated group.  
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Figure 6.10 IL-23 drives proinflammatory chemokine IL-8 production in LS174T cells via 
activation of the NFκB and p38 MAPK pathways. (A) LS174T cells were treated with TNF-α (50 
ng/ml) or IL-23 (50 ng/ml) for the indicated times. Whole cell lysate was subjected to SDS-PAGE 
electrophoresis and immunoblotted with indicated antibodies.  (B) IL-8 production in LS174T 
cells ± 50 ng/mL IL-23, 20 μM NFκB Ihb (BAY11-7082) and 20 μM phospho-p38 MAPK Ihb (SB 
203580) for 24 h. (C) Flow chart showing proposed mechanism of IL-23 induced IL-8 production 
in colonic epithelial cells. Statistics: B: Box plots showing median and inter-quartile range, n=4-6, 
experiment performed three times; One-way ANOVA with Bonferroni’s multiple comparison 
test (##P< 0.01, ***/###P< 0.001). *Compared to the control group; # Compared to the IL-23 
treated group.  
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6.4. Discussion 
The experiments reported in this chapter demonstrate that neutralization of IL-23 
with an anti-p19 antibody suppressed emerging and established colitis in Winnie mice. The 
anti-p19 antibody was superior to anti-p40 antibody in suppressing intestinal inflammation. 
As predicted, anti-IL-23 treatment suppressed emerging colitis in the Winnie model, 
accompanied by restrained production of the proinflammatory cytokines, IL-1β and IL-17A.   
However, in mice with more advanced colitis, anti-p19 antibody treatment alleviated 
intestinal inflammation without suppressing IL-1β and IL-17A, and also partially restored 
the mucin production in intestinal goblet cells and reduced chemokine Mip-2α release by 
colonic epithelial cells.  
 
Compared to mice treated with anti-p40 antibody, older Winnie mice with advanced 
colitis receiving anti-p19 antibody had elevated IFN-γ production from mesenteric lymph 
node leucocytes, suggesting that suppressing the IL-23/TH17 axis promotes TH1 cytokine 
production. Interestingly, this increased IFN-γ production was accompanied by decreased 
intestinal pathology. Aligned with this finding, it has been shown in an anti-CD40 colitis 
model that IL-12/TH1 is responsible for acute systemic inflammation, but not local intestinal 
pathology. In this model IL-23 and the innate sources of IL-17A, such as NK cells and 
innate lymphoid cells, may be essential for local intestinal inflammation, but play no role in 
systemic responses (Uhlig et al., 2006).  
 
Although anti-p40 antibodies have been shown to be effective in inducing remission 
and clinical response in patients with active CD in several clinical trials (Mannon et al., 
2004; Sandborn et al., 2008; Sandborn et al., 2012), our results in this model suggest that 
in some forms of colitis, perhaps more likely in forms of ulcerative colitis, anti-p19 antibody 
may be more efficacious than anti-p40 antibody in suppressing intestinal inflammation. 
The effects of anti-p40 antibody in suppressing colitis needs further evaluation; particularly 
useful would be comparison with an anti-IL-12p35 antibody.  These assessments of the 
efficacy of the anti-p19 antibody in the Winnie colitis model provide an interesting 
relevance for clinical therapy, as Winnie mice have a competent immune system and 
respond well to the anti-inflammatory drugs used clinically in IBD. Our results provide 
support for future clinical treatment strategies targeting IL-23 to suppress intestinal 
inflammation.  
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In Winnie mice with established colitis, anti-IL-23 treatment significantly reduced 
neutrophil infiltration which was not observed with either anti-IL-17A or anti-IL-17Ra 
treatment (see 5.3.1 to 5.3.3), indicating that IL-23 directly or indirectly mediates neutrophil 
recruitment independently of IL-17A. Supporting this hypothesis, other studies have shown 
that IL-23-dependent neutrophil recruitment is protective for colonic epithelial cells in the 
resolution stage of DSS colitis (Zindl et al., 2013). However, results from this chapter show 
that 50 ng/ml IL-23 treatment or pre-exposure did not modify the activation state of 
neutrophils as assessed by intra-cellular ROS.  The discrepancy with a previous study 
(Taylor et al., 2014) could be due to pre-activation of neutrophils during the isolation and 
preparation process. A recent study has demonstrated that IL-23 and IL-6 are directly 
involved in neutrophil activation and recruitment during fungal infection (Taylor et al., 2014). 
In this study, cytokine stimulated (IL-6 at 20 µg/ml and IL-23 at 2 µg/ml) neutrophils had 
higher intracellular ROS compared to unstimulated neutrophils (Taylor et al., 2014). 
However, I was unable to replicate these results, perhaps because I used lower 
concentrations of cytokines than the extremely high concentration of cytokines used in the 
previous study. Interestingly, another study revealing a novel mechanism of neutrophil 
activation shows that neutrophils are a major cell source for IL-1β during acute infection 
via the NLRC4 inflammasome, despite the fact that they are also a cellular target of IL-1β 
(Chen et al., 2014). It is possible that IL-23-dependent colonic neutrophil infiltration is 
sustained and amplified through an autocrine loop of neutrophil-derived IL-1β together with 
colonic epithelial cell inflammasome activation. Blocking IL-23 may alleviate local 
neutrophil infiltration as well as suppressing IL-1β-sustained local neutrophil activation. 
 
Prior to this study, the effects of IL-23 on non-lymphoid cells and IL-23 receptor 
expression on epithelial cells have only been reported in human lung cancer cells (Li et al., 
2013) and colon cancer cells (Suzuki et al., 2012). Results in this chapter show that IL-23 
has direct effects on intestinal epithelial cells by STAT3 and STAT5-dependent induction 
of ROS, which in turn induces ER stress. Increased oxidative stress and ER stress further 
stimulate proinflammatory chemokine production and reduces MUC2 production, the major 
component of the intestinal mucus which separates the microbiota from the epithelium. 
However, I used LS174T colon cancer cells and it is possible that cancer cells express 
higher level of IL-23R than normal epithelial cells.  IL-23R expression in intestinal epithelial 
cells in health and during inflammation requires careful evaluation. 
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NF-ĸB mediated IL-8 secretion has been extensively studied in various cell types 
and inflammation models. Two major pathways mediate NF-ĸB activation, namely the 
canonical and non-canonical pathways. Canonical pathway activation is mediated by 
inducible degradation of IκBα via its phosphorylation by the IκB kinase (IKK). IĸBα 
phosphorylation is associated with ubiquitination and dissociation from NFĸB (p65/p50), 
which leads to the translocation of the activated transcription factor into the nucleus and 
induction of gene expression (Oeckinghaus and Ghosh, 2009). The non-canonical 
pathway activates other NF-κB complexes independent of IκBα degradation (Sun, 2012). 
Considering the fact that BAY 11-7082 is an IKK inhibitor with poor selectivity for IKKα and 
IKKβ (Rauert-Wunderlich et al., 2013) and IKKα (not IKKβ or IKKγ) is required for non-
canonical NF-κB signalling (Claudio et al., 2002; Hacker and Karin, 2006), it is possible 
that IL-23-induced IL-8 production is via non-canonical NF-κB activation. The basal level of 
p65 phosphorylation at serine 536 in LS174T cells could also due to activation of the non-
canonical pathway, as p65 specific serine 536 phosphorylation has been shown to be 
independent of canonical NF-ĸB activation (Rauert-Wunderlich et al., 2013). Therefore IL-
23-stimulated chemokine production could be dependent on both oxidative and ER stress-
triggered MAPK activation and non-canonical NF-ĸB activation by other inflammatory or 
cell-intrinsic factors. 
 
In summary, due to IL-23’s multiple mechanisms of action, neutralization of IL-23 in 
colitis is likely to prove efficacious by reducing T cell and ILC activation, reducing 
chemokine-mediated recruitment of inflammatory cells into the intestine, and by 
replenishing intestinal mucus, thereby helping restore the normal homeostatic state. The 
previously unrecognized action of IL-23 on epithelial cells also suggests that the protection 
from IBD conveyed by hypomorphic IL-23R alleles may be at least partially explained by 
reduced adverse effects of IL-23 on intestinal epithelial cells. 
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7.0 Discussion  
The intestinal epithelium is a critical regulator of the intestinal immune system, 
and the cross talk between the intestinal epithelium and underlying immune system is 
likely to be crucial in IBD pathogenesis. Currently there is enormous interest from 
researchers and the pharmaceutical industry in targeting proinflammatory immune 
responses, including the TH17 response, to treat IBD. Anti-cytokine monoclonal 
antibodies are a promising form of biological therapy, with anti-TNF-α antibodies in 
routine use to induce remission in CD and, to a lesser extent, UC patients. Given anti -
IL-17A antibodies show substantial efficacy in treating autoimmune diseases like 
plaque psoriasis (Blauvelt et al., 2014) and ankylosing spondylitis (Baeten et al., 
2013), secukinumab, an anti-IL-17A monoclonal antibody has been trialed for 
treatment of moderate to severe Crohn's disease.  Unfortunately, secukinumab was 
ineffective and increased adverse events were reported compared with placebo 
(Hueber et al., 2012).  Therefore, the specific role of the TH17 immune response in 
intestinal inflammation needs further examination, as a number of different interacting 
cytokines and complex cross-talk between epithelial cells and leukocytes are involved. 
This project aimed to investigate the physiological role of the IL-17A - IL-17Ra 
pathway in intestinal inflammation and to assess the efficacy of monoclonal antibodies 
against TH17 cytokines, including IL-23, in suppressing intestinal inflammation utilizing 
a spontaneous chronic colitis model in mice.  
 
The major findings from this project are summarized as follows:  
 After transfer of naïve T cells, lymphopenic RaW recipients with an epithelial 
defect had more severe intestinal inflammation compared to Rag1−/− recipients. 
Although IL-17A deficiency in T cells had no effects on transfer colitis 
development in recipient mice, transfer of IL-17Ra-deficient T cells exacerbated 
colitis compared to WT T cells, suggesting that the IL-17A – IL-17Ra pathway in 
does not promote this form of colitis and in fact may repress T cell-mediated 
pathophysiology. 
 
 Systemic deficiency of IL-17A suppressed the age-related progression of colitis 
in Winnie mice. However, neutralizing IL-17A, IL-17Ra or other TH17 associated 
cytokines using monoclonal antibodies failed to suppress Winnie colitis. Thus, 
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the therapeutic efficacy of targeting the TH17 pathway alone with antibodies is 
minimal.  
 
 Neutralizing IL-23 using anti-p40 and anti-p19 antibodies suppressed emerging 
and established colitis in Winnie mice and anti-p19 was more efficacious than 
anti-p40 antibody. Based on previous knowledge the efficacy of anti-IL-23 is 
attributable to its multiple effects on immune cells including recruiting 
neutrophils, promoting the maturation of inflammatory TH17 cells and ILCs, and 
suppressing the activity of regulatory T cells (Figure 7.1). 
 
 In a novel finding, IL-23 drove intra-cellular ROS production in intestinal 
epithelial cells via STAT3 and STAT5, which further promoted ER stress. 
Increased ROS concentrations and subsequent ER stress inhibited MUC2 
biosynthesis and stimulated secretion of the chemokine, IL-8, via NF-κB and p38 
MAPK activation. Thus it is likely that the efficacy of anti-IL-23 in suppressing 
colitis is also due to the previous unrecognized effects of IL-23 on intestinal 
epithelial cells (Figure 7.1). 
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Figure 7.1 IL-23 has multiple effects on immune and non-immune cells that drive intestinal 
inflammation.  IL-23 produced by antigen presenting cells drives inflammatory TH17 cell and ILC 
maturation and cytokine production. IL-23 could directly recruit or activate neutrophils via an IL-
17A-independent mechanism and also via IL-17. IL-23 suppresses regulatory T cell function 
which further promotes expansion of inflammatory T cells and ILCs.  Besides the effects on 
immune cells, IL-23 acts directly on colonic epithelial cells by STAT3 and STAT5-dependent 
induction of ROS, which in turn induces ER stress. Increased oxidative stress and ER stress 
stimulates release of the IL-8 chemokine and reduces MUC2 production, the major component 
of the intestinal mucus which separates the microbiota from the epithelium. IL-23 induced IL-8 
production in epithelial cells is dependent on NF-κB and p38 activation, and this chemokine 
further contributes to local neutrophil recruitment and tissue damage. IL-23 is a major 
contributor to local intestinal inflammation mediated by diverse adverse effects on immune and 
non-immune cells as colitis progress.  
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In contrast to the findings of O’Connor et al. showing that IL-17A-/- T cells are more 
colitogenic than wild type T cells in driving transfer colitis (O'Connor Jr et al., 2009), we 
found that IL-17A deficiency did not modify the colitogenic ability of T cells. However, our 
finding is supported by three other studies (Izcue et al., 2008; Leppkes et al., 2009; 
Noguchi et al., 2007). Although we concur with O’Connor’s findings that IL-17Ra-/- T cells 
generate more severe colitis than wild type T cells, we could not find evidence of skewing 
to a TH1 immune response, which is supported by similar finding from Izcue et al. (Izcue et 
al., 2008). Reasons for the discrepancy between results is unknown, but differences in the 
microbiota between facilities may partly explain the divergence, as transfer colitis 
development is intestinal microbiota dependent (Feng et al., 2010). The difference 
observed between IL-17A-/- T cell and IL-17Ra-/- T cell transfer experiments could be due 
to the unresponsiveness of IL-17Ra-/- T cells to other cytokines like IL-17F or IL-17E 
(Iwakura et al., 2011). The transfer colitis model is a useful tool to investigate the role of T 
cell-mediated inflammatory responses in colitis development, but it has limitations in 
translating findings to clinical therapy. IBD patients are not lymphopenic, and multiple 
subsets of immune cells contribute to the immune pathogenesis including innate lymphoid 
cells, γδT cells and regulatory T cells.  
 
In contrast to the results of IL-17A deficiency in T cells, systemic deficiency of IL-
17A alleviated colitis progression in Winnie mice, suggesting that non T cell-derived IL-17A 
is involved in colitis progression. Previous findings from our group show that Il17a gene 
expression in the intestinal mucosa of Winnie mice is significantly upregulated while aging 
(Eri et al., 2011), suggesting that IL-17A contributes more to the progression than the 
initiation stage of colitis. It is possible that immune cell-derived IL-17A has different effects 
in different stages as colitis progresses. An interesting finding from another study shows 
that naïve T cells from aged C57BL/6 mice have dramatically elevated Il17a gene 
expression compared to T cells from young mice, which resulted in more severe transfer 
colitis in Rag1-/- recipients compared to cells from young mice (Ouyang et al., 2011). 
Based on these findings, it is likely that potentiation of IL-17A in the aging process 
contributes to the development of chronic colitis. However, impacts of genetic deficiency of 
IL-17A on chronic colitis development have not been comprehensively studied in general.  
A previous study showed that IL-17A-/- mice had exacerbated DSS-colitis compared to wild 
type mice (Yang et al., 2008a), suggesting a regulatory effect of IL-17A in this acute model 
of intestinal inflammation. It is possible that IL-17A plays different roles in chronic and 
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acute intestinal inflammation. It’s been reported that IL-17A is able to promote claudin 
expression and regulate intestinal epithelial tight junctions (Kinugasa et al., 2000).  
 
Although IL-17A contributes to chronic colitis progression, targeting IL-17A or IL-
17Ra failed to show efficacy in the Winnie colitis model. A recent study shows that anti-IL-
17A antibody alone failed to suppress naïve T cell induced transfer colitis (Wedebye 
Schmidt et al., 2013). In an IL-10-deficiency induced colitis model, blockade of IL-17A by 
monoclonal antibody also lacked efficacy unless IL-6 was also neutralized (Yen et al., 
2006). Similar disappointing results were reported in human trials. Two different anti-IL-
17A antibodies failed to show efficacy in treating active CD patients (Hueber et al., 2012; 
Targan et al., 2012). Increased fungal infections (Hueber et al., 2012) and increased 
disease severity (Targan et al., 2012) were reported. These results are not entirely 
surprising, considering the evidence that colonization by the commensal flora drives TH17 
cell development (Chung et al., 2012; Ivanov et al., 2009; Yang et al., 2014) and the 
physiological function of TH17 cells is to fight against extra-cellular pathogens at mucosal 
sites (Ivanov et al., 2009; Yang et al., 2014). In the Winnie spontaneous colitis model 
induced by a defect in the secretory epithelial cells that produce the mucus barrier, the 
protective aspects of TH17 immunity dealing with microbes that penetrate the defective 
barrier is probably as important as restraining the TH17 response to alleviate associated 
tissue damage. Within this complex inflammatory environment, we found that taking out 
single effector cytokines or blocking specific cytokine receptors was insufficient to fine tune 
the balance and suppress local inflammation, with the exception of neutralization of IL-23. 
The contrast with the constitutive loss of IL-17 from birth in IL-17-/-Winnie mice may relate 
to different evolution of mucosal immunity in the complete absence of IL-17, and therefore 
not reflect the clinical situation in IBD. 
 
Since IL-17A negatively regulates IFN-γ-producing TH1 cells (O'Connor Jr et al., 
2009) and increased IFN-γ production was observed in Winnie mice receiving anti-IL-17A 
antibody (see 5.3.1 for details), a more rational approach to suppress intestinal 
inflammation may be to simultaneously target the TH1 and TH17 pathways. The efficacy of 
neutralizing IFN-γ and IL-17A together using monoclonal antibodies is worth exploring.  
Another possible cytokine to target is IL-21, as IL-21 sustains both TH1 and TH17 cytokine 
production in cells isolated from the mucosa of IBD patients (Fina et al., 2008; Monteleone 
et al., 2005b). Furthermore, IL-21-deficient mice were protected against DSS and TNBS 
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colitis and were unable to upregulate TH1 and TH17 proinflammatory cytokines during 
intestinal inflammation (Fina et al., 2008). Administration of an IL-21 receptor fusion 
protein suppressed inflammatory cytokine production and DSS colitis in wild type mice 
(Fina et al., 2008). In the future, it would also be interesting to explore the efficacy of anti-
IL-17A antibodies as maintenance therapy after induction of remission by steroids or 5-
ASA in the Winnie model which responds well to these agents. However, long-term use of 
anti-IL-17A could also potentially increase the risk of opportunistic infections in this setting. 
In summary, targeting the major TH17 effector cytokine, IL-17A, appears in multiple murine 
models and human trials to have little efficacy in suppressing colitis.  
  
IL-23 plays a crucial role in colitis development due to its effects on multiple 
immune cells including TH17 cells (Stritesky et al., 2008; Yen et al., 2006), ILCs (Eken et 
al., 2014; Uhlig et al., 2006) and Treg cells (Izcue et al., 2008; Liu et al., 2012). GWAS 
reveal that IL23R gene polymorphisms are strongly associated with IBD susceptibility 
(Jostins et al., 2012a). The most common polymorphism appears to be a protective 
hypomorphic allele (Duerr et al., 2006b), suggesting that IL-23 signalling is involved in the 
development of disease. To date, blocking IL-23 using monoclonal antibody therapy is still 
under clinical investigation and its potential to suppress intestinal inflammation is yet to be 
fully characterized. Murine studies have demonstrated significant efficacy of anti-IL-23 
antibody in treating inflammatory or autoimmune diseases, including arthritis (Yago et al., 
2007), spondyloarthritis (Benham et al., 2014) and autoimmune encephalomyelitis (Chen 
et al., 2006). In a recent clinical trial in moderate-to-severe psoriasis, more patients treated 
with guselkumab (anti-IL-23 antibody) had clinical responses compared to a placebo 
control group (Sofen et al., 2014). The efficacy of anti-IL-23 therapy has been associated 
with suppression of IL-17-dependent inflammatory responses. Targeting IL-23 shows 
promising efficacy in treating inflammatory or TH17-mediated autoimmune diseases. In 
targeting IL-23, antibodies against p40, a shared subunit of IL-12/23 cytokines, have been 
trialed in treating active CD. Two fully humanised IgG1 monoclonal antibodies against p40 
subunit have been developed: briakinumab and ustekinumab. Although ustekinumab is 
effective as induction and maintenance therapy in treating subsets of CD patients who had 
previously failed anti-TNF therapy (Sandborn et al., 2012), the overall efficacy of targeting 
the p40 subunit in suppressing intestinal inflammation is not impressive (Mannon et al., 
2004; Sandborn et al., 2008). To date, these antibodies haven’t been tested or trialed in 
UC yet. 
110 
 
 
 
One of the most important and unexpected findings of this project was that IL-23 
acts directly on colonic epithelial cells. This result not only defines IL-23 as a key cytokine 
driving intestinal inflammation, but also adds to a growing recognition that epithelial cells 
are actively involved in regulating local immune responses and maintaining homeostasis 
(Kagnoff, 2014; Kaser et al., 2011; McGuckin et al., 2009; McGuckin et al., 2010; Peterson 
and Artis, 2014).  Early evidence demonstrates that intestinal epithelial cells can respond 
to luminal microbial signals and condition antigen presenting cells and subsequently 
lymphocytes to elicit immune function (Rimoldi et al., 2005). With increasing evidence, it is 
now clear that epithelial cells can directly initiate and then promote inflammatory 
responses such as those associated with IBD pathogenesis. Multiple murine models with 
alterations in epithelial barrier function develop spontaneous intestinal inflammation with 
phenotypes similar to human IBD (Heazlewood et al., 2008; Kosiewicz et al., 2001; Nenci 
et al., 2007; Van der Sluis et al., 2006). We have shown here that in response to IL-23 
epithelial cells develop oxidative stress and ER stress which in turn can promote local 
intestinal inflammation by secreting proinflammatory chemokines. It is likely that this 
pathway has evolved so that APC-derived IL-23 can help protect epithelial cells from 
intracellular pathogens via the production of ROS and to amplify leukocyte recruitment by 
the epithelial cell chemokine production. This finding provides further evidence of the 
importance of oxidative stress and ER stress in colonic epithelial cells as both a primary 
cause of intestinal inflammation or a consequence of inflammation (Adolph et al., 2013; 
Hasnain et al., 2013; Kaser et al., 2011).  
 
We have shown evidence that IL-23 acts directly on colonic epithelial cells, but 
LS174T cells are malignant cancer cells which may not represent the real physiological 
scenario. Prior to our study, IL-23 receptor expression on epithelial cells has only been 
reported in human lung cancer cells (Li et al., 2013) and colon cancer cells (Suzuki et al., 
2012). Therefore, it would be interesting and necessary to examine the IL-23R expression 
level in vivo and the physiological role of IL-23R signaling in primary colonic epithelial cells 
in the future. To address this, intestinal epithelial cell conditional IL-23R knockout mice 
would be a useful tool. In fact supporting our findings, a very recent conference report 
using mice with conditional knockout of the Il23r in the intestinal epithelium (IL23RIEC-KO) 
shows that IL23RIEC-KO mice produce less antimicrobial peptides, have a disturbed 
colonic microflora and succumb to DSS colitis (Aden et al., 2014). Another approach to 
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study the physiological role of IL-23R in epithelial cells would be to generate bone marrow 
chimeras. For example, it would be interesting to compare the chemical toxin-induced 
intestinal inflammation between IL-23R-deficient and wild type mice reconstituted with wild 
type vs IL-23R-deficient bone marrow. 
 
Another interesting area needing further study is the effect of IL-23 on colonic 
epithelial cell IL-1β production and downstream neutrophil infiltration. Recently, an 
interesting study revealed a novel mechanism of neutrophil activation and showed that 
neutrophils are a major cell source for IL-1β during acute infection via the NLRC4 
inflammasome, despite the fact that they are also a cellular target of IL-1β (Chen et al., 
2014). It is possible that IL-23-dependent colonic neutrophil infiltration is sustained and 
amplified through an autocrine loop of neutrophil-derived IL-1β together with colonic 
epithelial cell inflammasome activation. Blocking IL-23 may alleviate local neutrophil 
infiltration as well as suppressing IL-1β-sustained local neutrophil activation. Direct 
inflammasome activation by IL-23 has not been reported before. However, it has been 
shown that ER stress can induce IL-1β secretion in macrophages via NLRP3 
inflammasome activation, and both potassium efflux and increased ROS levels are 
required for this process (Menu et al., 2012; Oslowski et al., 2012). Therefore, it is 
reasonable to hypothesize that IL-23 induces IL-1β production via inflammasome 
activation in colonic epithelial cells given the fact that IL-23 is a strong inducer of oxidative 
stress and ER stress. 
 
 Suppressing inflammation, maintaining remission and limiting side effects are the 
ultimate goals for treating IBD in the clinic. Consequently, biological therapies targeting 
specific proinflammatory cytokines to suppress intestinal inflammation are under extensive 
study. The major concept of this project was to identify potential therapeutic targets by 
using neutralizing monoclonal antibodies against TH17-associated proinflammatory 
cytokines. Disappointing results have demonstrated that neutralizing antibodies against IL-
17A and IL-17Ra failed to show any efficacy. One of the frequently raised questions 
regarding this negative result is how to evaluate the neutralizing efficiency of these 
antibodies in vivo. We were unable to assess this from our animal experiments; however, 
these same antibodies and doses have been used successfully to suppress 
immunopathology in other murine models of inflammatory disease. To address the 
question of efficacy of neutralization in the future, it would be necessary to investigate the 
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antibody binding efficiency in vivo through pharmacological studies including monitoring 
the systemic concentration as well as the local mucosa concentration of the antibody and 
both free and bound cytokine, which is technically challenging.  
 
This project using a unique mouse model of intestinal inflammation provided an 
opportunity to investigate the role of stressed epithelial cells in regulating DC and other 
immune responses. Unlike other murine experimental models where colitis is induced by 
exogenous chemical toxins or defects in the immune system, Winnie colitis arises from 
epithelial secretory cell ER stress and mucosal barrier defects which develop with an intact 
underlying immune system (Eri et al., 2011; Heazlewood et al., 2008).  Anti-inflammatory 
drugs which are efficacious in treating human UC can also successfully suppress Winnie 
colitis (Das et al., 2013). This makes Winnie mice a useful murine model to screen 
potential therapeutic targets and to evaluate the efficacy of new biological therapies. 
Although the epithelial defect driven colitis in Winnie mice shares phenotypic similarities 
with human UC, the mucin misfolding and goblet cell ER stress leading to inflammation in 
Winnie mice cannot represent the overall disparate and complex disease pathogenesis in 
human UC. Differences between the physiology of the mouse and human intestine, 
including the distribution and lifespan of goblet cells in the mouse colon, could influence 
the translation of our findings to the treatment of human colitis.  
 
 In this project, I have shown that blocking IL-23 using an anti-p19 antibody is more 
efficacious than an anti-p40 antibody in suppressing Winnie colitis. The different efficacy of 
these two antibodies suggests that IL-23, not IL-12, is the major contributor to pathology in 
Winnie intestinal inflammation. However, to further dissect the difference, an anti-IL-12p35 
antibody needs to be included to further evaluate the effects of anti-p40 antibody in 
suppressing colitis.  
 
To date, there is no comprehensive study directly comparing the efficacy of anti-IL-
17A and anti-IL-23 antibodies in experimental colitis models. I have shown that blocking 
TH17 effector responses in colitis by targeting single effector cytokines or cytokine 
receptors was ineffective. However, neutralizing IL-23 not only suppressed leukocytes, but 
limited neutrophil infiltration into the intestinal mucosa and alleviated epithelial cell 
oxidative stress and ER stress.  These findings deepen our understanding of the IL-
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23/TH17 axis and may help guide therapeutic approaches for patients with active 
inflammatory bowel disease. 
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